var title_f14_35_14896="Algorithm narrow complex SVT";
var content_f14_35_14896=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 576px\">",
"   <div class=\"ttl\">",
"    Narrow complex supraventricular tachycardia algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 556px; height: 609px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2000 I-162.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_35_14896=[""].join("\n");
var outline_f14_35_14896=null;
var title_f14_35_14897="Adult TB case 2 PA view";
var content_f14_35_14897=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 486px\">",
"   <div class=\"ttl\">",
"    Classic adult TB PA view case 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 416px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 40 year-old automobile mechanic from the Dominican Republic, in the US 8 years, presented to the urgent care clinic with 4 months of productive cough, fevers, progressive hoarseness, and a 40 pound weight loss. A chest radiograph (PA view) demonstrates diffuse parenchymal disease with multiple cavities and bulla formation on the left. Sputum smear was positive for AFB.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Bernardo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_35_14897=[""].join("\n");
var outline_f14_35_14897=null;
var title_f14_35_14898="Spermatic cord course";
var content_f14_35_14898=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Spermatic cord course",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This transverse section of the anterior abdominal wall demonstrates the structures that form the external and internal inguinal rings. The external inguinal ring is formed by the external oblique aponeurosis. The internal inguinal ring is located in the transversalis fascia and composed of the transversus abdominus and internal oblique muscles. The broad arrow represents the course of the spermatic cord.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from O'Rahilly. Abdominal walls. In: Basic Human Anatomy, W.B. Saunders Company, Philadelphia 1983. p.230.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_35_14898=[""].join("\n");
var outline_f14_35_14898=null;
var title_f14_35_14899="Gastric ulcer on fluoroscopy";
var content_f14_35_14899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F59040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F59040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric ulcer on fluoroscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 297px; height: 572px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Air contrast upper gastrointestinal (UGI) series demonstrates a penetrating ulcer along the lesser curvature of the gastric body (arrow). Note the thickened gastric folds that radiate from the ulcer crater.",
"    <br>",
"     (B) Air contrast UGI series demonstrates a profile view of the ulcer along the lesser curvature of the gastric body (arrow). The ulcer projects beyond the wall of the stomach consistent with a benign ulcer.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of J Pierre Sasson, MD.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_35_14899=[""].join("\n");
var outline_f14_35_14899=null;
var title_f14_35_14900="Peripheral artery disease and claudication";
var content_f14_35_14900=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Peripheral artery disease and claudication (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/35/14900/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/35/14900/contributors\" id=\"au5205\">",
"       Emile R Mohler III, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/35/14900/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/35/14900/contributors\" id=\"se1346\">",
"       Denis L Clement, MD, PhD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/35/14900/contributors\" id=\"se3367\">",
"       John F Eidt, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/35/14900/contributors\" id=\"se3365\">",
"       Joseph L Mills, Sr, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/35/14900/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/35/14900/contributors\" id=\"de2771\">",
"       Kathryn A Collins, MD, PhD, FACS",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?14/35/14900?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      CLAUDICATION OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Claudication, which literally means &ldquo;to limp&rdquo;, is one of the symptoms of lower extremity peripheral artery disease (PAD), but can also occur in patients who have other vascular problems (eg, aneurysm). Claudication is defined as a pain or discomfort in a group of muscles, usually the legs, thighs, or buttocks, that is worsened by exercise (ie, walking) and relieved with rest.",
"    </p>",
"    <p>",
"     Although many underlying medical problems can cause claudication, the most common cause is peripheral artery disease, which causes deposits of fatty plaques (atherosclerosis) on the vessel walls. These plaques may progress and result in narrowing or completely block blood flow in the leg arteries (",
"     <a class=\"graphic graphic_figure graphicRef60105 \" href=\"UTD.htm?6/23/6514\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Another important, but less common, arterial cause of claudication is aneurysm. An aneurysm is an abnormally dilated artery, which is often filled with debris or blood clots that can break off and clog arteries in the leg, sometimes causing claudication as a first symptom. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3065?source=see_link&amp;anchor=H1314527#H1314527\">",
"      \"Popliteal artery aneurysm\", section on 'Chronic ischemia'",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link&amp;anchor=H15830656#H15830656\">",
"      \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Asymptomatic AAA'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      PERIPHERAL ARTERY DISEASE RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     The major risk factors for developing PAD include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Cigarette smoking (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"        \"Patient information: Quitting smoking (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Diabetes (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"        \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Hyperlipidemia (elevated blood levels of lipids, including cholesterol and triglycerides). (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"        \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Hypertension (high blood pressure). (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=see_link\">",
"        \"Patient information: High blood pressure in adults (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     One study found that these risk factors cause claudication in 69 percent of patients with PAD; cigarette smoking was the most important factor [",
"     <a class=\"abstract\" href=\"UTD.htm?14/35/14900/abstract/1\">",
"      1",
"     </a>",
"     ]. In contrast, alcohol consumption, in moderation, may reduce the risk of PAD and claudication.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      CLAUDICATION SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The pain and discomfort associated with claudication varies from person to person. Some people have severe, debilitating discomfort while others have minimal symptoms.",
"    </p>",
"    <p>",
"     The severity of your symptoms will depend upon how many arteries are affected, how narrowed your arteries are, the number of \"alternate\" secondary (collateral or detour) vessels available to provide blood when the damaged vessels cannot (so-called collateral circulation), how quickly you walk, and whether you walk up an incline or stairs.",
"    </p>",
"    <p>",
"     The location of your pain depends upon the location of PAD. A person may have foot, calf, thigh or buttock pain, either alone or in combination. Calf claudication is the most frequent location of pain, and most commonly results from blockage of the superficial femoral artery in the mid thigh. Foot claudication may occur from narrowing of an artery in the lower part of the leg (the tibial or peroneal artery).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Calf pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;Calf pain is the most common complaint. It is usually described as a gradually restrictive cramp-like pain that always occurs with exercise and is relieved with rest. Claudication pain in the upper two-thirds of the calf is usually due to the narrowing of the main artery in the thigh (the superficial femoral artery), whereas pain in the lower third of the calf is due to disease in the artery behind the knee (the popliteal artery).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H393967\">",
"     <span class=\"h2\">",
"      Thigh pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;Thigh claudication often results from the narrowing of the superficial femoral artery in the upper thigh or from the artery in the groin (the common femoral artery), but can also be caused by blockage of the vessels above the groin (iliac arteries).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Buttock pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;When symptomatic, people with a blockage in the artery of their abdomen (the aorta) complain of buttock, hip, or thigh pain. The pain is often described as aching, and there may also be weakness while walking up stairs. Other physical signs include loss of muscle mass and hair loss on the lower extremities. Erectile dysfunction (ED) may also occur when the aorta or iliac arteries are blocked. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=see_link&amp;anchor=H189242040#H189242040\">",
"      \"Overview of male sexual dysfunction\", section on 'Association with cardiovascular disease'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      CLAUDICATION DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     The diagnosis of claudication is based upon the signs and symptoms described above. Noninvasive tests can be performed to confirm the diagnosis and estimate the severity of the disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Ankle-arm index",
"     </span>",
"     &nbsp;&mdash;&nbsp;The ankle-brachial index (ABI), also called the ankle-arm index, is used to confirm the diagnosis of PAD. The ABI measures the resting blood pressure at the ankle compared with the blood pressure in the arm. A normal value is between 0.9 and 1.3. If the test is normal at rest in a patient with symptoms of claudication, it is often repeated following exercise, comparing values at rest and following treadmill walking.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Segmental blood pressure",
"     </span>",
"     &nbsp;&mdash;&nbsp;Blood pressure can be measured at other levels in the legs (calf, low thigh, high thigh) to determine the level and extent of PAD. Such measurements are called segmental limb pressures.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H393982\">",
"     <span class=\"h2\">",
"      Imaging",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ultrasonography is a noninvasive test that can be used to see the location and severity of the narrowing in the blood vessels. Computed tomography (CT) and magnetic resonance angiography (MRA) are other noninvasive ways of looking at blood vessels. These tests are usually used if symptoms do not improve with medical treatment or if they suddenly get worse. In this situation, invasive imaging tests (ie, arteriography) might also be considered, especially if your doctor thinks that a procedure (revascularization) to treat PAD would be helpful. (See",
"     <a class=\"local\" href=\"#H17\">",
"      'Percutaneous angioplasty and stenting'",
"     </a>",
"     below and",
"     <a class=\"local\" href=\"#H19\">",
"      'Surgery'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      CLAUDICATION TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The treatment of claudication involves medical therapy with or without some form of revascularization",
"     <span class=\"nowrap\">",
"      (angioplasty/stenting,",
"     </span>",
"     surgical bypass). Most people with claudication are treated medically, which includes reducing risk factors, exercise training and using medications that may improve walking distance [",
"     <a class=\"abstract\" href=\"UTD.htm?14/35/14900/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     In spite of appropriate medical treatment, some people may have incapacitating claudication that prevents them from working or carrying out other important daily tasks. These patients may be candidates for revascularization procedures, which include percutaneous angioplasty and stenting of the narrowed or blocked vessels, or a surgical procedure that opens or bypasses the blockage.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Reduce risk factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;As mentioned above, the main risk factors for PAD are cigarette smoking, diabetes mellitus, high blood pressure, and high cholesterol or lipids. All people with claudication should work to control these risk factors.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Lowering cholesterol can prevent worsening of PAD and can reduce the symptoms of claudication. A blood LDL-cholesterol level below 100",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (2.6",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"       is recommended. Treatment may include lifestyle changes (diet and exercise)",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       lipid-lowering medications. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"        \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Quitting smoking and improving control of diabetes and high blood pressure may also improve claudication symptoms (ie, pain), but even more importantly, it helps to reduce the risk of coronary artery disease. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"        \"Patient information: Quitting smoking (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Antiplatelet agents (medications that reduce blood clotting in an artery, vein, or the heart) are recommended for",
"     <strong>",
"      all",
"     </strong>",
"     patients with PAD. While these medications may only modestly improve claudication symptoms, treatment reduces the need for surgery and decreases the risk of myocardial infarction (heart attack), stroke, or death from PAD.",
"    </p>",
"    <p>",
"     Aspirin (81 to 325",
"     <span class=\"nowrap\">",
"      mg/day)",
"     </span>",
"     is an accepted antiplatelet medication for people with PAD. Treatment with another antiplatelet agent, clopidogrel (Plavix&reg;), has modest advantages compared with aspirin alone in preventing stroke, myocardial infarction, and PAD [",
"     <a class=\"abstract\" href=\"UTD.htm?14/35/14900/abstract/3\">",
"      3",
"     </a>",
"     ]. Some patients do not respond as expected to antiplatelet therapy. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=see_link\">",
"      \"Nonresponse and resistance to clopidogrel\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Exercise",
"     </span>",
"     &nbsp;&mdash;&nbsp;Exercise programs reduce the symptoms of claudication, including increasing the distance and time that one can walk before developing symptoms [",
"     <a class=\"abstract\" href=\"UTD.htm?14/35/14900/abstract/4\">",
"      4",
"     </a>",
"     ]. Patients who respond to an exercise program can expect improvement within two months. Motivated patients achieve the best results. The benefits of exercise diminish when exercise training stops.",
"    </p>",
"    <p>",
"     Supervised exercise training involves walking on a treadmill or a track for 45 to 60 minutes at least three times per week. The sessions are supervised by an exercise physiologist, physical therapist, or nurse. The intensity of exercise can be adjusted based upon symptoms or other cardiovascular problems (such as an abnormal heart rhythm or chest pain) that develop during exercise. Supervised training is not reimbursed by most insurance companies, and although encouraged, non-supervised walking programs do not result in the same amount of improvement.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Medication to improve walking distance",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of medical therapies may be helpful in people with claudication to help improve walking distance. &nbsp;",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H393840\">",
"     <span class=\"h3\">",
"      Cilostazol",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cilostazol (Pletal&reg;) is the most effective medication for treatment of claudication symptoms, particularly when combined with exercise. A clinician may also recommend cilostazol for people who have a limited ability to walk due to claudication. This is especially true for people who do not respond adequately to other measures and those who do not want or who are not healthy enough for revascularization.",
"    </p>",
"    <p>",
"     Cilostazol should be taken one-half hour before or two hours after eating because high fat meals increase the amount of drug absorbed by the body. Diltiazem, omeprazole, and grapefruit juice should not be taken at the same time as cilostazol. Cilostazol may be taken safely with aspirin",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     clopidogrel.",
"    </p>",
"    <p>",
"     Potential side effects of cilostazol include headache, loose or soft stools, diarrhea, dizziness, and palpitations. Cilostazol is not used in patients with heart failure.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H88971068\">",
"     <span class=\"h3\">",
"      Naftidrofuryl",
"     </span>",
"     &nbsp;&mdash;&nbsp;Another medication, naftidrofuryl (Dusodril&reg;), has anti-spasmodic activity and also helps patients have more pain-free walking compared with taking placebos [",
"     <a class=\"abstract\" href=\"UTD.htm?14/35/14900/abstract/5\">",
"      5",
"     </a>",
"     ]. This medication is commonly used in Europe.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H393849\">",
"     <span class=\"h3\">",
"      Pentoxifylline",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pentoxifylline (Trental&reg;) has been available for many years for treatment of claudication, although studies of its effectiveness have shown mixed results. It is less effective than cilostazol, but may be used if cilostazol fails to reduce symptoms. Potential side effects include upset stomach, nausea, and vomiting.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H393857\">",
"     <span class=\"h3\">",
"      Ginkgo biloba",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of studies have suggested that ginkgo biloba may improve symptoms of claudication. However, most studies had a flawed design, making it difficult to conclude that ginkgo is safe and effective. In addition, herbal products are not monitored or regulated in the United States, raising concerns about purity and consistency of doses in some formulations. Ginkgo biloba, therefore, cannot be recommended for claudication based on the available scientific data.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H393865\">",
"     <span class=\"h3\">",
"      Ineffective treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chelation therapy (the repeated intravenous infusion of EDTA) and vitamin E supplementation have been investigated as treatments for claudication. However, studies have shown no benefit and these treatments are not recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H108753408\">",
"     <span class=\"h2\">",
"      Revascularization",
"     </span>",
"     &nbsp;&mdash;&nbsp;In selected patients with severe lifestyle-limiting claudication, particularly if medical therapy has been unsuccessful, your doctor may recommend a procedure to increase the amount of blood flow to the extremities. Revascularization procedures can be generally divided into two general categories: &ldquo;catheter-based&rdquo; procedures, such as balloon angioplasty with or without stenting, or &ldquo;surgery&rdquo;, such as bypass or endarterectomy. Increasingly, revascularization may involve a combination of multiple techniques and devices, called &ldquo;hybrid&rdquo; procedures, all sharing the objective of improving blood flow. The selection of revascularization technique depends upon a variety of factors, such as your particular anatomy, severity of symptoms, prior interventions, suitability for anesthesia, skill-set and experience of your physician, as well as your personal preferences. There is no &ldquo;standardized&rdquo; revascularization procedure for claudication.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Percutaneous angioplasty and stenting",
"     </span>",
"     &nbsp;&mdash;&nbsp;A percutaneous intervention (without incisions) is generally attempted before surgery since it is less invasive and has fewer cardiovascular risks. &nbsp;Percutaneous procedures are performed through a catheter placed in the groin region into the femoral artery. Balloon angioplasty involves threading a guidewire through the narrowed or blocked vessel. A deflated balloon is placed over the wire and the balloon is inflated and then deflated. This opens the vessel and allows blood to flow more freely.",
"    </p>",
"    <p>",
"     A stent is often used to hold the vessel open after angioplasty. A stent is an expandable tube made of a wire mesh. The goal of a stent is to prevent restenosis, meaning the vessel becomes narrowed again. Stents work better in some vessels compare with others.",
"    </p>",
"    <p>",
"     Angioplasty and stenting are most successful for treating single, short segment blockages, but advancements in technology have allowed treatment of multiple, longer and even completely blocked segments. However, restenosis is more common when longer or blocked segments are treated. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38921?source=see_link\">",
"      \"Percutaneous interventional procedures in the patient with lower extremity claudication\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Revascularization involves sewing in a graft (usually a vein, but sometimes man-made material) to go around (bypass) the narrowed or blocked area of the blood vessel, which improves blood flow to the rest of the leg. The best candidates for surgery are those who are under the age of 70 years, do not have diabetes, and have little disease in the vessels below the knee. Many people with diabetes or over age 70 years are able to have successful surgery, but it is important for these patients to understand that they have a higher risk for postoperative complications. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44376?source=see_link\">",
"      \"Indications for surgery in the patient with lower extremity claudication\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804361157\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29859616\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/49/34578?source=see_link\">",
"      Patient information: Peripheral artery disease and claudication (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/5/23635?source=see_link\">",
"      Patient information: Atherosclerosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30242?source=see_link\">",
"      Patient information: Doppler ultrasound (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/49/12051?source=see_link\">",
"      Patient information: Vasculitis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29859634\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=see_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link\">",
"      Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14486?source=see_link\">",
"      Clinical manifestations and evaluation of chronic critical limb ischemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44376?source=see_link\">",
"      Indications for surgery in the patient with lower extremity claudication",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link\">",
"      Medical management of claudication",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38921?source=see_link\">",
"      Percutaneous interventional procedures in the patient with lower extremity claudication",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/peripheralarterialdisease.html\">",
"      file://www.nlm.nih.gov/medlineplus/peripheralarterialdisease.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/health/dci/Diseases/pad/pad_what.html\">",
"      www.nhlbi.nih.gov/health/dci/Diseases/pad/pad_what.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.heart.org/HEARTORG/Conditions/More/PeripheralArteryDisease/About-Peripheral-Artery-Disease-PAD_UCM_301301_Article.jsp\">",
"      file://www.heart.org/HEARTORG/Conditions/More/PeripheralArteryDisease/About-Peripheral-Artery-Disease-PAD_UCM_301301_Article.jsp",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Vascular Disease Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.vdf.org/diseaseinfo/pad/\">",
"      www.vdf.org/diseaseinfo/pad/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Peripheral Arterial Disease (PAD) Coalition",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.padcoalition.org/\">",
"      www.padcoalition.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?14/35/14900/abstract/1-4,6\">",
"      1-4,6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 1, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?14/35/14900?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14900/abstract/1\">",
"      Meijer WT, Grobbee DE, Hunink MG, et al. Determinants of peripheral arterial disease in the elderly: the Rotterdam study. Arch Intern Med 2000; 160:2934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14900/abstract/2\">",
"      Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14900/abstract/3\">",
"      CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14900/abstract/4\">",
"      Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database Syst Rev 2000; :CD000990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14900/abstract/5\">",
"      De Backer TL, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication. Cochrane Database Syst Rev 2008; :CD001368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14900/abstract/6\">",
"      Mohler ER 3rd. Peripheral arterial disease: identification and implications. Arch Intern Med 2003; 163:2306.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f14_35_14900=[""].join("\n");
var outline_f14_35_14900=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           CLAUDICATION OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           PERIPHERAL ARTERY DISEASE RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           CLAUDICATION SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           CLAUDICATION DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           CLAUDICATION TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/23/6514\" title=\"figure 1\">",
"           Peripheral artery disease PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f14_35_14901="Resectoscope instruments";
var content_f14_35_14901=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hysteroscopy: resectoscopic instruments",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Roller ball. (B) Loop electrode. (C) Punctate electrode.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_35_14901=[""].join("\n");
var outline_f14_35_14901=null;
var title_f14_35_14902="Antihemophilic factor concentrates (human): Pediatric drug information";
var content_f14_35_14902=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Antihemophilic factor concentrates (human): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?0/12/198?source=see_link\">",
"    see \"Antihemophilic factor concentrates (human): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/24/23940?source=see_link\">",
"    see \"Antihemophilic factor concentrates (human): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F135729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hemofil M;",
"     </li>",
"     <li>",
"      Ko��te&reg;-DVI;",
"     </li>",
"     <li>",
"      Monoclate-P&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F135730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hemofil M",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihemophilic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Blood Product Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/12/198?source=see_link\">",
"      see \"Antihemophilic factor concentrates (human): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults: I.V.: Individualize dosage based on coagulation studies performed prior to and during treatment at regular intervals:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Hemophilia A: For every 1 international unit per kg body weight of AHF (human) administered, factor VIII level should increase by 2%; calculated dosage should be adjusted to the actual vial size",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Formula to calculate dosage required, based on desired increase in factor VIII (% of normal) (",
"     <b>",
"      Note:",
"     </b>",
"     This formula assumes that the patient's baseline AHF level is &lt;1%): International units required =  Body weight (kg) x 0.5 x desired increase in factor VIII (international units/dL or % of normal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hospitalized patients: 20-50 units/kg/dose; may be higher for special circumstances. Dose can be given every 12-24 hours and more frequently in special circumstances.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemophilia A with high titer of inhibitor antibody: 50-75 units/kg/hour has been given",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      General dosing guidelines",
"     </b>",
"     (consult individual product labeling for specific dosage recommendations):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minor hemorrhage (required peak postinfusion AHF level: 20% to 40%): 10-20 international units/kg; repeat every 12-24 hours for 1-3 days until bleeding is resolved or healing achieved; mild superficial or early hemorrhages may respond to a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate hemorrhage (required peak postinfusion AHF level: 30% to 60%): 15-30 international units/kg; repeat every 12-24 hours for &ge;3 days until pain and disability are resolved",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Alternatively (to achieve peak postinfusion AHF level: 50%) Initial: 25 international units/kg; maintenance: 10-15 international units/kg every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe/life-threatening hemorrhage (required peak postinfusion AHF level: 60% to 100%): 30-50 international units/kg; repeat every 8-24 hours until threat is resolved",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Alternatively (to achieve peak postinfusion AHF level: 80% to 100%): 40-50 international units/kg; maintenance: 20-25 international units/kg every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minor surgery (required peak postinfusion AHF level: Range 30% to 80%): 15-40 international units/kg; dose is highly dependent upon procedure and specific product recommendations; for some procedures, a single dose plus oral antifibrinolytic therapy within 1 hour is sufficient; in other procedures, may repeat dose every 12-24 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Major surgery (required peak pre- and postsurgery AHF level: 80% to 100%): 40-50 international units/kg; repeat every 8-24 hours depending on state of healing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prophylaxis: May also be given on a regular schedule to prevent bleeding",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F135714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemofil M: ~250 units, ~500 units, ~1000 units,  ~1700 units [contains albumin (human), mouse protein; packaging may contain natural rubber latex]. Supplied with diluent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ko��te&reg;-DVI: ~250 units, ~500 units, ~1000 units [contains albumin (human), aluminum, polysorbate 80]. Supplied with diluent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Monoclate-P&reg;: ~250 units, ~500 units, ~1000 units, ~1500 units [contains albumin (human), mouse protein]. Supplied with diluent.",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F135700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: I.V. administration only; see Stability for reconstitution and dosage preparation; administer through a separate line, do not mix with drugs or other I.V. fluids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum rate of administration is product dependent:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemofil&reg; M: 10 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Monoclate-P&reg;: 2 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Koate&reg;-DVI: Total dose may be given over 5-10 minutes; adjust administration rate based on patient response",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1051115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Storage: Store unopened vials under refrigeration 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); avoid freezing (to prevent damage to diluent vial)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemofil M: May also be stored at room temperature (&le;30&deg;C or 86&deg;F)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Koate&reg;-DVI: May also be stored at room temperature (&le;25&deg;C or 77&deg;F) for up to 6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Monoclate-P&reg;: May also be stored at room temperature (&le;30&deg;C or 86&deg;F) for up to 6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Reconstitution: If refrigerated, the dried concentrate and diluent should be warmed to room temperature before reconstitution; see individual product labeling for specific reconstitution guidelines; gently agitate or rotate vial after adding diluent, do not shake vigorously (",
"     <b>",
"      Note:",
"     </b>",
"     For Koate&reg;-DVI: Swirl vigorously without creating excessive foaming); use filter needle provided by manufacturer to draw product into syringe; use one filter needle per vial; do",
"     <b>",
"      not",
"     </b>",
"     refrigerate after reconstitution (precipitation may occur); administer within 3 hours after reconstitution;",
"     <b>",
"      Note:",
"     </b>",
"     Use plastic syringes, since AHF may stick to the surface of glass syringes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of hemorrhagic episodes in patients with hemophilia A (classical hemophilia); perioperative management of patients with hemophilia A; can provide therapeutic effects in patients with acquired factor VIII inhibitors &lt;10 Bethesda units/mL",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F11595784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Factor VIII may be confused with Factor XIII",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Confusion may occur due to the omitting of  &ldquo;Factor VIII&rdquo; from some product labeling. Review product contents carefully prior to dispensing any antihemophilic factor.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F135749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rare but important or life-threatening: Acute hemolytic anemia, AHF inhibitor development, allergic reactions (rare), anaphylaxis (rare), bleeding tendency increased, blurred vision, chest tightness, chills, fever, headache, hyperfibrinogenemia, jittery feeling, lethargy, nausea, somnolence, stinging at the infusion site, stomach discomfort, tingling, urticaria, vasomotor reactions with rapid infusion, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     All products: Hypersensitivity to any component (see table)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Antihemophilic factor, human (Method M, monoclonal purified); Hemofil M; Monoclate-P&reg;: Hypersensitivity to mouse protein",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Antihemophilic Factor (Human) [Factor VIII (Human)] Products",
"     </caption>",
"     <col align=\"left\" width=\"121\">",
"     </col>",
"     <col align=\"left\" width=\"129\">",
"     </col>",
"     <col align=\"left\" width=\"110\">",
"     </col>",
"     <col align=\"left\" width=\"130\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Product",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Preparation and Purification Methods",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Viral Inactivation",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Stabilizers and Excipients",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"top\">",
"      <tr>",
"       <td align=\"left\" colspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Note:",
"         </b>",
"         Source of all products is pooled human plasma.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Listed as a stabilizer in the product's package insert.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Hemofil M",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         &bull; Method M process",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Immunoaffinity chromatography using murine monoclonal antibody",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Ion exchange chromatography",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Organic solvent/detergent treatment",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         &bull; Albumin (human)",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Polyethylene glycol",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Histidine",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Glycine",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Mouse protein",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Tri-n-butyl phosphate",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Octoxynol 9",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Ko��te&reg;-DVI",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Purified from cold insoluble fraction of fresh-frozen plasma",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Gel permeation chromatography",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Organic solvent/detergent treatment",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Heat treatment (dry; in lyophilized form in final container; 80&deg;C x 72 hours)",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         &bull; Albumin (human)",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Polyethylene glycol",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Glycine",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Polysorbate 80",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Tri-n-butyl phosphate",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Calcium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Aluminum",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Histidine",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Monoclate-P&reg;",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Immunoaffinity chromatography using murine monoclonal antibody",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Heat treatment in aqueous solution (pasteurization; 60&deg;C x 10 hours)",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         &bull; Albumin (human)",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Sodium (300-450 millimoles/L)",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Calcium chloride",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Mannitol",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Histidine",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:0em;\">",
"         &bull; Hydrochloric acid and/or sodium hydroxide (pH adjustment)",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         &bull; Mouse protein",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clinical response to recommended doses may vary; dosage must be individualized based on coagulation studies (performed prior to treatment and at regular intervals during treatment) and clinical response. Human antihemophilic factor is prepared from pooled plasma and even with heat treated or other viral attenuated processes, the risk of viral transmission (ie, viral hepatitis, HIV, parvovirus B19, and theoretically, Creutzfeldt-Jacob disease agent) is not totally eradicated. Hepatitis B vaccination is recommended for all patients receiving human antihemophilic factor and hepatitis A vaccination is recommended for seronegative patients. [",
"     <b>",
"      Note:",
"     </b>",
"     The use of recombinant antihemophilic factor products (such as Advate, Helixate&reg; FS, Kogenate&reg; FS, Recombinate&trade;, or ReFacto&reg;) substantially decreases the risk of viral transmission because these products are biosynthetically prepared]. Progressive anemia and hemolysis may occur in individuals with blood groups A, B, and AB who receive large or frequent doses of human antihemophilic factor due to trace amounts of blood group A and B isohemagglutinins.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Formation of factor VIII inhibitors (neutralizing antibodies to AHF human) may occur; reported incidence is 3% to 52%; an increase of inhibitor antibody concentration is seen at 2-7 days, with peak concentrations at 1-3 weeks after therapy; children &lt;5 years of age are at greatest risk; higher doses of AHF may be needed if antibody is present; if antibody concentration is &gt;10 Bethesda units/mL, patients may not respond to larger doses and alternative treatment modalities may be needed; monitor patients appropriately. Allergic-type hypersensitivity reactions including anaphylaxis may occur; discontinue therapy immediately if urticaria, hives, hypotension, tightness of the chest, wheezing, dyspnea, faintness, or anaphylaxis develop; emergency treatment and resuscitative measures (eg, epinephrine, oxygen) may be needed. Products vary by preparation method (see table); final formulations contain human albumin",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1051111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemofil M contains natural rubber latex (in certain components of the product packaging) which may cause allergic reactions in susceptible individuals; avoid use in patients with allergy to latex. Ko��te&reg;-DVI contains polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. In premature neonates, thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). Infusion of polysorbate 80-containing solutions through polyvinyl chloride tubing may cause DEHP to leach into the solution; in immature animals, exposure to DEHP may adversely affect the development of the male reproductive tract.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6217988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F135710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F135722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. Safety and efficacy in pregnant women have not been established. Use during pregnancy only if clearly needed. Parvovirus B19 or hepatitis A, which may be present in plasma-derived products, may affect a pregnant woman more seriously than nonpregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1051119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bleeding; heart rate and blood pressure (before and during I.V. administration); AHF levels prior to and during treatment; monitor for development of inhibitor antibodies by clinical observation (eg, inadequate control of bleeding with adequate doses) and laboratory tests (eg, inhibitor level, Bethesda assay). In patients with blood groups A, B, or AB who receive large or frequent doses, monitor Hct, direct Coombs' test, and signs of intravascular hemolysis",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1051122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Plasma antihemophilic factor level:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Normal range: 50% to 150%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Level to prevent spontaneous hemorrhage: 5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Required peak postinfusion AHF activity in blood (as % of normal or units/dL plasma):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Early hemarthrosis, muscle bleed, or oral bleed: 20% to 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     More extensive hemarthrosis, muscle bleed, or hematoma: 30% to 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Life-threatening bleeds (such as head injury, throat bleed, severe abdominal pain): 80% to 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minor surgery, including tooth extraction: 60% to 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Major surgery: 80% to 100% (pre- and postoperative)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Factor VIII is a protein in normal plasma which is necessary for clot formation and maintenance of hemostasis; it activates factor X in conjunction with activated factor IX; activated factor X converts prothrombin to thrombin, which converts fibrinogen to fibrin and with factor XIII forms a stable clot",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1051126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maximum effect: 1-2 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1051127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Does not readily cross the placenta",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 4-24 hours; mean = 12 hours (biphasic)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1051117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/24/23940?source=see_link\">",
"      see \"Antihemophilic factor concentrates (human): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     This medication can only be given intravenously. Stop taking antihemophilic factor human and notify physician immediately if any of the following signs or symptoms of an allergic (hypersensitivity) reaction occur: Itching, hives, low blood pressure, tightness in chest, wheezing, or anaphylaxis. Wear identification indicating that you have a hemophilic condition.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1051129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     One international unit of AHF is equal to the factor VIII activity present in 1 mL of normal human plasma. If bleeding is not controlled with adequate dose, test for the presence of factor VIII inhibitor; larger doses of AHF may be therapeutic with inhibitor titers &lt;10 Bethesda units/mL; it may not be possible or practical to control bleeding if inhibitor titers &gt;10 Bethesda units/mL (due to the very large AHF doses required); other treatments [eg, antihemophilic factor (porcine), factor IX complex concentrates, recombinant factor VIIa, or anti-inhibitor coagulant complex] may be needed in patients with inhibitor titers &gt;10 Bethesda units/mL.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alade SL, Brown RE, and Paquet A Jr, \"Polysorbate 80 and E-Ferol Toxicity,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1986, 77(4):593-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/35/14902/abstract-text/3960626/pubmed\" id=\"3960626\" target=\"_blank\">",
"        3960626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control (CDC), \"Unusual Syndrome With Fatalities Among Premature Infants: Association With a New Intravenous Vitamin E Product,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1984, 33(14):198-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/35/14902/abstract-text/6423951/pubmed\" id=\"6423951\" target=\"_blank\">",
"        6423951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liesner RJ, &ldquo;Prophylaxis in Haemophilic Children,&rdquo;",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 1997, 8(Suppl 1):S7-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/35/14902/abstract-text/9351529/pubmed\" id=\"9351529\" target=\"_blank\">",
"        9351529",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scharrer I, Bray GL, and Neutzling O, &ldquo;Incidence of Inhibitors in Haemophilia A Patients--A Review of Recent Studies of Recombinant and Plasma-Derived Factor VIII Concentrates,&rdquo;",
"      <i>",
"       Haemophilia",
"      </i>",
"      , 1999, 5(3):145-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/35/14902/abstract-text/10444280/pubmed\" id=\"10444280\" target=\"_blank\">",
"        10444280",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shord SS and Lindley CM, &ldquo;Coagulation Products and Their Uses,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2000, 57(15):1403-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/35/14902/abstract-text/10938981/pubmed\" id=\"10938981\" target=\"_blank\">",
"        10938981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12748 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-4EAA1F1B94-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_35_14902=[""].join("\n");
var outline_f14_35_14902=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135729\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135730\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051120\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051113\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135714\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135700\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051124\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051115\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051123\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595784\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135749\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051128\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051112\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051111\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298757\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6217988\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135710\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135722\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051119\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051122\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051110\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051126\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051127\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051117\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051129\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12748\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12748|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/12/198?source=related_link\">",
"      Antihemophilic factor concentrates (human): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/24/23940?source=related_link\">",
"      Antihemophilic factor concentrates (human): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_35_14903="Metatarsal and toe fractures in children";
var content_f14_35_14903=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Metatarsal and toe fractures in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/35/14903/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/35/14903/contributors\">",
"     Kathy Boutis, MD, FRCPC, FAAP, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/35/14903/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/35/14903/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/35/14903/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/35/14903/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/35/14903/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most pediatric foot fractures are minor, involve the metatarsal or phalangeal bones, and require a short period of immobilization [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14903/abstract/1\">",
"     1",
"    </a>",
"    ]. Although recovery is usually uneventful, specific metatarsal and toe fractures (eg, Jones fractures, Salter-Harris III or IV fractures of the great toe) require early orthopedic care to avoid significant long-term complications.",
"   </p>",
"   <p>",
"    The management of metatarsal and toe fractures in children will be reviewed here. Other foot fractures in children and toe fractures in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35079?source=see_link\">",
"     \"Foot fractures (other than metatarsal or phalangeal) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44358?source=see_link\">",
"     \"Toe fractures in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metatarsal fractures account for the majority of pediatric foot fractures. In children &le;5 years of age, the first metatarsal is most commonly injured [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14903/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In older children, the base of the fifth metatarsal is more frequent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14903/abstract/2\">",
"     2",
"    </a>",
"    ]. Approximately one-third of metatarsal fractures involve the shaft or distal portion of the metatarsal [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14903/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Toe fractures also occur commonly in children. The first phalanx (great toe) is most frequently involved. Distal phalangeal fractures may be complicated by nail bed injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RELEVANT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;From an anatomic perspective, the foot is divided into three regions (",
"    <a class=\"graphic graphic_figure graphicRef78924 graphicRef61079 graphicRef71857 \" href=\"UTD.htm?30/38/31338\">",
"     figure 1A-C",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Forefoot &ndash; Metatarsal and phalangeal bones",
"     </li>",
"     <li>",
"      Midfoot &ndash; Navicular, cuboid, and cuneiform bones",
"     </li>",
"     <li>",
"      Hindfoot &ndash; Talus and calcaneus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Lisfranc joint separates the forefoot from the midfoot. The Chopart joint divides the hindfoot and the midfoot.",
"   </p>",
"   <p>",
"    Additional foot anatomy common to children and adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12614?source=see_link&amp;anchor=H3#H3\">",
"     \"Metatarsal shaft fractures\", section on 'Relevant anatomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44358?source=see_link&amp;anchor=H2#H2\">",
"     \"Toe fractures in adults\", section on 'Relevant anatomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pediatric toe and forefoot differ from the adult foot due to the presence of growth plates (",
"    <a class=\"graphic graphic_figure graphicRef79444 \" href=\"UTD.htm?26/18/26918\">",
"     figure 2",
"    </a>",
"    ). Injury to the growth plate may rarely lead to growth arrest and permanent deformity. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These growth plates typically close around age 16 years in females and age 18 years in males. Thus, management of metatarsal and toe fractures in older adolescents is the same as for adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44358?source=see_link\">",
"     \"Toe fractures in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of metatarsal and toe fractures are [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14903/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Axial loading (eg, stubbing a toe)",
"     </li>",
"     <li>",
"      Abduction injury, often involving the fifth digit",
"     </li>",
"     <li>",
"      Crush injury caused by a heavy object falling on the foot or motor vehicle tire running over the foot",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less commonly, joint hyperextension or hyperflexion can lead to spiral or avulsion fractures. Crush injuries are more likely to involve soft tissue and neurovascular damage.",
"   </p>",
"   <p>",
"    Metatarsal stress fractures may occur in adolescents who rapidly undertake heavy physical activity or in those who are involved in repetitive intense training. This injury commonly affects the second metatarsal and reflects bone matrix fatigue with bone resorption that exceeds the rate of remodeling and repair [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14903/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children typically present for evaluation because of pain and difficulty walking.",
"   </p>",
"   <p>",
"    Ecchymosis and swelling are usually present and occur within the first few hours after injury. Palpation along the foot or digit frequently reveals point tenderness at the fracture site. However, the dorsum of the foot or toe may be diffusely swollen and tender, making it difficult to pinpoint the fracture location by examination alone.",
"   </p>",
"   <p>",
"    Of note, tenderness at the base of the fifth metatarsal after an inversion injury is highly suggestive of a fracture and may not be accompanied by significant swelling soon after the injury.",
"   </p>",
"   <p>",
"    With displaced fractures and dislocations, deformity is usually apparent. Rotational deformity is assessed by examining the orientation of the nail bed of the fractured toe. Rotational deformity is present if the nail bed does not lie in the same plane as that of the corresponding toe on the opposite foot [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14903/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In all cases, capillary refill should be assessed and the skin of the digit carefully inspected, seeking lacerations and devitalized skin. Any wound should be carefully examined to exclude communication with the fracture site (ie, an open fracture). Devitalized skin may slough and convert a closed fracture into an open one. Injury to surrounding soft tissue including the nail and nail bed can occur, particularly with crush injuries.",
"   </p>",
"   <p>",
"    Subungual hematoma is often a marker of an underlying distal phalanx fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14903/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/8/9351?source=see_link\">",
"     \"Subungual hematoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that patients with significant pain, swelling, or deformity of the forefoot or toe receive plain radiographs, including anterior-posterior, lateral, and oblique views [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14903/abstract/4\">",
"     4",
"    </a>",
"    ]. Growth plate injuries are described using the Salter-Harris classification system (",
"    <a class=\"graphic graphic_figure graphicRef54582 \" href=\"UTD.htm?20/55/21361\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Radiographic findings include growth plate, cortical, and buckle fractures. Salter-Harris I through Salter-Harris III fractures are most common in the great toe (",
"    <a class=\"graphic graphic_figure graphicRef54582 \" href=\"UTD.htm?20/55/21361\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20104?source=see_link&amp;anchor=H4#H4\">",
"     \"General principles of fracture management: Fracture patterns and description in children\", section on 'Fracture patterns in children'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial radiographs are typically normal in children with Salter-Harris I fractures or metatarsal stress fractures. Repeat radiographs two weeks later show periosteal reaction and callus formation. Bone scan is helpful in doubtful cases, especially for the diagnosis of early stress fractures in adolescents.",
"   </p>",
"   <p>",
"    The following normal variants may be mistaken for fractures on radiograph (",
"    <a class=\"graphic graphic_figure graphicRef78924 graphicRef61079 graphicRef71857 \" href=\"UTD.htm?30/38/31338\">",
"     figure 1A-C",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sesamoid bones of the first metatarsal",
"     </li>",
"     <li>",
"      Accessory ossicles (eg, os trigonum, os subfibulare)",
"     </li>",
"     <li>",
"      Bipartite epiphysis of the great toe (normal variant)",
"     </li>",
"     <li>",
"      Os vesalianum or apophyseal ossification center at the base of the fifth metatarsal. The apophyseal center appears around eight years of age. Fusion usually is complete by 12 years in girls and 15 years in boys. This is typically distinguished from fracture due to the longitudinal orientation of the ossified apophysis, absence of local tenderness, swelling, or separation of this ossification center from the base of the fifth metatarsal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Emergency conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should obtain emergent orthopedic consultation in the patients with the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Open fractures &ndash; These injuries are usually crush or machine-related, often involving a lawn mower, chainsaw, or heavy weight. They frequently involve multiple digits [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14903/abstract/1,5\">",
"       1,5",
"      </a>",
"      ]. Patients who have sustained these injuries should be managed in accordance with the principles of advanced trauma life support (ATLS), including a thorough examination of the entire lower extremity (",
"      <a class=\"graphic graphic_figure graphicRef64241 \" href=\"UTD.htm?42/51/43834\">",
"       figure 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"       \"Trauma management: Approach to the unstable child\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Open fractures are frequently grossly contaminated wounds and should undergo empiric antibiotic treatment with a thorough operative irrigation and debridement (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/61/31701?source=see_link\">",
"       cefuroxime",
"      </a>",
"      50",
"      <span class=\"nowrap\">",
"       mg/kg;",
"      </span>",
"      maximum single dose 1.5 grams). In addition, tetanus prophylaxis should be provided, as needed (",
"      <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=see_link&amp;anchor=H17#H17\">",
"       \"Minor wound preparation and irrigation\", section on 'Irrigation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Compartment syndrome &ndash; Compartment syndrome presents with marked swelling and pain out of proportion to the degree of injury. Pallor, paresthesias, and pulselessness are late signs. Emergent orthopedic consultation is indicated. Once the clinician suspects an acute compartment syndrome, compartment pressures must be measured to determine whether they are elevated, or a clinical decision to perform a fasciotomy is needed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link&amp;anchor=H15#H15\">",
"       \"Acute compartment syndrome of the extremities\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vascular compromise &ndash; Vascular compromise following forefoot fractures most commonly occurs due to compartment syndrome as direct vascular insufficiency due to a displaced fracture is rare in this region because of the robust collateral circulation to the toes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Analgesia and initial care",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with no signs of neurovascular compromise, initial therapy consists of measures to reduce swelling and pain management.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The affected foot should be elevated above the level of the heart. An insulated ice pack should be applied to help manage swelling.",
"     </li>",
"     <li>",
"      Oral analgesia (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg;",
"      </span>",
"      maximum single dose 800 mg) may suffice for patients with mild pain who have suffered a nondisplaced metatarsal or toe fracture, especially a Salter-Harris I fracture or buckle fracture. Parenteral analgesia (eg, intravenous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32233?source=see_link\">",
"       morphine",
"      </a>",
"      0.1 to 0.15",
"      <span class=\"nowrap\">",
"       mg/kg;",
"      </span>",
"      maximum single dose: 10 mg) is most appropriate for initial pain control in patients with moderate to severe pain and should be given prior to radiographic evaluation. We suggest that the clinician avoid the oral route for patients likely to require sedation or general anesthesia for fracture reduction or repair.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Injury to the nail bed",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nail bed injuries are seen frequently with distal phalanx fractures sustained from a fallen object. Subungual hematomas can cause severe pain, often indicate the presence of a distal phalanx fracture, and should be drained within 24 hours if painful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/8/9351?source=see_link\">",
"     \"Subungual hematoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of nail bed lacerations is controversial. Some recommend removing the nail to detect the presence of a laceration if there is significant traumatic deformity of the nail or a sizable subungual hematoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14903/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. They advocate laceration repair with absorbable sutures, following irrigation, if the wound is less than eight hours old [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14903/abstract/6\">",
"     6",
"    </a>",
"    ]. The primary justification for this approach lies in the high correlation between nail bed injury and distal phalanx fracture, with the consequent risk of osteomyelitis associated with open fractures. Others, citing data showing no difference in outcome, advocate against removal of the nail and nail bed laceration repair [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14903/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. We do not advocate routine nail removal and nail bed laceration repair, and perform this procedure only when obvious malalignment of the nail bed laceration is present.",
"   </p>",
"   <p>",
"    Since a distal phalanx fracture with a subungual hematoma is technically an open fracture, some clinicians prescribe prophylactic oral antibiotics for five to seven days (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/5/30804?source=see_link\">",
"     cephalexin",
"    </a>",
"    33",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every eight hours; maximum single dose 1 gram).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ORTHOPEDIC CONSULTATION OR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should obtain prompt orthopedic consultation for children with any of the following metatarsal or toe fractures:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fractures with vascular compromise or suspected compartment syndrome",
"     </li>",
"     <li>",
"      Open fractures of the proximal phalanx or metatarsal bones",
"     </li>",
"     <li>",
"      Displaced Salter-Harris I or II physeal fractures",
"     </li>",
"     <li>",
"      Salter-Harris III, IV, or V fractures",
"     </li>",
"     <li>",
"      Metatarsal fractures that are completely displaced or have more than 20 degrees of angulation",
"     </li>",
"     <li>",
"      Acute fractures of the proximal diaphysis (Jones fracture)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DEFINITIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment will vary according to the location and characteristics of the fracture. Treatment recommendations for metatarsal and toe fractures in children are guided by case series and empiric observation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Metatarsal fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;These fractures are typically managed nonoperatively in skeletally immature children because of the extensive correction of deformity that occurs with remodeling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Nondisplaced",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nondisplaced and minimally displaced solitary metatarsal fractures may be treated with a cast boot, posterior splint, or a short leg walking cast. These patients should be evaluated by an orthopedist with pediatric expertise within one week to 10 days. Casting should be avoided in patients with marked foot swelling to avoid the development of a tight cast or compartment syndrome.",
"   </p>",
"   <p>",
"    Children with multiple nondisplaced or minimally displaced metatarsal fractures should be placed in a non-weight bearing splint or cast and referred to an orthopedist with pediatric expertise within one week. Any proximal metatarsal fractures should be evaluated for possible injury to the tarsometatarsal joint complex (",
"    <a class=\"graphic graphic_figure graphicRef78924 graphicRef61079 graphicRef71857 \" href=\"UTD.htm?30/38/31338\">",
"     figure 1A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14903/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Duration of immobilization ranges from three to six weeks. Younger children require less total immobilization time than older children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Displaced",
"    </span>",
"    &nbsp;&mdash;&nbsp;Completely displaced metatarsal fractures and those with more than 20 degrees of angulation in children over eight years of age warrant closed reduction followed by immobilization with a non-weight bearing short leg cast or short leg splint. Sedation in the emergency department usually suffices to control the pain of the fracture reduction. Follow-up orthopedic evaluation should occur within one week. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Duration of immobilization depends on the age of the child and whether percutaneous pinning is required and ranges from three to six weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Proximal fifth metatarsal",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, avulsion of the base of the fifth metatarsal may be confused with an apophyseal center called the os vesalianum (",
"    <a class=\"graphic graphic_figure graphicRef78924 graphicRef61079 graphicRef71857 \" href=\"UTD.htm?30/38/31338\">",
"     figure 1A-C",
"    </a>",
"    ). Avulsion fractures will have localized tenderness at the base of the fifth metatarsal.",
"   </p>",
"   <p>",
"    As in adults, avulsion fractures arising from the tuberosity of the proximal fifth metatarsal heal well, typically within four weeks, with symptomatic and supportive treatment (eg, stiff soled shoe or cast boot, ice application, elevation, and rest) (",
"    <a class=\"graphic graphic_figure graphicRef56014 \" href=\"UTD.htm?38/52/39759\">",
"     figure 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/54/873?source=see_link&amp;anchor=H4#H4\">",
"     \"Proximal fifth metatarsal fractures\", section on 'Tuberosity (styloid) avulsion fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In adolescents, an apophysis (growth center associated with a tendon insertion) can often be seen in the tuberosity. It always lies parallel to the long axis of the fifth metatarsal and has smooth, corticated edges (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56985 \" href=\"UTD.htm?38/49/39711\">",
"     image 1",
"    </a>",
"    ). Apophysitis, an inflammation of the apophysis, may develop in active adolescents. This self-limiting condition resolves with completion of growth and is treated with rest.",
"   </p>",
"   <p>",
"    Acute fractures of the proximal diaphysis (Jones fracture), first described by Jones in 1902, occur within 1.5 cm of the metatarsal tuberosity and extend towards or into the intermetatarsal joint (",
"    <a class=\"graphic graphic_figure graphicRef56014 \" href=\"UTD.htm?38/52/39759\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69829 \" href=\"UTD.htm?12/39/12912\">",
"     figure 6",
"    </a>",
"    ). The area where these fractures occur is referred to using different terms, including \"proximal diaphysis\" and \"junction of the metaphysis and diaphysis.\" As in adults, operative repair typically results in more rapid healing (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67602 \" href=\"UTD.htm?37/3/37942\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54742 \" href=\"UTD.htm?3/32/3588\">",
"     image 3",
"    </a>",
"    ). Initial care consists of immobilization with a below-knee non-weight bearing cast or splint and orthopedic consultation within one week. Symptomatic nonunion can occur frequently in children with a Jones fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14903/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/54/873?source=see_link&amp;anchor=H15#H15\">",
"     \"Proximal fifth metatarsal fractures\", section on 'Acute fractures of the proximal diaphysis (Jones fracture)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Stress fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;These fractures most frequently affect young athletes (eg, long distance runners, gymnasts) and most commonly occur in the neck of the second metatarsal. They usually respond well to cessation of the causative activity for four to eight weeks. Crutches and partial weight bearing for several weeks may be helpful in patients who have mild to moderate pain with walking. A short leg cast with non-weight bearing is appropriate for patients with severe pain. Metatarsal stress fractures are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33747?source=see_link\">",
"     \"Stress fractures of the metatarsal shaft\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although relatively uncommon, stress fractures of the proximal diaphysis of the fifth metatarsal have high rates of nonunion. They generally occur as a result of repetitive stress. We advise early referral to an orthopedist with pediatric expertise. These injuries are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/54/873?source=see_link&amp;anchor=H29#H29\">",
"     \"Proximal fifth metatarsal fractures\", section on 'Stress fractures of the proximal diaphysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Toe fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nondisplaced toe fractures heal rapidly within three to four weeks. Treatment includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Strapping of the injured toe to its neighboring toe (buddy taping) (",
"      <a class=\"graphic graphic_figure graphicRef74291 \" href=\"UTD.htm?41/25/42397\">",
"       figure 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ice, rest, and elevation above the level of the heart to reduce swelling and pain",
"     </li>",
"     <li>",
"      Ambulation with a stiff soled shoe or cast boot",
"     </li>",
"     <li>",
"      Analgesia as needed with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every four hours; Maximum single dose 1 gram) or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every six hours; Maximum single dose 800 mg)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Follow-up with the patient's primary care provider or an orthopedic surgeon may occur in one to two weeks.",
"   </p>",
"   <p>",
"    Salter-Harris III or IV fractures of the proximal phalanx of the big toe are often intraarticular. If more than one-third of the joint surface is involved or if the displacement is more than 2 to 3 mm, then the clinician should urgently consult an orthopedist with pediatric expertise to perform closed or open reduction with percutaneous pinning [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14903/abstract/11\">",
"     11",
"    </a>",
"    ]. Healing may require up to eight weeks.",
"   </p>",
"   <p>",
"    Open fractures of the proximal phalanxes warrant urgent orthopedic consultation for operative debridement and alignment. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Emergency conditions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malunion, nonunion, and growth arrest are rare complications of metatarsal fractures in children (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57130 \" href=\"UTD.htm?1/13/1239\">",
"     image 4",
"    </a>",
"    ). Salter-Harris III or IV fractures of the great toe may cause joint stiffness or growth arrest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children rapidly and fully recover from metatarsal or toe fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/22/355?source=see_link\">",
"       \"Patient information: Toe fracture (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metatarsal fractures account for the majority of pediatric foot fractures. Toe fractures are also common in children. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most frequent causes of metatarsal and toe fractures are (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Mechanism of injury'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Axial loading (eg, stubbing a toe)",
"     </li>",
"     <li>",
"      Abduction injury, often involving the fifth digit",
"     </li>",
"     <li>",
"      Crush injury caused by a heavy object falling on the foot or motor vehicle tire running over the foot",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Clinical findings and imaging",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ecchymosis and swelling are usually present and occur within the first few hours after injury. Palpation along the foot or digit frequently reveals point tenderness at the fracture site. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical presentation and examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tenderness at the base of the fifth metatarsal after an inversion injury is highly suggestive of a fracture. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical presentation and examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Subungual hematomas after trauma are often markers of an underlying distal phalanx fracture. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/8/9351?source=see_link\">",
"       \"Subungual hematoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that patients with significant pain, swelling or deformity of the forefoot or toe receive plain radiographs, including anterior-posterior, lateral, and oblique views. Common injury patterns include growth plate (",
"      <a class=\"graphic graphic_figure graphicRef54582 \" href=\"UTD.htm?20/55/21361\">",
"       figure 3",
"      </a>",
"      ), buckle, and cortical fractures. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinician should obtain emergent orthopedic consultation in patients with vascular compromise, compartment syndrome, or open fractures of the metatarsal bone or proximal phalanx. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Emergency conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with no signs of neurovascular compromise, initial therapy consists of analgesia and measures to reduce swelling and pain, including evacuation of a painful subungual hematoma. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Analgesia and initial care'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/8/9351?source=see_link\">",
"       \"Subungual hematoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The clinician should obtain urgent orthopedic consultation, generally within one to two days, for children with any of the following metatarsal or toe fractures (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Indications for orthopedic consultation or referral'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Displaced Salter-Harris I or II physeal fractures",
"     </li>",
"     <li>",
"      Salter-Harris III, IV, or V fractures",
"     </li>",
"     <li>",
"      Metatarsal fractures that are completely displaced or have more than 20 degrees of angulation",
"     </li>",
"     <li>",
"      Acute fractures of the proximal diaphysis (Jones fracture)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nondisplaced and minimally displaced solitary metatarsal fractures may be treated with a cast boot, posterior splint, or a short leg walking cast. These patients should be evaluated by an orthopedist with pediatric expertise within one week to 10 days. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Nondisplaced'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nondisplaced toe fractures heal rapidly within three to four weeks. Treatment includes (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Toe fractures'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Strapping of the injured toe to its neighboring toe (buddy taping) (",
"      <a class=\"graphic graphic_figure graphicRef74291 \" href=\"UTD.htm?41/25/42397\">",
"       figure 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ice, rest, and elevation above the level of the heart to reduce swelling and pain",
"     </li>",
"     <li>",
"      Ambulation with a stiff soled shoe or cast boot",
"     </li>",
"     <li>",
"      Oral analgesia, as needed (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      [15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every four hours; maximum single dose 1 gram] or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      [10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every six hours; maximum single dose 800 mg])",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Definitive treatment for displaced fractures, proximal fifth metatarsal fractures, growth plate fractures, or stress fractures varies according to the location and characteristics of the fracture. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Definitive management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Jarvis JG, Moroz PJ. Fractures and dislocations of the foot. In: Fractures in Children, 6th, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1129.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14903/abstract/2\">",
"      Singer G, Cichocki M, Schalamon J, et al. A study of metatarsal fractures in children. J Bone Joint Surg Am 2008; 90:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14903/abstract/3\">",
"      Owen RJ, Hickey FG, Finlay DB. A study of metatarsal fractures in children. Injury 1995; 26:537.",
"     </a>",
"    </li>",
"    <li>",
"     Swischuk LE. Emergency Imaging of the Acutely Ill or Injured Child, 4th, Lippincott Williams &amp; Wilkins, Philadelphia 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14903/abstract/5\">",
"      Hatch RL, Hacking S. Evaluation and management of toe fractures. Am Fam Physician 2003; 68:2413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14903/abstract/6\">",
"      Schnaue-Constantouris EM, Birrer RB, Grisafi PJ, Dellacorte MP. Digital foot trauma: emergency diagnosis and treatment. J Emerg Med 2002; 22:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14903/abstract/7\">",
"      Zook EG, Guy RJ, Russell RC. A study of nail bed injuries: causes, treatment, and prognosis. J Hand Surg Am 1984; 9:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14903/abstract/8\">",
"      Simon RR, Wolgin M. Subungual hematoma: association with occult laceration requiring repair. Am J Emerg Med 1987; 5:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14903/abstract/9\">",
"      Seaberg DC, Angelos WJ, Paris PM. Treatment of subungual hematomas with nail trephination: a prospective study. Am J Emerg Med 1991; 9:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14903/abstract/10\">",
"      Roser SE, Gellman H. Comparison of nail bed repair versus nail trephination for subungual hematomas in children. J Hand Surg Am 1999; 24:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14903/abstract/11\">",
"      Ribbans WJ, Natarajan R, Alavala S. Pediatric foot fractures. Clin Orthop Relat Res 2005; :107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14903/abstract/12\">",
"      Herrera-Soto JA, Scherb M, Duffy MF, Albright JC. Fractures of the fifth metatarsal in children and adolescents. J Pediatr Orthop 2007; 27:427.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6548 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-2D9DC08A38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_35_14903=[""].join("\n");
var outline_f14_35_14903=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RELEVANT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL PRESENTATION AND EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Emergency conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Analgesia and initial care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Injury to the nail bed",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INDICATIONS FOR ORTHOPEDIC CONSULTATION OR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DEFINITIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Metatarsal fractures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Nondisplaced",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Displaced",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Proximal fifth metatarsal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Stress fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Toe fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Clinical findings and imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6548\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6548|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/49/39711\" title=\"diagnostic image 1\">",
"      Normal fifth metatarsal apophysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/3/37942\" title=\"diagnostic image 2\">",
"      Jones fracture operative healing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/32/3588\" title=\"diagnostic image 3\">",
"      Jones fracture nonoperative healing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/13/1239\" title=\"diagnostic image 4\">",
"      Metatarsal fracture nonunion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6548|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/7/30835\" title=\"figure 1A\">",
"      Foot anatomy lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/40/38530\" title=\"figure 1B\">",
"      Foot anatomy medial view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/20/2375\" title=\"figure 1C\">",
"      Foot anatomy superior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/18/26918\" title=\"figure 2\">",
"      Growth plate anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/55/21361\" title=\"figure 3\">",
"      Salter-Harris classification system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/51/43834\" title=\"figure 4\">",
"      Initial trauma management in the severely injured child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/52/39759\" title=\"figure 5\">",
"      Proximal fifth metatarsal fracture zones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/39/12912\" title=\"figure 6\">",
"      Detailed anatomy fifth metatarsal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/25/42397\" title=\"figure 7\">",
"      Buddy taping",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6548|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8013\" title=\"table 1\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35079?source=related_link\">",
"      Foot fractures (other than metatarsal or phalangeal) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20104?source=related_link\">",
"      General principles of fracture management: Fracture patterns and description in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12614?source=related_link\">",
"      Metatarsal shaft fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32567?source=related_link\">",
"      Minor wound preparation and irrigation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/22/355?source=related_link\">",
"      Patient information: Toe fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/54/873?source=related_link\">",
"      Proximal fifth metatarsal fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33747?source=related_link\">",
"      Stress fractures of the metatarsal shaft",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/8/9351?source=related_link\">",
"      Subungual hematoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44358?source=related_link\">",
"      Toe fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_35_14904="Treatment of retroperitoneal fibrosis";
var content_f14_35_14904=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of retroperitoneal fibrosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/35/14904/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/35/14904/contributors\">",
"     Augusto Vaglio, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/35/14904/contributors\">",
"     Alessandra Palmisano, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/35/14904/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/35/14904/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/35/14904/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/35/14904/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/35/14904/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retroperitoneal fibrosis, also referred to as Ormond's disease, is an uncommon but treatable cause of obstructive uropathy. This disorder involves chronic inflammation and fibroblast proliferation with excessive extracellular matrix deposition. Untreated patients may develop severe complications or progress to end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retroperitoneal fibrosis is also sometimes associated with venous or arterial occlusion due to compression, or abdominal aortic aneurysms if in the setting of chronic periaortitis. In addition to medical therapy for the retroperitoneal fibrosis, these situations may require endovascular or surgical management. The management of these issues requires consultation with the appropriate specialists. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34136?source=see_link\">",
"     \"Clinical manifestations and diagnosis of retroperitoneal fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of idiopathic retroperitoneal fibrosis is reviewed here. The clinical manifestations, pathogenesis, and diagnosis of this disorder are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34136?source=see_link\">",
"     \"Clinical manifestations and diagnosis of retroperitoneal fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of therapy are to relieve the obstruction caused by fibrosis, stop the progression of the fibrotic process, and to prevent recurrence.",
"   </p>",
"   <p>",
"    If the retroperitoneal fibrosis is due to a secondary cause (",
"    <a class=\"graphic graphic_table graphicRef74731 \" href=\"UTD.htm?12/44/13003\">",
"     table 1",
"    </a>",
"    ), treatment is aimed at the underlying etiology. If the disease is idiopathic, we initiate immunosuppressive therapy.",
"   </p>",
"   <p>",
"    Although some patients may respond to medical therapy within a few weeks, the response is unpredictable, and continued obstruction of the urinary tract may cause irreversible damage. Thus, if significant obstruction of the urinary tract is present, immediate relief of obstruction is advised, using either an open surgical, percutaneous, or endoureteral approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24276?source=see_link\">",
"     \"Recovery of renal function after relief of urinary tract obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, procedures to relieve obstruction may be associated with significant risks and complications, including ureteric leakage, thromboembolism, and recurrent fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, patients who have mild, unilateral hydronephrosis but who do not have significant impairment in renal function can be closely followed with medical therapy alone (eg, with plasma creatinine concentration and renal ultrasound), and then later referred for surgical decompression of the urinary tract if there is deterioration of kidney function or no improvement or worsening of the hydronephrosis. In most cases, the initial approach will combine upper urinary tract decompression and medical therapy.",
"   </p>",
"   <p>",
"    A variety of medical therapies, including glucocorticoids, other immunosuppressive agents, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , used alone or in combination, are available to treat idiopathic retroperitoneal fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/1,3-7\">",
"     1,3-7",
"    </a>",
"    ]. Glucocorticoids are the mainstay of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INTERVENTION IN PATIENTS WITH URINARY TRACT OBSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with renal failure due to obstruction of the urinary tract, or if one kidney is severely obstructed even if renal function is normal, should undergo upper urinary tract decompression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84999994\">",
"    <span class=\"h2\">",
"     Selection of an interventional procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reversal of urinary tract obstruction in retroperitoneal fibrosis can be performed by cystoscopy with placement of in-dwelling double-J stents situated in the renal pelvis and bladder, percutaneously with placement of percutaneous nephrostomy tubes, or via an open approach [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/5\">",
"     5",
"    </a>",
"    ]. There have been no studies that have compared the efficacy of these procedures in this setting. Percutaneous nephrostomy allows monitoring the response to therapy with descending ureterography, while endoureteral stents may be associated with a better quality of life.",
"   </p>",
"   <p>",
"    Some authorities have advocated an initial open surgical approach in all patients since it can provide simultaneous relief of mechanical obstruction in combination with an open biopsy and exploration to exclude malignancies (eg, lymphoma, other primary retroperitoneal cancer, or metastatic cancer) as the etiology of the fibrotic process.",
"   </p>",
"   <p>",
"    However, patients who have a typical localization of the fibrotic mass and no clinical or laboratory indicators of a malignant process are unlikely to require an open biopsy or open surgery if the mass regresses sufficiently with medical therapy to relieve the obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34136?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations and diagnosis of retroperitoneal fibrosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, we believe open surgery should be reserved for the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Technical difficulties or complications with other cystoscopic or endoscopic obstruction-relieving maneuvers",
"     </li>",
"     <li>",
"      Radiological, laboratory or clinical findings suggesting underlying malignancy, to obtain a definitive diagnosis",
"     </li>",
"     <li>",
"      Lack of regression of the retroperitoneal mass after medical therapy, with persistent encasement of the ureters or other structures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When surgery is performed, it consists of open exploration with ureterolysis, although laparoscopy has also been reported as a feasible approach and may be associated with a shorter hospital stay and reduced need for blood transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/5,8\">",
"     5,8",
"    </a>",
"    ]. After ureterolysis is accomplished, the encased ureters are manipulated to prevent recurrent obstruction. Different techniques have been used either alone or in combination [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wrapping the ureters with omental fat. This serves as a barrier to prevent encasement by fibrous tissue, and may promote revascularization of the ureters (the process of removing fibrotic tissue devascularizes the ureters) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. Based on this benefit, we favor this approach if surgery is required.",
"     </li>",
"     <li>",
"      Transplantation of the ureters to an intraperitoneal position.",
"     </li>",
"     <li>",
"      Transposition of the ureters laterally, with interposition of retroperitoneal fat between the ureters and the fibrous tissue",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Monitoring the response to interventional therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediately postprocedure, a renal ultrasound is often done to ascertain that the urinary tract obstruction was relieved. If a procedure has been deferred, sequential ultrasonography is performed every two to four weeks to monitor for progression of obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MEDICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical therapy of retroperitoneal fibrosis depends upon whether it is secondary or idiopathic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11676078\">",
"    <span class=\"h2\">",
"     Medical treatment of secondary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy for secondary retroperitoneal fibrosis (",
"    <a class=\"graphic graphic_table graphicRef74731 \" href=\"UTD.htm?12/44/13003\">",
"     table 1",
"    </a>",
"    ) is aimed at treating the underlying etiology or stopping the causative drug. In the case of drug-induced retroperitoneal fibrosis, discontinuation of the offending agent is mandatory, and often leads to improvement or resolution within a few months.",
"   </p>",
"   <p>",
"    Although there are no data, in our experience, therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    may be beneficial in drug-induced disease if there are severe disease manifestations, such as severe symptoms and ureteral obstruction, or there is no significant improvement on computerized tomography (CT) scan by three to four months after discontinuation of the drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34136?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of retroperitoneal fibrosis\", section on 'Etiology and pathogenesis'",
"    </a>",
"    .) When treating patients who have drug-induced retroperitoneal fibrosis with prednisone therapy, we use the same protocol that we do for treatment of idiopathic disease. (See",
"    <a class=\"local\" href=\"#H85000215\">",
"     'Medical treatment of idiopathic disease'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85000215\">",
"    <span class=\"h2\">",
"     Medical treatment of idiopathic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of medical therapies may be utilized in patients with idiopathic disease. These include glucocorticoids, other immunosuppressive agents, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . We initiate therapy with glucocorticoids alone, beginning as soon as the diagnosis is made (even the same day as urologic intervention).",
"   </p>",
"   <p>",
"    In patients who have not responded adequately to glucocorticoids after approximately four to six months of therapy, we prefer to add either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . Given the risk of toxicity in those with renal dysfunction, methotrexate should",
"    <strong>",
"     not",
"    </strong>",
"    be administered to patients with a plasma creatinine concentration above 2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     &micro;mol/L).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Initial therapy with glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are traditionally considered the mainstay of therapy for idiopathic retroperitoneal fibrosis. If an interventional procedure is not absolutely necessary, some investigators have advocated using glucocorticoids alone, since these procedures may be associated with significant risks and complications [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Intervention in patients with urinary tract obstruction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The best data supporting the use of glucocorticoids as initial therapy come from a trial in which 36 of 39 patients with idiopathic retroperitoneal fibrosis who responded to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    induction therapy (1",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for one month) were randomly assigned to a tapering dose of prednisone or a fixed dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    for an additional eight months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/12\">",
"     12",
"    </a>",
"    ]. The primary endpoint was relapse of disease, defined as the new onset or recurrence of one or more of the following three findings: hydronephrosis; a 20 percent or larger increase in the size of a retroperitoneal mass; or symptoms (eg, back or abdominal pain, constipation) in combination with a 50 percent or greater increase in C-reactive protein and erythrocyte sedimentation rate. At the end of eight months, the relapse rate was significantly lower in patients receiving prednisone therapy (6 versus 39 percent). Five of the seven patients who relapsed during tamoxifen therapy were switched to prednisone therapy, and each of these individuals achieved remission. All patients were followed for an additional 18 months after termination of study therapy. Through 26 months, the relapse rate was significantly lower with prednisone therapy (17 versus 50 percent). Although the relapse rate was lower, prednisone was associated with significantly more adverse effects, including cushingoid changes, weight gain, and hyperlipidemia.",
"   </p>",
"   <p>",
"    Based upon the results of this trial, combined with our prior experience [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/1,6\">",
"     1,6",
"    </a>",
"    ], we treat patients with idiopathic retroperitoneal fibrosis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (maximum dose 80",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for approximately four weeks. If improvement is observed, the dose is then tapered over approximately two to three months to 10",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    and maintained for an additional 6 to 18 months.",
"   </p>",
"   <p>",
"    Other dosing regimens may be effective, however, with nearly 90 percent of patients responding to glucocorticoids alone [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/6,13,14\">",
"     6,13,14",
"    </a>",
"    ]. The following studies describe alternative strategies for glucocorticoid therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One case series reported use of an initial dose of 60 mg every other day for two months, tapered over the subsequent few months to 5 mg daily, and continued for a total duration of therapy of two years [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/15\">",
"       15",
"      </a>",
"      ]. Nine of 11 patients who completed this regimen responded with relief of symptoms and regression of the retroperitoneal mass.",
"     </li>",
"     <li>",
"      In another study, 24 patients were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      for one year [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/14\">",
"       14",
"      </a>",
"      ]. The regimen consisted of 60 mg once daily for six weeks, which was usually tapered within the following two to three months to a maintenance dose of 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and continued for one year [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/14\">",
"       14",
"      </a>",
"      ]. If severe ureteral obstruction was present, decompression was allowed using nephrostomy tubes or in-dwelling ureteral stents. Twenty-two patients reported significant regression of symptoms and 19 had a progressive reduction in size of the retroperitoneal mass, as assessed by CT. In addition, 13 patients with initial treatment success showed disease recurrence after steroid withdrawal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients with retroperitoneal fibrosis appear to derive greater benefit from glucocorticoid therapy than others. This includes patients in whom the biopsy reveals a substantial inflammatory component, and the elderly, in whom glucocorticoids may obviate the need for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/7,16\">",
"     7,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no established predictors of response to glucocorticoid therapy. A retrospective study of 37 patients examined whether erythrocyte sedimentation rates and C-reactive protein levels predicted whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy would lead to a reduction in retroperitoneal mass size. Although these acute-phase reactant levels tended to be higher in those who showed regression compared with those who did not, this difference was not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85000568\">",
"    <span class=\"h4\">",
"     Glucocorticoid-resistant disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure to detect clinical or radiologic improvement within four to six weeks of initiation of medical therapy should prompt a repeat evaluation with CT scan and biopsy, to ascertain that the diagnosis is correct (eg, not a misdiagnosed infection, or lymphoma). (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Monitoring the response to medical therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, some cases of correctly diagnosed idiopathic retroperitoneal fibrosis may be intrinsically resistant to steroids, possibly because there is more fibrosis than inflammation.",
"   </p>",
"   <p>",
"    If the diagnosis is confirmed,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is usually continued at a high dose (1",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    for another month, then tapered for two to four additional months. If the disease does not adequately respond to glucocorticoids alone, other agents can be used concurrently to improve the response or to reduce the duration of treatment with high-dose glucocorticoids. Agents that have been tried with apparent success in case reports or case series include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/2,4,18-23\">",
"     2,4,18-23",
"    </a>",
"    ]. There are no published direct comparisons of the effectiveness or the toxicity of various immunosuppressants plus steroids versus steroids alone.",
"   </p>",
"   <p>",
"    The efficacy of different immunosuppressive regimens was reported in a retrospective single-center study of 26 patients with idiopathic retroperitoneal fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/4\">",
"     4",
"    </a>",
"    ]. All patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (at a dose of 1.0 to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for three weeks, which was tapered to zero within six months), as well as ureteral stenting",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a percutaneous nephrostomy. Among 15 patients, prednisone was combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (at a dose of 2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for six months, then 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for another six months). With the remaining 11 patients, prednisone was administered with either oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for three months, which was then tapered to zero by six months), or intravenous cyclophosphamide (1000",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per month for six months). At a mean period of follow-up of 49 months, remission, which was defined as stable clinical and radiographic disease, was observed in all patients, except one who died of pneumonia. Seven patients required retreatment.",
"   </p>",
"   <p>",
"    As second-line therapy in patients who do not respond after four to six months of therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    alone, we prefer to add",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , due to the favorable responses in other immune-mediated diseases with a chronic clinical course, such as giant cell arteritis or rheumatoid arthritis, in which methotrexate has been extensively used as a steroid-sparing agent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/22\">",
"     22",
"    </a>",
"    ]. Methotrexate is given at a starting dose of 7.5",
"    <span class=\"nowrap\">",
"     mg/week,",
"    </span>",
"    with the dose increased by 2.5 mg increments monthly until an effect is seen or toxicity limits further increase, to a maximum dose of 20",
"    <span class=\"nowrap\">",
"     mg/week.",
"    </span>",
"    Once the methotrexate is started, we decrease the dose of prednisone, and taper it to 5",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    The total duration of therapy is based on clinical and radiographic response, but is usually at least 8 to 10 months. A review of dosing and monitoring can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the risk of toxicity in those with renal dysfunction,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be administered to patients with a plasma creatinine concentration above 2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    Given the encouraging results obtained with the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    as initial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/24\">",
"     24",
"    </a>",
"    ], we believe that this agent should also be considered a feasible option for patients with glucocorticoid-resistant disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85000331\">",
"    <span class=\"h3\">",
"     Initial therapy with tamoxifen in patients who cannot take glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    has been widely used for idiopathic retroperitoneal fibrosis, based on possible benefits observed in the treatment of desmoid tumors. Desmoid tumors and retroperitoneal fibrosis are characterized by locally invasive fibroblast proliferation, although the pathobiology, clinical and histologic features differ. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34136?source=see_link\">",
"     \"Clinical manifestations and diagnosis of retroperitoneal fibrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30906?source=see_link\">",
"     \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The randomized trial described above suggests that maintenance therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    (after inducing remission with one month of high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) is inferior to continuation of prednisone [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/12\">",
"     12",
"    </a>",
"    ]. Based upon these results, it is reasonable to try tamoxifen only in patients who have contraindications to steroids or to explore its role as steroid-sparing agent.",
"   </p>",
"   <p>",
"    Positive responses to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , used alone or in combination with glucocorticoids, have been reported among patients with retroperitoneal fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/25-31\">",
"     25-31",
"    </a>",
"    ]. In one report of 19 cases of nonmalignant retroperitoneal fibrosis diagnosed by CT scan, 15 had clinical improvement after only a few weeks of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/29\">",
"     29",
"    </a>",
"    ]. CT scan at four months demonstrated moderate or significant mass regression in 12 patients. In 10 patients who were followed for 15 months, there was continued mass regression. However, relatively few patients in this series had significant renal involvement, and the effects of therapy on relapse rates are unknown, as most patients were still on therapy at the final analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53159905\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total duration of therapy depends upon the severity of disease, particularly the extension of the retroperitoneal mass, and also the response to therapy. As an example, patients with mild disease who quickly respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    may be treated for shorter durations (eg, 8 months). On the other hand, patients with extensive retroperitoneal masses that regress slowly may require prolonged therapy. In such patients, a slow taper of prednisone over the course of a year or longer would be appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53159885\">",
"    <span class=\"h3\">",
"     Alternative initial therapy with combined immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;We prefer to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    as sole therapy for initial treatment of idiopathic retroperitoneal fibrosis. However, in patients with relative contraindications to long-term, high dose prednisone (eg, patients with poorly controlled diabetes), alternative initial therapies may provide effective treatment with lower total doses of glucocorticoid:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty-eight patients, most of whom had not previously received medical therapy, were treated with a combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/24\">",
"       24",
"      </a>",
"      ]. Prednisone was given at an initial dose of 40",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      which was tapered over a six-month period. Treatment with mycophenolate mofetil (1000 mg twice a day) continued until six months after clinical improvement occurred (clinical improvement was variably defined); the total duration of therapy averaged 24 months. The mean serum creatinine concentration improved from 2.2 to 1.1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (191 to 97",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      Among the patients who had ureteral obstruction, 25 of 29 stents (86 percent) were able to be discontinued. Two patients had recurrent disease following discontinuation of treatment.",
"     </li>",
"     <li>",
"      A study of seven patients suggested that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      administered with glucocorticoids may provide effective treatment with lower total doses of glucocorticoid [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/32\">",
"       32",
"      </a>",
"      ]. Colchicine (1",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      administered with glucocorticoid allowed substantial steroid tapering in most patients and no disease relapses were observed during the follow-up. Colchicine was well tolerated, with only two patients requiring dose reduction because of diarrhea [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the lack of direct comparisons, it is not possible to conclude whether these combination therapies are superior to glucocorticoid therapy alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Monitoring the response to medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sequential evaluation is required to follow the response to medical therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We evaluate the patient clinically within one month of beginning therapy for resolution of pain and resolution of obstruction. Thereafter, we evaluate clinically every two to three months, or more frequently as dictated by symptoms.",
"     </li>",
"     <li>",
"      We usually obtain erythrocyte sedimentation rate, C-reactive protein level and serum creatinine concentration monthly for the first three months, then every two to three months.",
"     </li>",
"     <li>",
"      We obtain a CT scan one month after initiation of therapy, then approximately every three months, to follow the size of the fibrotic mass.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A renal ultrasound may be performed in the interval to evaluate for obstruction, particularly if a procedure was not performed, or following removal of nephrostomies or stents.",
"   </p>",
"   <p>",
"    Resolution of the mass, or lack of further reduction in size on serial CTs provides guidance regarding duration of immunosuppressive therapy. Failure to detect clinical or radiologic improvement within four to six weeks of initiation of medical therapy should prompt a repeat evaluation with CT scan and biopsy, to ascertain that the diagnosis is correct.",
"   </p>",
"   <p>",
"    In addition, an increase in the size of the mass, or a new complication related to the mass, may prompt surgical intervention. Full resolution of the fibrotic plaque may not occur. However, this is not indicative of treatment failure. In such cases, positron emission tomography with 18F-fluorodeoxyglucose may be useful to assess the metabolic activity of the residual retroperitoneal tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following discontinuation of steroids (or other immunosuppressive agents), we suggest monitoring for disease relapse by obtaining a renal ultrasound, erythrocyte sedimentation rate, C-reactive protein level and serum creatinine concentration every three to six months, and a CT scan every six months for the first year. Thereafter, we suggest testing every 6 to 12 months, with a CT scan every one to two years. We continue surveillance indefinitely, since disease relapse has been described up to ten years after discontinuation of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11676225\">",
"    <span class=\"h2\">",
"     Recurrence after discontinuation of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported rate of recurrence following therapy with immunosuppression ranges from less than 10 to 30 percent, although one series reported a recurrence rate of over 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/4,14,30,34,35\">",
"     4,14,30,34,35",
"    </a>",
"    ]. Different treatment schedules and, above all, different durations of therapy or follow-up may account for the discrepancies in recurrence rates among the studies. It is unclear whether these represent recurrence or regrowth of partially treated retroperitoneal fibrosis.",
"   </p>",
"   <p>",
"    As there are no data, our treatment strategy for disease recurrence is based upon our clinical experience. In patients who relapse after remitting with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy, we initiate a combination of prednisone and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . We use high dose prednisone at first (1",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    for four weeks, tapering over the next five months to a dose of 2.5 to 5 mg per day. We give 12.5 to 17.5 mg of methotrexate per week. In our experience, relapsing patients are often frequent relapsers; thus, we continue this therapy for one to two years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Within a few days of beginning steroid therapy, pain and constitutional symptoms usually improve, and the erythrocyte sedimentation rate falls dramatically. Improvement in urinary tract obstruction as manifested by diuresis or ultrasound may be observed within a few weeks, and CT resolution of the mass may begin within a few weeks of initiating medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Full resolution of the associated manifestations may depend in part on the duration of entrapment. As an example, renal insufficiency with associated hypertension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anemia may persist despite relief of obstruction if there has been permanent renal damage. In patients who respond to steroids, mortality is less than 10 percent over many years of follow-up (excluding cases associated with malignancy) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14904/abstract/6,36\">",
"     6,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retroperitoneal fibrosis is an uncommon cause of obstructive uropathy. Untreated patients may develop severe complications or progress to end-stage renal disease. The goals of therapy are to relieve the obstruction, stop the progression of the fibrotic process, and to prevent recurrence. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with significant renal dysfunction due to obstruction of the urinary tract by retroperitoneal fibrosis, as with any other cause of obstructive uropathy, we recommend immediate relief of obstruction (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). A variety of surgical interventions are available (open or laparoscopic surgical, percutaneous or endoureteral); open and laparoscopic interventions may be associated with significant risks and complications, whereas percutaneous and endoureteral techniques appear to be safer. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Intervention in patients with urinary tract obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with retroperitoneal fibrosis who have hydronephrosis but no significant impairment in renal function, we suggest initiating a trial of medical therapy without surgical intervention (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If a surgical procedure has been deferred, renal function should be closely followed, and sequential ultrasonography should be performed every two to four weeks to monitor for progression of obstruction. These patients should be referred for surgical decompression of the urinary tract if there is deterioration of kidney function or if there is no improvement or worsening of the hydronephrosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General approach to therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Monitoring the response to interventional therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medical therapy of retroperitoneal fibrosis depends upon the cause. Therapy for secondary retroperitoneal fibrosis (",
"      <a class=\"graphic graphic_table graphicRef74731 \" href=\"UTD.htm?12/44/13003\">",
"       table 1",
"      </a>",
"      ) is aimed at treating the underlying etiology or stopping the offending agent, although some cases of drug-induced disease respond to immunosuppressive therapy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with idiopathic retroperitoneal fibrosis, we recommend induction therapy with one month of high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      followed by maintenance therapy with tapering doses of prednisone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). If there is a contraindication to prednisone therapy, we suggest initial therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Initial therapy with glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H85000331\">",
"       'Initial therapy with tamoxifen in patients who cannot take glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Within a few days of beginning glucocorticoid therapy, pain and constitutional symptoms usually improve, and the erythrocyte sedimentation rate should fall dramatically. Improvement in urinary tract obstruction indicated by diuresis or by ultrasound may be observed within a few weeks, and resolution of the mass by computerized tomography (CT) may begin within a few weeks of initiating medical therapy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After one month of therapy, we evaluate patients for resolution of symptoms and also perform CT and laboratory studies (including assessments of renal function, erythrocyte sedimentation rate, and C-reactive protein). If regression of disease is noted at one month, we continue maintenance therapy for another 6 to 18 months, depending upon the severity of disease and speed of resolution. After the first month, we repeat the evaluation every two to three months or more frequently as dictated by symptoms. Following discontinuation of steroids (or other immunosuppressive agents), we monitor for disease relapse by obtaining a renal ultrasound, erythrocyte sedimentation rate, C-reactive protein level and serum creatinine concentration every three to six months, and a CT scan every six months for the first year. Thereafter, we evaluate patients every 6 to 12 months and perform a CT scan every one to two years. (See",
"      <a class=\"local\" href=\"#H53159905\">",
"       'Duration of therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Monitoring the response to medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with idiopathic retroperitoneal fibrosis who fail to achieve clinical or radiologic improvement within four to six months of initiating",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      therapy, we suggest adding therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H85000568\">",
"       'Glucocorticoid-resistant disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Full resolution of the associated manifestations may depend in part on the duration of entrapment. As an example, renal insufficiency may persist despite relief of obstruction if there has been permanent renal damage. In patients with idiopathic retroperitoneal fibrosis who respond to steroids, mortality is less than 10 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24176585\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Carlo Buzio, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/1\">",
"      Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet 2006; 367:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/2\">",
"      Harreby M, Bilde T, Helin P, et al. Retroperitoneal fibrosis treated with methylprednisolon pulse and disease-modifying antirheumatic drugs. Scand J Urol Nephrol 1994; 28:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/3\">",
"      Cogan E, Fastrez R. Azathioprine. An alternative treatment for recurrent idiopathic retroperitoneal fibrosis. Arch Intern Med 1985; 145:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/4\">",
"      Marcolongo R, Tavolini IM, Laveder F, et al. Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases. Am J Med 2004; 116:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/5\">",
"      Jois RN, Gaffney K, Marshall T, Scott DG. Chronic periaortitis. Rheumatology (Oxford) 2004; 43:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/6\">",
"      van Bommel EF. Retroperitoneal fibrosis. Neth J Med 2002; 60:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/7\">",
"      Ross JC, Goldsmith HJ. The combined surgical and medical treatment of retroperitoneal fibrosis. Br J Surg 1971; 58:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/8\">",
"      Srinivasan AK, Richstone L, Permpongkosol S, Kavoussi LR. Comparison of laparoscopic with open approach for ureterolysis in patients with retroperitoneal fibrosis. J Urol 2008; 179:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/9\">",
"      Tiptaft RC, Costello AJ, Paris AM, Blandy JP. The long-term follow-up of idiopathic retroperitoneal fibrosis. Br J Urol 1982; 54:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/10\">",
"      Zhang QX, Magovern CJ, Mack CA, et al. Vascular endothelial growth factor is the major angiogenic factor in omentum: mechanism of the omentum-mediated angiogenesis. J Surg Res 1997; 67:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/11\">",
"      Lodde M, Pycha A, Palermo S, et al. Uretero-ureterocutaneostomy (wrapped by omentum). BJU Int 2005; 95:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/12\">",
"      Vaglio A, Palmisano A, Alberici F, et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet 2011; 378:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/13\">",
"      van Bommel EF, van Spengler J, van der Hoven B, Kramer P. Retroperitoneal fibrosis: report of 12 cases and a review of the literature. Neth J Med 1991; 39:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/14\">",
"      van Bommel EF, Siemes C, Hak LE, et al. Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone. Am J Kidney Dis 2007; 49:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/15\">",
"      Kardar AH, Kattan S, Lindstedt E, Hanash K. Steroid therapy for idiopathic retroperitoneal fibrosis: dose and duration. J Urol 2002; 168:550.",
"     </a>",
"    </li>",
"    <li>",
"     Resnick, MI, Kursh, ED. Extrinsic obstruction of the ureter. In: Campbell's Urology, 6th ed, WB Saunders, Philadelphia, 1992, p. 514.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/17\">",
"      Magrey MN, Husni ME, Kushner I, Calabrese LH. Do acute-phase reactants predict response to glucocorticoid therapy in retroperitoneal fibrosis? Arthritis Rheum 2009; 61:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/18\">",
"      Grotz W, von Zedtwitz I, Andre M, Schollmeyer P. Treatment of retroperitoneal fibrosis by mycophenolate mofetil and corticosteroids. Lancet 1998; 352:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/19\">",
"      Jois RN, Kerrigan N, Scott DG. Mycophenolate mofetil for maintenance of remission in idiopathic retroperitoneal fibrosis. Rheumatology (Oxford) 2007; 46:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/20\">",
"      Marzano A, Trapani A, Leone N, et al. Treatment of idiopathic retroperitoneal fibrosis using cyclosporin. Ann Rheum Dis 2001; 60:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/21\">",
"      Al-Harthy F, Esdaile J, Berean KW, Chalmers A. Multifocal idiopathic fibrosclerosis: treatment of 2 cases with cyclosporine. J Rheumatol 2006; 33:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/22\">",
"      Scavalli AS, Spadaro A, Riccieri V, et al. Long-term follow-up of low-dose methotrexate therapy in one case of idiopathic retroperitoneal fibrosis. Clin Rheumatol 1995; 14:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/23\">",
"      Scheel PJ Jr, Piccini J, Rahman MH, et al. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis. J Urol 2007; 178:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/24\">",
"      Scheel PJ Jr, Feeley N, Sozio SM. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series. Ann Intern Med 2011; 154:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/25\">",
"      Bourouma R, Chevet D, Michel F, et al. Treatment of idiopathic retroperitoneal fibrosis with tamoxifen. Nephrol Dial Transplant 1997; 12:2407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/26\">",
"      Clark CP, Vanderpool D, Preskitt JT. The response of retroperitoneal fibrosis to tamoxifen. Surgery 1991; 109:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/27\">",
"      Ozener C, Kiri�� S, Lawrence R, et al. Potential beneficial effect of tamoxifen in retroperitoneal fibrosis. Nephrol Dial Transplant 1997; 12:2166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/28\">",
"      Tziomalos K, Krikis N, Karagiannis A, et al. Treatment of idiopathic retroperitoneal fibrosis with combined administration of corticosteroids and tamoxifen. Clin Nephrol 2004; 62:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/29\">",
"      van Bommel EF, Hendriksz TR, Huiskes AW, Zeegers AG. Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med 2006; 144:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/30\">",
"      Moroni G, Gallelli B, Banfi G, et al. Long-term outcome of idiopathic retroperitoneal fibrosis treated with surgical and/or medical approaches. Nephrol Dial Transplant 2006; 21:2485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/31\">",
"      Costanzi S, Zoli A, Ferraro PM, et al. A paraneoplastic retroperitoneal fibrosis resistant to corticosteroids treated with tamoxifen. Clin Nephrol 2008; 70:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/32\">",
"      Vega J, Goecke H, Tapia H, et al. Treatment of idiopathic retroperitoneal fibrosis with colchicine and steroids: a case series. Am J Kidney Dis 2009; 53:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/33\">",
"      Vaglio A, Greco P, Versari A, et al. Post-treatment residual tissue in idiopathic retroperitoneal fibrosis: active residual disease or silent \"scar\" ? A study using 18F-fluorodeoxyglucose positron emission tomography. Clin Exp Rheumatol 2005; 23:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/34\">",
"      Heidenreich A, Derakhshani P, Neubauer S, Krug B. [Treatment outcomes in primary and secondary retroperitoneal fibrosis]. Urologe A 2000; 39:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/35\">",
"      Alexopoulos E, Memmos D, Bakatselos S, et al. Idiopathic retroperitoneal fibrosis: a long-term follow-up study. Eur Urol 1987; 13:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14904/abstract/36\">",
"      Baker LR, Mallinson WJ, Gregory MC, et al. Idiopathic retroperitoneal fibrosis. A retrospective analysis of 60 cases. Br J Urol 1987; 60:497.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7213 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-217.16.9.173-E29AE5AA73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_35_14904=[""].join("\n");
var outline_f14_35_14904=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL APPROACH TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INTERVENTION IN PATIENTS WITH URINARY TRACT OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84999994\">",
"      Selection of an interventional procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Monitoring the response to interventional therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11676078\">",
"      Medical treatment of secondary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85000215\">",
"      Medical treatment of idiopathic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Initial therapy with glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H85000568\">",
"      Glucocorticoid-resistant disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H85000331\">",
"      - Initial therapy with tamoxifen in patients who cannot take glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H53159905\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H53159885\">",
"      - Alternative initial therapy with combined immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Monitoring the response to medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11676225\">",
"      Recurrence after discontinuation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24176585\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7213\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7213|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/44/13003\" title=\"table 1\">",
"      2ndary Retroperitoneal fibrosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34136?source=related_link\">",
"      Clinical manifestations and diagnosis of retroperitoneal fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30906?source=related_link\">",
"      Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24276?source=related_link\">",
"      Recovery of renal function after relief of urinary tract obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_35_14905="Cytogenetics and molecular genetics of myelodysplastic syndromes";
var content_f14_35_14905=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cytogenetics and molecular genetics of myelodysplastic syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/35/14905/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/35/14905/contributors\">",
"     Yanming Zhang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/35/14905/contributors\">",
"     Michelle M Le Beau, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/35/14905/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/35/14905/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/35/14905/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/35/14905/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/35/14905/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H5771332\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The myelodysplastic syndromes (MDS) encompass a series of hematologic conditions characterized by chronic cytopenias (anemia, neutropenia, thrombocytopenia) accompanied by abnormal cellular maturation. As a result, patients with MDS are at risk for symptomatic anemia, infection, and bleeding, as well as progression to acute myeloid leukemia (AML), which is often refractory to standard treatment.",
"   </p>",
"   <p>",
"    MDS develops as the consequence of a series of genetic changes in a hematopoietic precursor cell. These changes alter normal hematopoietic growth and differentiation, resulting in an accumulation of abnormal, immature myeloid cells in the bone marrow and the impairment of normal hematopoiesis. Advances in the identification of recurring chromosomal abnormalities and translocations have provided insight into the pathobiology of MDS.",
"   </p>",
"   <p>",
"    Specific cytogenetic abnormalities identified by karyotype analysis or fluorescence in situ hybridization (FISH) analysis have prognostic significance for patients with primary MDS and affect treatment planning. Certain gene mutations also confer prognostic significance in adult patients with MDS, but it is not yet clear how to incorporate these changes into treatment planning. Even those patients without obvious abnormalities detected by karyotypic analysis, FISH, or gene mutation analyses likely have abnormalities in gene expression profiles or have acquired copy number alterations that may help to identify genes important for the pathogenesis of MDS.",
"   </p>",
"   <p>",
"    Characteristic chromosomal abnormalities have also been identified in patients who developed MDS or AML (often preceded by MDS) after chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy for an earlier disorder, such as Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), or a solid tumor, as well as non-malignant disorders, such as rheumatoid arthritis, or following organ transplantation (",
"    <a class=\"graphic graphic_table graphicRef77909 \" href=\"UTD.htm?29/24/30093\">",
"     table 1",
"    </a>",
"    ). This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=see_link&amp;anchor=H13#H13\">",
"     \"Cytogenetics in acute myeloid leukemia\", section on 'Therapy-related myeloid neoplasms (t-MDS/t-AML)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cytogenetic and molecular genetic features of primary MDS and the use of genetic studies in predicting both progression to AML and survival will be reviewed here. An overview of cytogenetic abnormalities in hematologic malignancies (including definitions, methods of detection, the genetic consequences of chromosomal translocations) and a more detailed discussion of the prognosis of MDS are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34425?source=see_link\">",
"     \"Prognosis of the myelodysplastic syndromes in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6489?source=see_link\">",
"     \"General aspects of cytogenetic analysis in hematologic malignancies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18167?source=see_link\">",
"     \"Chromosomal translocations, deletions, and inversions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CHROMOSOMAL ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MDS may have single or multiple chromosomal changes at the time of diagnosis, or abnormal clones may appear during the course of the disease. Simple chromosome changes may involve a numerical change (ie, monosomy or trisomy), a structural abnormality involving only one chromosome (eg, inversion and interstitial deletion), or, less commonly, a balanced translocation involving two chromosomes. Ten to 15 percent of patients exhibit complex karyotypes with multiple abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Additional chromosomal aberrations may evolve during the course of MDS, or an abnormal clone may emerge in a patient with a previously normal karyotype; these changes appear to portend progression to acute leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Notably, all of these common chromosome abnormalities observed in MDS are also frequently detected in other myeloid diseases (ie, acute myeloid leukemia and myeloproliferative neoplasms).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256827820\">",
"    <span class=\"h2\">",
"     Recurring abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clonal chromosomal abnormalities can be detected in bone marrow cells in 40 to 70 percent of patients with primary MDS (",
"    <a class=\"graphic graphic_table graphicRef77909 \" href=\"UTD.htm?29/24/30093\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/1,2,4,6-9\">",
"     1,2,4,6-9",
"    </a>",
"    ]. This fraction is somewhat lower than the 70 to 80 percent detected in patients with acute myeloid leukemia (AML) de novo. The likelihood of chromosomal abnormalities is increased in patients with advanced MDS.",
"   </p>",
"   <p>",
"    Although rates vary depending upon the technique used and the population studied, the most common chromosomal abnormalities seen in MDS are del(5q), -7 or del(7q), trisomy 8, del(20q), and loss of the Y chromosome (",
"    <a class=\"graphic graphic_table graphicRef77909 \" href=\"UTD.htm?29/24/30093\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef71654 \" href=\"UTD.htm?9/48/9996\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/3\">",
"     3",
"    </a>",
"    ]. As an example, a series of 1029 patients with MDS seen at two medical centers between 1995 and 2006 reported that an abnormal karyotype was seen in 44 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/2\">",
"     2",
"    </a>",
"    ]. The most common abnormalities were a complex karyotype, del(5q), trisomy 8, and del(20q), which were present in 18, 6, 4, and 3 percent, respectively. Loss of the Y chromosome is common in men without hematologic disorders and is not thought to play a role in the pathogenesis of MDS [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two features that distinguish the cytogenetic changes in primary MDS from those in de novo AML:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although +8, del(5q),",
"      <span class=\"nowrap\">",
"       -7/del(7q),",
"      </span>",
"      and del(20q) are common in both disorders, the specific structural rearrangements (balanced translocations) that are closely associated with distinct subsets of de novo AML are not commonly seen in MDS [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/1,2,4,5,9,11,12\">",
"       1,2,4,5,9,11,12",
"      </a>",
"      ]. Exceptions include the t(3;21),",
"      <span class=\"nowrap\">",
"       inv(3)/t(3;3),",
"      </span>",
"      and t(11;16), which are observed in primary MDS and in AML with myelodysplastic features, as well as in therapy-related myeloid neoplasms (t-MN) and in chronic myeloid leukemia (CML) during accelerated and blast phases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=see_link&amp;anchor=H11#H11\">",
"       \"Cytogenetics in acute myeloid leukemia\", section on 't(3;3) and inv(3) in AML with thrombocytosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Deletions of chromosomes 5 and",
"      <span class=\"nowrap\">",
"       -7/del(7q)",
"      </span>",
"      are particularly characteristic (up to 70 percent) of therapy-related",
"      <span class=\"nowrap\">",
"       MDS/AML",
"      </span>",
"      induced by alkylating agents",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiation therapy. How these deletions might promote myeloid leukemogenesis is described elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=see_link&amp;anchor=H19#H19\">",
"       \"Cytogenetics in acute myeloid leukemia\", section on 'Mechanisms of dysplasia and leukemogenesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      With occasional exceptions (such as the 5q-",
"      <span class=\"nowrap\">",
"       syndrome/MDS",
"      </span>",
"      with isolated del(5q)), chromosomal abnormalities in MDS have not correlated with specific clinical or morphological subsets using the WHO classification system (",
"      <a class=\"graphic graphic_table graphicRef71654 \" href=\"UTD.htm?9/48/9996\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H256821606\">",
"       '5q- syndrome'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256828282\">",
"    <span class=\"h3\">",
"     Deletions of chromosome 5",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deletion of the long arm of chromosome 5 (5q) is the most common chromosomal abnormality seen in MDS, occurring in approximately 15 percent of cases overall [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/3,13\">",
"     3,13",
"    </a>",
"    ]. Although the deletions are large and interstitial (two breaks occur in the long arm, with loss of the intervening segment), cytogenetic and molecular analysis has led to the identification of two small commonly deleted regions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      5q33.1 &mdash; Deletion of this locus is most commonly associated with the 5q minus syndrome and a relatively good prognosis, and all patients with the 5q- syndrome have this region deleted. (See",
"      <a class=\"local\" href=\"#H256821606\">",
"       '5q- syndrome'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      5q31 &mdash; Deletion of this locus is more commonly seen with therapy-related MDS and is associated with more aggressive disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In each case, these deletions occur on a single chromosome resulting in a heterozygous (haploinsufficient) state with retention of one normal allele of all of the genes contained within the deleted segment. As yet, mutations in the non-deleted alleles have not been detected by gene sequencing nor have cases of acquired uniparental disomy (also known as copy-neutral loss of heterozygosity) of 5q been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Uniparental disomy ordinarily is a genetic phenomenon that occurs during early embryogenesis where a mitotic recombination event results in homozygosity of both copies of a chromosome or chromosome segment. In contrast, acquired uniparental disomy occurs as a result of a mitotic recombination event in a hematopoietic stem or progenitor cell resulting in homozygosity of a chromosome or chromosome segment, followed by clonal hematopoiesis. Because most patients have very large deletions, these regions are not exclusive and most cases will have a deletion that spans both regions. In addition, del(5q) is commonly accompanied by other chromosomal abnormalities.",
"   </p>",
"   <p>",
"    The long arm of chromosome 5 contains numerous genes that have been implicated in the pathogenesis of MDS",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sensitization to specific therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/3\">",
"     3",
"    </a>",
"    ]. Gene expression profiling, knock-down experiments using RNA interference, and forced expression studies have implicated the RPS14 protein, required for the maturation of 40S ribosomal subunits, in the genesis of the 5q- syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. Of interest, the ribosomal processing defect caused by haploinsufficiency of RPS14 in the 5q- syndrome is highly analogous to the functional ribosomal defect seen in Diamond-Blackfan anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26954?source=see_link&amp;anchor=H3#H3\">",
"     \"Anemia in children due to decreased red blood cell production\", section on 'Diamond-Blackfan anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies have shown that haploinsufficiency of two micro-RNAs (miRNAs) that are abundant in hematopoietic",
"    <span class=\"nowrap\">",
"     stem/progenitor",
"    </span>",
"    cells (HSPCs), miR-145 and miR-146a, are encoded by sequences near the RPS14 gene, and cooperate with loss of RPS14. The Toll-interleukin-1 receptor domain-containing adaptor protein (TIRAP) and tumor necrosis factor receptor-associated factor-6 (TRAF6) are respective targets of these miRNAs, implicating inappropriate activation of innate immune signals in the pathogenesis of the 5q- syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Studies in a mouse model suggest that a p53-dependent mechanism underlies this syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In one report, the low expression of RPS14 in 23 patients with the 5q- syndrome was not due to promoter hypermethylation, suggesting that the use of hypomethylating agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    ) is unlikely to benefit this MDS variant [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other genes located on 5q that are deleted in MDS, AML, or therapy-related",
"    <span class=\"nowrap\">",
"     MDS/AML",
"    </span>",
"    with a del(5q) include EGR1, NPM1, CTNNA1, and APC. Loss of function of Apc (adenomatosis polyposis coli gene, APC tumor suppressor gene) in animal models produces a condition simulating MDS",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    contributes to its development [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Similarly, loss of function of EGR1 cooperates with mutations induced by alkylating agents to induce myeloid neoplasms in mouse models [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/32\">",
"     32",
"    </a>",
"    ]. These results provide support for the current model that the cooperative loss of multiple genes on 5q is required for the pathogenesis of myeloid disorders with a del(5q).",
"   </p>",
"   <p>",
"    Cases of MDS where del(5q) is the sole chromosomal abnormality have a relatively good prognosis and good chance of responding to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    . In comparison, monosomy 5 (now known to result from structural rearrangements of chromosome 5, rather than actual chromosome loss) or del(5q) with other chromosomal changes is associated with advanced MDS and a worse outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link&amp;anchor=H2443602#H2443602\">",
"     \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'Patients with 5q deletion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256828394\">",
"    <span class=\"h3\">",
"     Monosomy 7 and deletions of chromosome 7",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 percent of patients with de novo MDS and up to 50 percent of patients with therapy-related MDS demonstrate",
"    <span class=\"nowrap\">",
"     -7/del(7q),",
"    </span>",
"    either alone or as part of a complex karyotype [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/3\">",
"     3",
"    </a>",
"    ]. Approximately 90 percent of cases have loss of a whole chromosome 7 (-7), and 10 percent are actual deletions, del(7q). Although some have been proposed, it is not yet known what genes located on 7q are involved in the pathogenesis of MDS. Multiple laboratories have identified mutations in EZH2 which are thought to alter chromatin structure and gene transcription; however, the vast majority of patients with EZH2 mutations do not have",
"    <span class=\"nowrap\">",
"     -7/del(7q)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256828429\">",
"    <span class=\"h3\">",
"     Trisomy 8",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trisomy 8 is seen in less than 10 percent of patients with MDS and is considered an intermediate risk finding in the International Prognostic Scoring System [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/3\">",
"     3",
"    </a>",
"    ]. Gain of chromosome 8 has been associated with higher expression of antiapoptotic genes compared with normal cells and may result in a selective advantage over normal hematopoietic precursors. Overexpression of the MYC oncogene at 8q24.1 has also been implicated in the pathogenesis of myeloid disorders with trisomy 8.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256828457\">",
"    <span class=\"h3\">",
"     Deletions of chromosome 20",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deletions of the long arm of chromosome 20, del(20q), occur in less than 5 percent of cases of MDS and are also seen in patients with acute myeloid leukemia and myeloproliferative disorders. When found as the sole chromosomal abnormality, del(20q) is associated with a favorable prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/1,7,37\">",
"     1,7,37",
"    </a>",
"    ]. Further studies are required to determine which genes are involved in the pathogenesis of MDS [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256820964\">",
"    <span class=\"h2\">",
"     Use in diagnosis and classification",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256827544\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of MDS is made based upon an evaluation of the bone marrow and peripheral smear in the appropriate clinical context. Detection of certain chromosomal abnormalities, either by routine cytogenetic analysis or FISH, aids in the classification of MDS and determination of prognostic risk group. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19880?source=see_link&amp;anchor=H516641#H516641\">",
"     \"Overview of the treatment of myelodysplastic syndromes\", section on 'Pretreatment evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the presence of one of the following chromosomal abnormalities is presumptive evidence of MDS in patients with otherwise unexplained refractory cytopenia and no morphologic evidence of dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/40\">",
"     40",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H5152246#H5152246\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'Genetic features'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       -7/del(7q)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       -5/del(5q)",
"      </span>",
"     </li>",
"     <li>",
"      del(13q)",
"     </li>",
"     <li>",
"      del(11q)",
"     </li>",
"     <li>",
"      del(12p) or t(12p)",
"     </li>",
"     <li>",
"      del(9q)",
"     </li>",
"     <li>",
"      idic(X)(q13)",
"     </li>",
"     <li>",
"      t(17p) (unbalanced translocations) or i(17q) (ie, loss of 17p)",
"     </li>",
"     <li>",
"      t(11;16)(q23;p13.3)",
"     </li>",
"     <li>",
"      t(3;21)(q26.2;q22.1)",
"     </li>",
"     <li>",
"      t(1;3)(p36.3;q21)",
"     </li>",
"     <li>",
"      t(2;11)(p21;q23)",
"     </li>",
"     <li>",
"      inv(3)(q21q26.2)",
"     </li>",
"     <li>",
"      t(6;9)(p23;q34)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similarly, the following cytogenetic abnormalities, if found, result in the diagnosis of acute myeloid leukemia, regardless of blast count [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/40\">",
"     40",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\", section on 'Bone marrow infiltration'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      t(8;21)(q22;q22); RUNX1-RUNX1T1 (previously AML1-ETO) &nbsp;",
"     </li>",
"     <li>",
"      inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 &nbsp;",
"     </li>",
"     <li>",
"      t(15;17)(q22;q21.1); PML-RARA",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256821606\">",
"    <span class=\"h3\">",
"     5q- syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification of isolated del(5q) is used in the World Health Organization (WHO) classification system of MDS to define the 5q- syndrome (",
"    <a class=\"graphic graphic_table graphicRef71654 \" href=\"UTD.htm?9/48/9996\">",
"     table 2",
"    </a>",
"    ). The 5q- syndrome is a distinctive type of primary MDS that primarily occurs in older women [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/12,41\">",
"     12,41",
"    </a>",
"    ]. The median age at diagnosis is 65 to 70 years, with a female predominance of 7:3 (in contrast to a male predominance in other forms of MDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/42\">",
"     42",
"    </a>",
"    ]. Affected patients typically present with a refractory macrocytic anemia and normal or elevated platelet counts and the absence of significant neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/12\">",
"     12",
"    </a>",
"    ]. Because of the typical absence of thrombocytopenia and significant neutropenia, there is a low incidence of bleeding and infection in these patients. Red blood cell transfusions are frequently required. (See",
"    <a class=\"local\" href=\"#H256828282\">",
"     'Deletions of chromosome 5'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    5q- syndrome may follow a relatively benign course that extends over several years. In one series, for example, the projected median survival was 63 months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/5\">",
"     5",
"    </a>",
"    ]. The likelihood of progression to AML is very low and 5q- syndrome often responds rapidly to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/5,43\">",
"     5,43",
"    </a>",
"    ]. With this treatment, the majority of patients with 5q- syndrome achieve red blood cell transfusion independence and complete cytogenetic remissions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link&amp;anchor=H2443602#H2443602\">",
"     \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'Patients with 5q deletion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cytogenetics as a predictor of prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of cytogenetic analysis to predict the outcome of any individual patient with MDS is difficult because many patients die from persistent and profound pancytopenia, regardless of whether or not progression to acute myeloid leukemia (AML) occurs. Despite this limitation, there are data demonstrating the prognostic significance of particular cytogenetic abnormalities for predicting survival, as well as progression to AML [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/7,44-46\">",
"     7,44-46",
"    </a>",
"    ]. Information regarding the presence or absence of chromosomal abnormalities is incorporated into the most commonly used prognostic scoring systems for MDS (eg, the original and revised International Prognostic Scoring Systems, the WHO Prognostic Scoring System, the MD Anderson Cancer Center MDS model). This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34425?source=see_link\">",
"     \"Prognosis of the myelodysplastic syndromes in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256819286\">",
"    <span class=\"h1\">",
"     GENE MUTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in certain genes have been identified in patients with MDS and acute myeloid leukemia (AML) with or without the presence of chromosomal abnormalities. Some of these are discussed below. While these gene mutations have been found to affect DNA methylation, tumor suppressor genes, and oncogenes, the prognostic significance of such mutations is not well characterized. Although many of these gene mutations are even more frequent in AML, particularly in AML with a normal karyotype, they are thought to provide insight into the pathobiology of MDS and its progression to AML.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TET2 mutations &mdash; DNA methylation is a prognostic marker and predictor of response to therapy among patients with MDS and appears to be a mechanism of disease progression to acute myeloid leukemia (AML) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. In addition, DNA hypomethylating agents that inhibit DNA methyltransferases (DNMTs) have demonstrated activity in MDS and have become a key component of the initial therapy of many patients with MDS. The TET (ten-eleven translocation) family of genes encode proteins involved in the epigenetic control of DNA expression through demethylation [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/49\">",
"       49",
"      </a>",
"      ]. Somatic mutations in TET2 occur in approximately 15 percent of myeloid cancers, including MDS [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/50\">",
"       50",
"      </a>",
"      ]. Loss of function mutations of TET2 results in increased methylation and silencing of genes that are normally expressed. When present in MDS, TET2 mutations have been associated with a more favorable prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/51\">",
"       51",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link&amp;anchor=H2447218#H2447218\">",
"       \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'DNA hypomethylating agents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      RUNX1 transcriptional core-binding factor gene &mdash; RUNX1 mutations are seen in 7 to 15 percent of cases of de novo MDS, are more common in cases of therapy-related MDS, and portend a poorer prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/4,52-54\">",
"       4,52-54",
"      </a>",
"      ]. In addition, RUNX1 is a translocation partner for RUNX1T1 (ETO) in cases of AML with t(8;21). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=see_link&amp;anchor=H7#H7\">",
"       \"Cytogenetics in acute myeloid leukemia\", section on '8;21 translocation in AML'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      TP53 tumor suppressor gene &mdash; The TP53 tumor suppressor gene is located on 17p and mediates cell cycle arrest in response to a variety of cellular stressors. In MDS, about 5 to 15 percent of cases have known TP53 mutations at the time of diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/4,55,56\">",
"       4,55,56",
"      </a>",
"      ]. Abnormalities in p53 are more common in patients with MDS associated with prior exposure to alkylating agents of radiation (ie, therapy-related MDS). Loss of wild-type TP53 is associated with resistance to treatment and is a marker of poor prognosis independent of the IPSS risk score [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/57-59\">",
"       57-59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      RAS oncogenes &mdash; The RAS (HRAS, KRAS, NRAS) proto-oncogenes play an important role in signal transduction [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/60\">",
"       60",
"      </a>",
"      ]. Mutations of RAS have been identified in 10 to 35 percent of cases of MDS and in a subset of patients with AML [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/4,61-63\">",
"       4,61-63",
"      </a>",
"      ]. The majority of the mutations in MDS are in the NRAS gene; KRAS and HRAS mutations occur less frequently. In both AML and MDS, RAS mutations have been reported more frequently in cases with a monocytic morphology (eg, chronic myelomonocytic leukemia) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/64\">",
"       64",
"      </a>",
"      ]. The significance of RAS mutations in MDS remains unclear; however RAS mutations are associated with MDS characterized by",
"      <span class=\"nowrap\">",
"       -7/del(7q)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ASXL1 mutations &mdash; The additional sex-comb like-1&rsquo; (ASXL1) gene encodes a protein involved in the epigenetic regulation of gene expression and is mutated in approximately 10 percent of MDS cases [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/65-68\">",
"       65-68",
"      </a>",
"      ]. The prognostic implications of these mutations are not yet known [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IDH mutations &mdash; Mutations in the isocitrate dehydrogenase oncogenes (ie, IDH1 and IDH2) have been reported in some cases of MDS, result in DNA hypermethylation and alteration of gene expression, and are thought to portend a poor prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/69-71\">",
"       69-71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      FLT3 gene mutations &mdash; While mutations in the FLT3 gene are uncommon in MDS, they have been associated with a worse prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/72,73\">",
"       72,73",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36730?source=see_link&amp;anchor=H10#H10\">",
"       \"Prognosis of acute myeloid leukemia\", section on 'FLT3 gene'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      SF3B1 gene mutations &mdash; The SF3B1 gene encodes for part of a nuclear ribonucleoprotein that complexes with other nuclear ribonucleoproteins to create the spliceosome that is responsible for splicing messenger RNA. Recurrent somatic point mutations in this gene were identified 72 of 352 patients (20 percent) with MDS in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/74\">",
"       74",
"      </a>",
"      ]. Within this group, mutations of SF3B1 were common among patients with MDS with prominent ring sideroblasts (65 percent), but less common in patients with refractory anemia (10 percent), refractory cytopenia and multilineage dysplasia (6 percent), and refractory anemia with excess blasts (5 percent). Subsequent studies have confirmed the presence of SF3B1 gene mutations in a subgroup of patients with MDS and also identified mutations in other genes affecting mRNA splicing (eg, U2AF1, U2AF35, ZRSR2, and SRSF2) in patients with MDS [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/75-83\">",
"       75-83",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     GENOMIC MICROARRAY STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single nucleotide polymorphism (SNP) microarray or array comparative genomic hybridization techniques provide much higher resolution than conventional cytogenetic analysis in detecting genomic and chromosomal abnormalities leading to copy number alterations in hematological neoplasms.",
"   </p>",
"   <p>",
"    SNP arrays can detect genomic imbalances such as loss or gain of gene copy numbers, and copy-neutral loss of heterozygosity (copy-neutral LOH), so-called acquired uniparental disomy (UPD), due to incomplete chromosome segregation or to mitotic recombination. Various cryptic copy number changes and copy-neutral LOH have been found in up to 80 percent of MDS patients, and in about 30 percent of MDS patients with a normal karyotype [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/19,84\">",
"     19,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A cryptic defect at chromosome band 4q24 was initially identified in a series of patients with MDS and other myeloid diseases using SNP microarrays and DNA sequencing [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/50,85\">",
"     50,85",
"    </a>",
"    ]. These studies also identified the TET2 gene as the most frequently mutated gene thus far identified in MDS. TET2 mutations are now detected by DNA sequencing. Although the prognostic value of most newly-discovered genomic and chromosomal aberrations in MDS by SNP arrays is unclear at this time [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/14\">",
"     14",
"    </a>",
"    ], a study of 96 patients with MDS reported that TET mutations are an independent favorable prognostic factor in MDS [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14905/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H196106698\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clonal chromosomal abnormalities can be detected in bone marrow cells in 40 to 70 percent of patients with primary myelodysplastic syndromes (MDS). Although rates vary depending upon the technique used and the population studied, the most common chromosomal abnormalities seen in MDS are del(5q), -7 or del(7q), trisomy 8, del(20q), and loss of the Y chromosome (",
"      <a class=\"graphic graphic_table graphicRef77909 \" href=\"UTD.htm?29/24/30093\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef71654 \" href=\"UTD.htm?9/48/9996\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H256827820\">",
"       'Recurring abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of MDS is usually made based upon an evaluation of the bone marrow and peripheral smear in the appropriate clinical context. Certain cytogenetic abnormalities result in the diagnosis of MDS in patients with otherwise unexplained refractory cytopenia and no morphologic evidence of dysplasia. Similarly, there are cytogenetic abnormalities that result in the diagnosis of acute myeloid leukemia rather than MDS, regardless of blast count. (See",
"      <a class=\"local\" href=\"#H256827544\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The identification of isolated del(5q) is used in the World Health Organization (WHO) classification system of MDS to define the 5q- syndrome (",
"      <a class=\"graphic graphic_table graphicRef71654 \" href=\"UTD.htm?9/48/9996\">",
"       table 2",
"      </a>",
"      ). The 5q- syndrome is a distinctive type of primary MDS that has a relatively good prognosis and good chance of responding to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      . In comparison, del(5q) or structural rearrangements of 5q with other chromosomal changes is associated with advanced MDS and a worse outcome. (See",
"      <a class=\"local\" href=\"#H256821606\">",
"       '5q- syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are data demonstrating the prognostic significance of particular cytogenetic abnormalities for predicting survival, as well as progression to AML. Information regarding the presence or absence of chromosomal abnormalities is incorporated into the most commonly used prognostic scoring systems for MDS (eg, the original and revised International Prognostic Scoring Systems, the WHO Prognostic Scoring System, the MD Anderson Cancer Center MDS model). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Cytogenetics as a predictor of prognosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34425?source=see_link\">",
"       \"Prognosis of the myelodysplastic syndromes in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Certain gene mutations also confer prognostic significance in adult patients with MDS, but it is not yet clear how to incorporate these changes into treatment planning. Many of these gene mutations are thought to provide insight into the pathobiology of MDS. (See",
"      <a class=\"local\" href=\"#H256819286\">",
"       'Gene mutations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Even those patients without obvious abnormalities detected by cytogenetic analysis, FISH, or gene mutation analyses likely have abnormalities in gene expression profiles or have acquired copy number alterations that may help to identify genes important for the pathogenesis of MDS. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Genomic microarray studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/1\">",
"      Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007; 110:4385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/2\">",
"      Pozdnyakova O, Miron PM, Tang G, et al. Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. Cancer 2008; 113:3331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/3\">",
"      Bejar R, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 2011; 29:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/4\">",
"      Olney HJ, Le Beau MM. Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes. Leuk Res 2007; 31:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/5\">",
"      Lewis S, Oscier D, Boultwood J, et al. Hematological features of patients with myelodysplastic syndromes associated with a chromosome 5q deletion. Am J Hematol 1995; 49:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/6\">",
"      Bernasconi P. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review. Br J Haematol 2008; 142:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/7\">",
"      Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/8\">",
"      Steensma DP, List AF. Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. Mayo Clin Proc 2005; 80:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/9\">",
"      Bacher U, Haferlach T, Kern W, et al. The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes. Cancer 2009; 115:4524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/10\">",
"      Wiktor A, Rybicki BA, Piao ZS, et al. Clinical significance of Y chromosome loss in hematologic disease. Genes Chromosomes Cancer 2000; 27:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/11\">",
"      Velloso ER, Michaux L, Ferrant A, et al. Deletions of the long arm of chromosome 7 in myeloid disorders: loss of band 7q32 implies worst prognosis. Br J Haematol 1996; 92:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/12\">",
"      Boultwood J, Lewis S, Wainscoat JS. The 5q-syndrome. Blood 1994; 84:3253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/13\">",
"      Jerez A, Gondek LP, Jankowska AM, et al. Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. J Clin Oncol 2012; 30:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/14\">",
"      Boultwood J, Fidler C, Strickson AJ, et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood 2002; 99:4638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/15\">",
"      Horrigan SK, Arbieva ZH, Xie HY, et al. Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31. Blood 2000; 95:2372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/16\">",
"      Liu TX, Becker MW, Jelinek J, et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med 2007; 13:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/17\">",
"      Zhao N, Stoffel A, Wang PW, et al. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci U S A 1997; 94:6948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/18\">",
"      Pedersen B. 5q(-)survival: importance of gender and deleted 5q bands and survival analysis based on 324 published cases. Leuk Lymphoma 1998; 31:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/19\">",
"      Gondek LP, Tiu R, O'Keefe CL, et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008; 111:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/20\">",
"      Graubert TA, Payton MA, Shao J, et al. Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. PLoS One 2009; 4:e4583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/21\">",
"      Heinrichs S, Kulkarni RV, Bueso-Ramos CE, et al. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia 2009; 23:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/22\">",
"      Boultwood J, Pellagatti A, Cattan H, et al. Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. Br J Haematol 2007; 139:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/23\">",
"      Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008; 451:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/24\">",
"      Pellagatti A, Hellstr&ouml;m-Lindberg E, Giagounidis A, et al. Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes. Br J Haematol 2008; 142:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/25\">",
"      Mohamedali A, Mufti GJ. Van-den Berghe's 5q- syndrome in 2008. Br J Haematol 2009; 144:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/26\">",
"      Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 2010; 16:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/27\">",
"      Liu Y, Asai T, Nimer SD. Myelodysplasia: battle in the bone marrow. Nat Med 2010; 16:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/28\">",
"      Barlow JL, Drynan LF, Hewett DR, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med 2010; 16:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/29\">",
"      Valencia A, Cervera J, Such E, et al. Lack of RPS14 promoter aberrant methylation supports the haploinsufficiency model for the 5q- syndrome. Blood 2008; 112:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/30\">",
"      Wang J, Fernald AA, Anastasi J, et al. Haploinsufficiency of Apc leads to ineffective hematopoiesis. Blood 2010; 115:3481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/31\">",
"      Lane SW, Sykes SM, Al-Shahrour F, et al. The Apc(min) mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS. Blood 2010; 115:3489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/32\">",
"      Joslin JM, Fernald AA, Tennant TR, et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood 2007; 110:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/33\">",
"      Kantarjian H, O'Brien S, Ravandi F, et al. The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS? Cancer 2009; 115:5202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/34\">",
"      Xu F, Li X, Wu L, et al. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring. Ann Hematol 2011; 90:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/35\">",
"      Makishima H, Jankowska AM, Tiu RV, et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 2010; 24:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/36\">",
"      Nikoloski G, Langemeijer SM, Kuiper RP, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010; 42:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/37\">",
"      Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25:3503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/38\">",
"      Bench AJ, Nacheva EP, Hood TL, et al. Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG). Oncogene 2000; 19:3902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/39\">",
"      Wang PW, Eisenbart JD, Espinosa R 3rd, et al. Refinement of the smallest commonly deleted segment of chromosome 20 in malignant myeloid diseases and development of a PAC-based physical and transcription map. Genomics 2000; 67:28.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/41\">",
"      Nimer SD. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. J Clin Oncol 2006; 24:2576.",
"     </a>",
"    </li>",
"    <li>",
"     Vardiman JW, Brunning RD, Arber DA, et al. Introduction and overview of the classification of the myeloid neoplasms. In: WHO classification of tumors of hematopoietic and lymphoid tissues, Swerdlow SH, Campo E, Harris NL, et al (Eds), WHO press, 2008. p.18.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/43\">",
"      List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/44\">",
"      Sanz GF, Sanz MA, Vallesp&iacute; T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/45\">",
"      Sol&eacute; F, Espinet B, Sanz GF, et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espa&ntilde;ol de Citogen&eacute;tica Hematol&oacute;gica. Br J Haematol 2000; 108:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/46\">",
"      Toyama K, Ohyashiki K, Yoshida Y, et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia 1993; 7:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/47\">",
"      Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010; 28:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/48\">",
"      Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009; 113:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/49\">",
"      Ito S, D'Alessio AC, Taranova OV, et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010; 466:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/50\">",
"      Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/51\">",
"      Kosmider O, Gelsi-Boyer V, Cheok M, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009; 114:3285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/52\">",
"      Chen CY, Lin LI, Tang JL, et al. RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol 2007; 139:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/53\">",
"      Steensma DP, Gibbons RJ, Mesa RA, et al. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia. Eur J Haematol 2005; 74:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/54\">",
"      Tang JL, Hou HA, Chen CY, et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood 2009; 114:5352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/55\">",
"      Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 2001; 19:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/56\">",
"      Kaneko H, Misawa S, Horiike S, et al. TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. Blood 1995; 85:2189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/57\">",
"      Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84:3148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/58\">",
"      Horiike S, Kita-Sasai Y, Nakao M, Taniwaki M. Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome. Leuk Lymphoma 2003; 44:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/59\">",
"      Kita-Sasai Y, Horiike S, Misawa S, et al. International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. Br J Haematol 2001; 115:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/60\">",
"      Zeleznik-Le NJ, Nucifora G, Rowley JD. The molecular biology of myeloproliferative disorders as revealed by chromosomal abnormalities. Semin Hematol 1995; 32:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/61\">",
"      Ahuja HG, Foti A, Bar-Eli M, Cline MJ. The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood 1990; 75:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/62\">",
"      Bartram CR. Molecular genetic aspects of myelodysplastic syndromes. Hematol Oncol Clin North Am 1992; 6:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/63\">",
"      Nakagawa T, Saitoh S, Imoto S, et al. Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia. Oncology 1992; 49:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/64\">",
"      Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49:4682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/65\">",
"      Gelsi-Boyer V, Trouplin V, Ad&eacute;la&iuml;de J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009; 145:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/66\">",
"      Boultwood J, Perry J, Pellagatti A, et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 2010; 24:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/67\">",
"      Carbuccia N, Murati A, Trouplin V, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009; 23:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/68\">",
"      Fisher CL, Randazzo F, Humphries RK, Brock HW. Characterization of Asxl1, a murine homolog of Additional sex combs, and analysis of the Asx-like gene family. Gene 2006; 369:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/69\">",
"      Thol F, Weissinger EM, Krauter J, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010; 95:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/70\">",
"      Kosmider O, Gelsi-Boyer V, Slama L, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 2010; 24:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/71\">",
"      Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/72\">",
"      Shih LY, Lin TL, Wang PN, et al. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome. Cancer 2004; 101:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/73\">",
"      Georgiou G, Karali V, Zouvelou C, et al. Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance. Br J Haematol 2006; 134:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/74\">",
"      Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011; 365:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/75\">",
"      Makishima H, Visconte V, Sakaguchi H, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012; 119:3203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/76\">",
"      Damm F, Kosmider O, Gelsi-Boyer V, et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 2012; 119:3211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/77\">",
"      Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/78\">",
"      Graubert TA, Shen D, Ding L, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2012; 44:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/79\">",
"      Visconte V, Makishima H, Jankowska A, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 2012; 26:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/80\">",
"      Malcovati L, Papaemmanuil E, Bowen DT, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 2011; 118:6239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/81\">",
"      Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012; 119:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/82\">",
"      Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012; 120:3080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/83\">",
"      Wu SJ, Kuo YY, Hou HA, et al. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood 2012; 120:3106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/84\">",
"      Mohamedali A, G&auml;ken J, Twine NA, et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007; 110:3365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14905/abstract/85\">",
"      Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41:838.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4483 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-3DA446CC7F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_35_14905=[""].join("\n");
var outline_f14_35_14905=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H196106698\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5771332\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CHROMOSOMAL ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H256827820\">",
"      Recurring abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H256828282\">",
"      - Deletions of chromosome 5",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H256828394\">",
"      - Monosomy 7 and deletions of chromosome 7",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H256828429\">",
"      - Trisomy 8",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H256828457\">",
"      - Deletions of chromosome 20",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H256820964\">",
"      Use in diagnosis and classification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H256827544\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H256821606\">",
"      - 5q- syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cytogenetics as a predictor of prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H256819286\">",
"      GENE MUTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GENOMIC MICROARRAY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196106698\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4483\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4483|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/24/30093\" title=\"table 1\">",
"      Chromosomal abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/48/9996\" title=\"table 2\">",
"      MDS classification WHO",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26954?source=related_link\">",
"      Anemia in children due to decreased red blood cell production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18167?source=related_link\">",
"      Chromosomal translocations, deletions, and inversions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=related_link\">",
"      Cytogenetics in acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6489?source=related_link\">",
"      General aspects of cytogenetic analysis in hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19880?source=related_link\">",
"      Overview of the treatment of myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36730?source=related_link\">",
"      Prognosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34425?source=related_link\">",
"      Prognosis of the myelodysplastic syndromes in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=related_link\">",
"      Treatment of intermediate, low, or very low risk myelodysplastic syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_35_14906="Hamstring injuries";
var content_f14_35_14906=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hamstring injuries",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/35/14906/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/35/14906/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/35/14906/contributors\">",
"     Spencer T Copland, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/35/14906/contributors\">",
"     John S Tipton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/35/14906/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/35/14906/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/35/14906/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/35/14906/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/35/14906/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H23894869\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hamstring muscle injuries occur frequently among recreational and elite athletes. Several terms, including posterior thigh injury, hamstring strain, hamstring tendinopathy, and hamstring tear, are used to describe such injuries, but they are not always synonymous. In most cases, the severity of the injury determines treatment and the amount of time the athlete must take off from sport [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/1-8\">",
"     1-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the purpose of this review, we will define hamstring injury as any strain or tear, including avulsion, of any of the muscles or tendons within the hamstring group, including the biceps femoris, semitendinosus, and semimembranosus muscles.",
"   </p>",
"   <p>",
"    The diagnosis, management, risk factors, and prevention of hamstring muscle and tendon injuries are reviewed here. Other musculoskeletal injuries of the lower extremity are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32138?source=see_link\">",
"     \"Anterior cruciate ligament injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34296?source=see_link\">",
"     \"Ankle sprain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23894877\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of hamstring injuries among athletes varies based upon the definition used. Nevertheless, most researchers agree that hamstring injuries comprise a substantial percentage of acute, sports-related musculoskeletal injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/9\">",
"     9",
"    </a>",
"    ]. Prevalence ranges from 8 to 25 percent, depending upon the sport. The timing for return to sport ranges from as early as two weeks to never, depending upon injury severity and the sport in question. One observational study reports a single-season prevalence rate greater than 50 percent among elite soccer players [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/10\">",
"     10",
"    </a>",
"    ]. Recurrent hamstring injuries develop in more than 30 percent of athletes, with most occurring during the ensuing sporting season [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/4,5,7,8\">",
"     4,5,7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1615166\">",
"    <span class=\"h1\">",
"     ANATOMY AND PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hamstring is composed of three muscles in the posterior thigh: the biceps femoris, semitendinosus, and semimembranosus (",
"    <a class=\"graphic graphic_picture graphicRef73719 \" href=\"UTD.htm?26/6/26722\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef53747 \" href=\"UTD.htm?12/34/12841\">",
"     figure 1",
"    </a>",
"    ). The long head of the biceps femoris originates at the ischial tuberosity, while the short head originates from the femoral shaft; both insert at the fibular head. The semitendinosus and semimembranosus both originate from the ischial tuberosity and insert at the medial tibia in the pes anserine region.",
"   </p>",
"   <p>",
"    An understanding of the anatomy of the posterior hip region, thigh muscles, and adjacent nerves and vascular structures is important when considering the differential diagnosis of posterior thigh pain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/11\">",
"     11",
"    </a>",
"    ]. As an example, the sciatic nerve&rsquo;s location adjacent to the hamstrings can lead to radicular symptoms following some hamstring muscle injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/12-17\">",
"     12-17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23894975\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The primary actions of the hamstring muscles are knee flexion and hip extension. In addition, the biceps femoris contributes to external rotation of the hip, while the semitendinosus and semimembranosus contribute to internal rotation.",
"   </p>",
"   <p>",
"    From a functional standpoint, the hamstring&rsquo;s key role is in deceleration during walking, running, and cutting (ie, making acute changes of direction at high speed). This deceleration is accomplished by eccentric muscle contraction (ie, contraction while the muscle lengthens). The hamstring muscles decelerate the lower limb during the forward swing phase of running, before the hip is extended to achieve forward motion. This braking function is also critical in kicking movements [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/6,18,19\">",
"     6,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During locomotion, the hamstring muscle group must act in coordinated fashion with the other muscles involved in extension, flexion, and stabilization of the knee and hip. Injury to any of the muscles involved in locomotion is likely to have ramifications elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23894884\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2453276\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide range of potential risk factors, both modifiable and non-modifiable, contribute to hamstring injury [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/1,2,5,20\">",
"     1,2,5,20",
"    </a>",
"    ]. Sport-specific risk factors are discussed separately. (See",
"    <a class=\"local\" href=\"#H23894891\">",
"     'Sport-specific risks'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Few large prospective studies addressing potential risk factors for hamstring injury or the best methods for reducing the risk of injury have been performed; as a result, any discussion is necessarily limited. According to one statistical model, approximately 20 to 50 injuries are needed to determine accurately whether a risk factor is strongly associated with hamstring injury, and 200 or more injuries are needed to assess risk factors with small to moderate associations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Modifiable risk factors may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inadequate warm-up",
"     </li>",
"     <li>",
"      Increased training volume",
"     </li>",
"     <li>",
"      Muscle fatigue",
"     </li>",
"     <li>",
"      Hamstring inflexibility",
"     </li>",
"     <li>",
"      Hamstring weakness (may be weakness relative to quadriceps)",
"     </li>",
"     <li>",
"      Cross-pelvic posture (ie, lumbar lordosis with anterior pelvic tilt)",
"     </li>",
"     <li>",
"      Lumbar-pelvic weakness",
"     </li>",
"     <li>",
"      Poor biomechanics (eg, running or change of direction)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Non-modifiable risk factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Previous hamstring or lower extremity muscle injury",
"     </li>",
"     <li>",
"      Older age",
"     </li>",
"     <li>",
"      African or Aboriginal ethnic origin",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2453283\">",
"    <span class=\"h2\">",
"     Previous injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;A previous hamstring injury is the most frequently noted risk factor for subsequent injury. Most studies showing this association involve Australian Rules football and report that athletes with a previous hamstring injury were two to six times more likely to suffer recurrent strains [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/5,22-25\">",
"     5,22-25",
"    </a>",
"    ]. While most subsequent injuries occur within the first two months after return to sport, increased risk persists thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/22,23,26\">",
"     22,23,26",
"    </a>",
"    ]. In some studies, the risk was three times that of an uninjured athlete up to one year or longer following the initial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased risk associated with previous injury is due in part to the weakness of the muscle during healing which, according to some laboratory and clinical studies, requires up to nine months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/1\">",
"     1",
"    </a>",
"    ]. However, debate persists about the relative importance of inadequate rehabilitation and premature return to sport and the role of permanent tissue damage created by the initial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/6,22,25,27,28\">",
"     6,22,25,27,28",
"    </a>",
"    ]. Some researchers believe that skeletal muscles are at risk for reinjury because of scar tissue formation and changes in the muscular architecture [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/22,25\">",
"     22,25",
"    </a>",
"    ], but others dispute this contention [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association between the severity of the initial injury (defined in some studies by the number of days missed from competition) and recurrence during the same season is unclear. Some studies report no relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/29\">",
"     29",
"    </a>",
"    ], while others found a high risk of recurrence within two seasons in athletes with severe strains (&gt;18 days missed) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/18\">",
"     18",
"    </a>",
"    ]. According to three prospective cohort studies, injury size (as determined by magnetic resonance imaging) did not clearly identify individuals at risk for reinjury, but did correlate with rehabilitation time [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. This suggests that premature return to sport increases the risk of reinjury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2453290\">",
"    <span class=\"h2\">",
"     Muscle inflexibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited hamstring flexibility may increase the risk of injuring these muscles. However, studies both supporting and contradicting this assertion have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/7,33\">",
"     7,33",
"    </a>",
"    ]. Adding to the confusion are the problems inherent in interpreting studies of muscle flexibility. Measuring hamstring flexibility can be difficult, since motion occurs at both the hamstring and the lumbo-pelvic junction, and many athletes participate in regular stretching routines and demonstrate good flexibility at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hamstring flexibility may be less important than the flexibility of the quadriceps muscles (the antagonists of the hamstrings) and hip flexor muscles in determining the risk of hamstring injury. One prospective study reported an inverse relationship between increased quadriceps flexibility and the incidence of hamstring strain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/3\">",
"     3",
"    </a>",
"    ]. Athletes able to achieve greater than approximately 50 degrees of knee flexion (using a modified Thomas test) were less likely to suffer a hamstring strain. In the same study, hip flexor tightness posed a significant risk for hamstring injury, although the older-aged athletes in this subgroup may have confounded the results.",
"   </p>",
"   <p>",
"    One reason why tight hip flexor muscles may predispose athletes to hamstring injury is the higher potential energy this tightness creates when the hip is extended and the knee flexed during the pre-swing phase of running [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/19\">",
"     19",
"    </a>",
"    ]. This energy generates greater forward propulsion of the leg from the passive recoil of these muscles during the subsequent swing phase. The more forceful propulsion increases the load on the hamstrings as they decelerate the leg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2453304\">",
"    <span class=\"h2\">",
"     Muscle weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is debate about whether isolated hamstring weakness predisposes to injury. In a prospective study of track and field athletes, injured runners demonstrated significant unilateral hamstring weakness compared to the uninjured side [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/35\">",
"     35",
"    </a>",
"    ]. Similar findings were reported in a prospective study of Australian Rules footballers that included 672 hamstring injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/5\">",
"     5",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    However, other studies do not the support the role of hamstring weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Strength imbalances between the quadriceps and hamstring muscle groups may play a larger role in hamstring injury than isolated hamstring weakness. Relative weakness of the hamstrings compared to the quadriceps in the injured leg has been noted in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/2,35,36\">",
"     2,35,36",
"    </a>",
"    ]. As described above, the hamstring muscles decelerate the leg during the swing phase of running and during kicking movements. The force of the leg swing may be greater in individuals with relatively stronger quadriceps, placing greater demands on the hamstrings during deceleration. Some researchers speculate that the quadriceps strength of many elite athletes may be too great, predisposing them to hamstring injury [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2453318\">",
"    <span class=\"h2\">",
"     Problems with related structures (kinetic chain)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injuries to other muscles in the affected leg may predispose to hamstring strain. This is consistent with the concept of the kinetic chain, whereby muscles act as one component in a series of interdependent musculoskeletal structures that work together to coordinate and control movement. The hamstring is an important structure in the posterior kinetic chain, a term often used to describe the inter-related structures in the back of the body involved in extending the hip and spine, among other functions.",
"   </p>",
"   <p>",
"    Weakness (eg, muscle injury) or tightness in any part of a kinetic chain increases the strain placed on other components, which must compensate, thereby increasing their risk of injury. For instance, a non-hamstring injury may alter an athlete&rsquo;s running biomechanics, placing added stress on the hamstring [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/5\">",
"     5",
"    </a>",
"    ]. As one example, the risk of subsequent hamstring injury is increased in individuals with a history of osteitis pubis or previous injury to the calf or quadriceps muscles or knee ligaments, according to observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/5,25\">",
"     5,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple abnormalities of the posterior kinetic chain occur with a cross pelvic posture, and preliminary research suggests that this posture increases the risk for hamstring injury [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/37\">",
"     37",
"    </a>",
"    ]. The cross pelvic posture is defined by an increased lumbar lordosis and anterior tilt of the pelvis and is associated with tight hip flexor (iliopsoas and rectus femoris) and lumbar extensor (lumbar erector spinae) muscles, weak hip extensor (gluteus maximus) and lumbar flexor (rectus abdominus) muscles, and sacroiliac joint dysfunction. These musculoskeletal abnormalities place added stress on the hamstring muscles during activity. Further studies are needed to determine more precisely the role of cross pelvic posture and sacroiliac joint dysfunction in hamstring strain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/2\">",
"     2",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Lumbar-pelvic weakness is another abnormality of the posterior kinetic chain that may increase the risk for hamstring muscle injury. Weakness in this region results in abnormal posture, joint malalignment, and inefficient movement patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2453311\">",
"    <span class=\"h2\">",
"     Age and other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the age ranges for athletes included in studies of hamstring injury are relatively narrow, increasing age appears to be another risk factor for hamstring injury, according to several studies of Australian footballers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/3,5,19,24-26\">",
"     3,5,19,24-26",
"    </a>",
"    ]. Specifically, athletes older than 23 years were 1.3 to 3.9 times more likely to suffer a hamstring injury than younger players [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/5,19\">",
"     5,19",
"    </a>",
"    ], while athletes older than 25 years were 2.8 to 4.4 times more likely [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/3,26\">",
"     3,26",
"    </a>",
"    ]. Data suggest that the overall risk of injury increases by 30 percent annually after the start of a professional playing career [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Different theories have been proposed to explain why hamstring injury risk increases with age. One theory suggests that aging correlates with a reduction in the hamstring muscles&rsquo; cross-sectional area, which reduces the muscles capacity to generate tension and resist loads before failure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/7\">",
"     7",
"    </a>",
"    ]. However, the studies supporting this theory involved younger athletes, possibly with less developed musculature, and older athletes, who may already have sustained subclinical hamstring injuries, and these factors may have confounded the results. A second theory is that age-related lumbar degeneration leads to L5 and S1 nerve impingement and subsequent hamstring muscle fiber degeneration, and ultimately, hamstring injury [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Race and ethnicity may also be risk factors, as athletes of African or Aboriginal ethnic origin appear significantly more likely to suffer hamstring strains [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/18,25\">",
"     18,25",
"    </a>",
"    ]. In Australian Rules football, professional Aboriginal footballers were 11.2 times more likely to suffer hamstring strains than non-Aboriginal footballers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/25\">",
"     25",
"    </a>",
"    ]. In a study of English professional football leagues, hamstring injury was not specific to any nationality or ethnic group, but was increased in all players of &ldquo;black ethnic origin&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of the relationship between increased weight or body mass index (BMI) and hamstring injury report inconsistent results [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/3,5,22,25,26,36\">",
"     3,5,22,25,26,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23894891\">",
"    <span class=\"h2\">",
"     Sport-specific risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hamstring injuries are common in sports that involve high-speed running. Track and field runners and hurdlers, who combine forceful hip flexion with full knee extension during their events, are prone to hamstring injury [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/35,39,40\">",
"     35,39,40",
"    </a>",
"    ]. Participants in sports that involve rapid deceleration and acceleration, such as football (soccer), American football, and Australian Rules football, are also prone to hamstring strain.",
"   </p>",
"   <p>",
"    With each of these sports, there are specific circumstances when hamstring injuries are more prevalent. As an example, playing at a higher level of competition increases the risk factor for hamstring injury. One observational study of English Premier League (EPL) soccer reported a significantly higher prevalence of hamstring strain in the first division versus the second [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/18\">",
"     18",
"    </a>",
"    ]. A similar study of Australian Rules football found a significantly higher prevalence (&gt;20 percent) of hamstring injuries among players in the Australian Football League (AFL) compared to the less competitive South Australian National Football League (SANFL) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/25\">",
"     25",
"    </a>",
"    ]. These differences may reflect the increased physical challenges of the higher leagues, where the tempo of games may be faster and training more demanding.",
"   </p>",
"   <p>",
"    Positions that require more running are associated with higher hamstring injury rates. As an example, outfield players exhibit a higher incidence (22 to 37 percent) of hamstring strain compared to goalkeepers in English football and Australian Rules football leagues [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/18,36\">",
"     18,36",
"    </a>",
"    ]. A 10-year study of hamstring injuries (n = 1716) in the National Football League of the United States reported that 43.9 percent were sustained by wide receivers or defensive secondary players [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exercises involving movements of the knee and hip joints at the outer limits of their range of motion, as with ballet dancers, represent another risk factor for hamstring injuries.",
"    <sup>",
"    </sup>",
"    Sports with physical demands similar to dance demonstrate similar patterns of symptoms, hamstring injury location, and recovery time. Such hamstring injuries usually occur during movements that combine extreme hip flexion and knee extension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4095688\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4095548\">",
"    <span class=\"h2\">",
"     History and mechanism of injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most individuals with hamstring injuries present acutely complaining of the sudden onset of posterior thigh pain while performing a high-risk activity. The individual may report a pop or feel localized warmth at the site of injury. (See",
"    <a class=\"local\" href=\"#H23894884\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Some researchers hypothesize that there are two primary mechanisms for hamstring injury [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/39,42,43\">",
"     39,42,43",
"    </a>",
"    ]. These can be referred to as a running or high-speed mechanism and a stretching or low-speed mechanism; although not all stretching movement (eg, high kick) injuries occur at truly low speeds.",
"   </p>",
"   <p>",
"    Classically, hamstring injury occurs during high-speed running. As noted above, the hamstrings contract eccentrically to decelerate the leg during the end of the swing phase of running (when the lower extremity is fully extended in front of the runner&rsquo;s body). Injury occurs when a sudden forceful eccentric contraction of the hamstring occurs against resistance (eg, concentric quadriceps contraction), overloading the muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/13,17,39\">",
"     13,17,39",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1615166\">",
"     'Anatomy and physiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    With the low-speed mechanism, hamstring strain occurs during stretching movements with the hip and knee joints at their extreme limits of motion, forcing the hamstring beyond its elastic capacities [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/9,39\">",
"     9,39",
"    </a>",
"    ]. Such injuries can occur in dancers performing movements involving forced hip flexion with simultaneous full knee extension (eg, high kick).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23894954\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of a potential hamstring injury follows the standard approach used for all musculoskeletal injuries: inspection, palpation, range of motion assessment, strength testing, and special testing. Gait abnormalities should be noted. These may include limited hip flexion on the affected side, lack of full hip extension, decreased lift in the float (ie, swing) phase of gait, or an antalgic gait (ie, limp). Inspect the leg and hip region for swelling, ecchymosis, muscular defects, and atrophy. Each of the three hamstring muscles should be palpated from origin to insertion, paying particular attention to the origin at the ischial tuberosity and to the popliteal fossa. Focal tenderness is common. (See",
"    <a class=\"local\" href=\"#H1615166\">",
"     'Anatomy and physiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Range of motion can be assessed clinically with the patient prone and is easily quantified with a goniometer. We advocate assessing concentric hamstring strength starting with the knee at 90 degrees of flexion (",
"    <a class=\"graphic graphic_picture graphicRef74953 \" href=\"UTD.htm?41/11/42162\">",
"     picture 2",
"    </a>",
"    ) and assessing eccentric strength with the knee extended between 15 and 30 degrees (full knee extension [ie, leg straight] equals zero degrees) (",
"    <a class=\"graphic graphic_picture graphicRef54986 \" href=\"UTD.htm?3/26/3489\">",
"     picture 3",
"    </a>",
"    ). During strength testing, greater emphasis can be placed on the biceps femoris by externally rotating the leg (",
"    <a class=\"graphic graphic_picture graphicRef69764 \" href=\"UTD.htm?9/3/9265\">",
"     picture 4",
"    </a>",
"    ), while internal rotation accentuates the role of the semimembranosus and semitendinosus (",
"    <a class=\"graphic graphic_picture graphicRef78444 \" href=\"UTD.htm?20/43/21168\">",
"     picture 5",
"    </a>",
"    ). With the patient supine, assess hip range of motion and the strength of the hip flexors, extensors, abductors, and adductors.",
"   </p>",
"   <p>",
"    Knee range of motion, hamstring strength, the degree of ecchymosis, and the presence or absence of palpable muscle defects all assist the physician in grading the severity of injury and creating an appropriate treatment plan. Severe injury is suggested by pain accompanied by diffuse ecchymosis, extensive swelling, palpable defects in the muscle,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    notable strength deficits compared to the uninjured hamstrings. Advanced imaging and referral to an orthopedic surgeon is needed in such cases. (See",
"    <a class=\"local\" href=\"#H4095799\">",
"     'Imaging'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H23894996\">",
"     'Indications for orthopedic consultation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If radiculopathy is present, neurologic testing and a straight leg raise test should be performed; if the injury is not clearly a hamstring tear, a complete back and hip examination is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/14-16,44\">",
"     14-16,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=see_link\">",
"     \"Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=see_link\">",
"     \"Approach to the diagnosis and evaluation of low back pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23894968\">",
"    <span class=\"h2\">",
"     Injury location",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most studies, the biceps femoris is the most commonly injured hamstring muscle, followed by the semimembranosus, while the semitendinosus is not often injured [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/25,29,42,45\">",
"     25,29,42,45",
"    </a>",
"    ]. However, numbers vary among studies and often more than one muscle is injured [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/39,45\">",
"     39,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proximal injuries, including tendon avulsion (which occurs above the origin of the short head of the biceps femoris), are more common than distal injuries regardless of the muscle involved. Most injuries occur in the musculotendinous junction, a 10 to 12 cm transition zone in which myofibrils merge with tendon. Avulsion fractures of the ischium involving a hamstring muscle origin rarely occur in adults but may occur in skeletally immature athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/17,29,39,42,45\">",
"     17,29,39,42,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sprinters tend to injure the long head of the biceps femoris, including the intramuscular tendon (or aponeurosis) and adjacent muscle fibers proximally [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/30,42\">",
"     30,42",
"    </a>",
"    ]. According to one study, hamstring injuries among sprinters are often disabling initially but tend to require shorter rehabilitation compared to those sustained by dancers. The closer the injury is to the ischial tuberosity, the longer the recovery time required [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dancers and other athletes who sustain hamstring injuries via a low-speed mechanism typically strain the semimembranosus muscle and its proximal tendon. They require a longer convalescent period, likely due to the involvement of free tendon (ie, tendon without presence of myofibrils) or a bone fragment. However, within this subset of proximal injuries there appears to be no correlation between the distance of the injury from the ischial tuberosity and recovery time [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/39,43,46\">",
"     39,43,46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4095548\">",
"     'History and mechanism of injury'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4095428\">",
"    <span class=\"h2\">",
"     Injury severity and grading system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hamstring injuries traditionally have been classified as mild (Grade I), moderate (Grade II), or severe (Grade III). Grade I injuries signify a small disruption of the structural integrity of the musculotendinous unit with minor swelling and pain and no, or minimal, strength loss. Grade II strains are partial tears with some intact musculotendinous fibers, pain is present, and there is a definite loss of strength. Grade III tears involve complete tears of the musculotendinous unit with complete loss of muscle function and are typically accompanied by a large hematoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4095799\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Musculoskeletal ultrasonography (US) and magnetic resonance imaging (MRI) are the best methods for assessing hamstring injuries. Both provide detailed information about the location and extent of injury.",
"   </p>",
"   <p>",
"    The advantages of US include low cost and portability. In addition, US allows for dynamic assessment of the hamstring tendon, which provides information about tendon and muscle integrity at varying degrees of resisted contraction. US has greater sensitivity during the acute phase of injury when inflammatory fluid is found in the soft tissue, but sensitivity declines when scanning is delayed. As the fluid resolves (usually within two weeks), US becomes less accurate at depicting myofibrillar abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Further study to determine the sensitivity and specificity of US more precisely are needed. A limitation of US is that accuracy depends upon the skill of the ultrasonographer.",
"   </p>",
"   <p>",
"    MRI is more reliable than US at depicting hamstring tendon and osseous avulsion injuries and injuries at the deeper musculotendinous junction (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85937 \" href=\"UTD.htm?39/27/40374\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87259 \" href=\"UTD.htm?24/17/24851\">",
"     image 2",
"    </a>",
"    ). MRI allows accurate assessment of the degree of tendon retraction and of tendon edge morphology (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86518 \" href=\"UTD.htm?19/42/20133\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83906 \" href=\"UTD.htm?9/45/9941\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/29\">",
"     29",
"    </a>",
"    ]. This gives the surgeon important information, as tendon avulsion may require surgical repair [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/7,13-15,47,48\">",
"     7,13-15,47,48",
"    </a>",
"    ]. In addition, MRI sensitivity does not wane over time and MRI is useful for estimating time away from sport since the length and cross sectional area of the injury can be measured [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/30,31,49\">",
"     30,31,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When experienced musculoskeletal ultrasonographers are available, initial imaging should be performed with US because of its low cost and high sensitivity. However, in current clinical practice in the United States, MRI remains the imaging modality of choice when severe injuries (eg, hamstring rupture) are suspected and it is a superior tool for estimating recovery time [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Standard radiographs may be useful in skeletally immature athletes, in whom bony avulsion injuries are more common (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87258 \" href=\"UTD.htm?41/3/42034\">",
"     image 5",
"    </a>",
"    ), although even in these circumstances US may be preferable. In one study of 243 young athletes, US demonstrated greater sensitivity for avulsion injury compared to plain radiography [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23894975\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, the mechanism of injury and localization of symptoms at the time of injury makes the diagnosis of acute hamstring strain or rupture straightforward. However, in athletes with long standing pain, recurrent symptoms, or an unclear mechanism of injury, diagnosis can be more difficult. The differential diagnosis for posterior thigh pain includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Proximal thigh:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Lumbar radiculopathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=see_link\">",
"       \"Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hamstring syndrome (see",
"      <a class=\"local\" href=\"#H15303406\">",
"       'Hamstring syndrome'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Adductor (groin) muscle strain",
"     </li>",
"     <li>",
"      Femoral neck or shaft stress fracture (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=see_link\">",
"       \"Overview of stress fractures\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Posterior thigh",
"      <span class=\"nowrap\">",
"       compartment/pseudo-compartment",
"      </span>",
"      syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28215?source=see_link\">",
"       \"Chronic exertional compartment syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sacroiliac dysfunction",
"     </li>",
"     <li>",
"      Piriformis syndrome",
"     </li>",
"     <li>",
"      Sciatic nerve irritation or compression &nbsp;",
"     </li>",
"     <li>",
"      Proximal hamstring tendinopathy",
"     </li>",
"     <li>",
"      Rarely, benign or malignant tumors affecting pelvic bones",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distal thigh:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Deep venous thrombosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=see_link\">",
"       \"Diagnosis of suspected deep vein thrombosis of the lower extremity\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Meniscal injury (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/15/16632?source=see_link\">",
"       \"Meniscal injury of the knee\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lateral gastrocnemius",
"      <span class=\"nowrap\">",
"       rupture/tear",
"      </span>",
"     </li>",
"     <li>",
"      Popliteus injury",
"     </li>",
"     <li>",
"      Popliteal artery entrapment syndrome",
"     </li>",
"     <li>",
"      Popliteal cyst (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27016?source=see_link\">",
"       \"Popliteal (Baker's) cyst\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23894996\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ORTHOPEDIC CONSULTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The great majority of hamstring injuries can be managed successfully with rest and physical therapy. However, in some circumstances, operative repair may yield favorable results. Such circumstances include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe avulsion injuries with significant hamstring retraction (generally occurs in children)",
"     </li>",
"     <li>",
"      Complete (Grade III) proximal hamstring rupture",
"     </li>",
"     <li>",
"      High grade (Grade II or III) distal hamstring tears",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest orthopedic consultation in such cases. However, it is important to note that no randomized trials have been performed to assess the effectiveness of surgery to treat such hamstring injuries. Any recommendation for surgical treatment is based upon expert opinion, case series, and cohort studies. MRI helps to determine the need for orthopedic referral by identifying complete versus partial ruptures and quantifying the degree of muscular retraction. (See",
"    <a class=\"local\" href=\"#H4095799\">",
"     'Imaging'",
"    </a>",
"    above.) The physical findings that typically accompany more severe hamstring injuries are described above. (See",
"    <a class=\"local\" href=\"#H23894954\">",
"     'Physical examination'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Typically, the initial treatment for pediatric patients with bony apophyseal injuries is conservative. However, significant avulsions should be referred to an orthopedist to determine whether surgical management may be needed. While opinions vary and the number of clinicians using more conservative approaches is substantial, classic references recommend surgery for larger bony avulsions with hamstring retraction greater than 2 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/15,17\">",
"     15,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complete proximal hamstring ruptures (Grade III) should be referred to an orthopedist for evaluation and possible repair (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86518 \" href=\"UTD.htm?19/42/20133\">",
"     image 3",
"    </a>",
"    ). In limited case series, complete proximal ruptures managed nonoperatively did poorly, and most patients ultimately underwent operative repair with improved outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/13-15,17,51-53\">",
"     13-15,17,51-53",
"    </a>",
"    ]. In addition, surgical repair of these injuries decreased the incidence of post-injury sciatica.",
"   </p>",
"   <p>",
"    Distal hamstring ruptures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85937 \" href=\"UTD.htm?39/27/40374\">",
"     image 1",
"    </a>",
"    ) are rare and there are few published studies on which to base management decisions. Functional outcomes may be better with surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the indications described above, we believe it is reasonable to obtain orthopedic consultation if there is no improvement of the patient&rsquo;s symptoms and function despite four to six months of appropriate rehabilitation and conservative care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23895003\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many interventions are used to treat hamstring injuries, but few are supported by evidence from randomized controlled trials or high quality prospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/54\">",
"     54",
"    </a>",
"    ]. The great majority of relevant studies involve small numbers of patients, raising the possibility of Type 2 error. Therefore, our treatment suggestions below are based primarily upon small case series and clinical experience. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8500?source=see_link&amp;anchor=H6#H6\">",
"     \"Proof, p-values, and hypothesis testing\", section on 'Explanation for the results of a study'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H515439\">",
"    <span class=\"h2\">",
"     Acute management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protection, rest, ice, compression, and elevation (PRICE) therapy is traditionally used to limit the extent of localized bleeding, swelling, and pain from acute muscle strains [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/55\">",
"     55",
"    </a>",
"    ]. Elastic wraps (eg, ACE bandage) or taping are frequently used by trainers acutely. During treatment, many athletes continue to use materials to protect and compress the muscles, such as fabric sleeves (",
"    <a class=\"graphic graphic_picture graphicRef51086 \" href=\"UTD.htm?8/46/8930\">",
"     picture 6",
"    </a>",
"    ) or compression pants. Cryotherapy appears to be a safe and effective means of reducing pain and likely plays a role in lowering tissue metabolism and reducing secondary hypoxic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/56\">",
"     56",
"    </a>",
"    ]. Observational data suggest that two to six days of restricted motion reduces scar formation and reinjury rates [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/4,8,9,57-59\">",
"     4,8,9,57-59",
"    </a>",
"    ]. Therefore, it seems reasonable to delay the start of stretching and rehabilitation for two to six days, depending upon injury severity.",
"   </p>",
"   <p>",
"    Over the counter analgesics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    are generally adequate for pain relief. In",
"    <strong>",
"     rare",
"    </strong>",
"    instances, a short course of opioids may be needed to treat severe injuries. Nonsteroidal antiinflammatories (NSAIDS) have been used for many years to reduce pain and inflammation. However, the only published study to assess the effectiveness of NSAID therapy for hamstring injury is a double-blinded, randomized trial of 75 injuries that reported no overall difference in pain, swelling, strength, or endurance between the NSAID and placebo groups [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/60\">",
"     60",
"    </a>",
"    ]. A nonsignificant trend towards reduction in pain was found in patients with more severe muscle strains.",
"   </p>",
"   <p>",
"    Concern has been raised that NSAID therapy for muscle injury may delay healing, weaken tissue, and lead to impaired function [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/9,55,61\">",
"     9,55,61",
"    </a>",
"    ]. However, there is no clinical evidence to suggest that short-term use of NSAIDS in the treatment of hamstring injury has important deleterious effects. If NSAIDS are used, the duration of treatment should be limited (generally no longer than five to seven days) and based upon patient response. The effect of NSAIDs on tendon healing is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link&amp;anchor=H22#H22\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\", section on 'Healing of musculoskeletal injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H515446\">",
"    <span class=\"h2\">",
"     Glucocorticoid injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest not performing local glucocorticoid injections for the treatment of acute hamstring injuries because of the catabolic effects of glucocorticoids upon skeletal muscle and the absence of strong evidence supporting the benefits of this therapy. In addition, glucocorticoids may cause tendon degradation and increase the risk of tendon rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. However, our suggestion is based upon scant evidence and glucocorticoid injection may be beneficial in some cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=see_link\">",
"     \"Glucocorticoid-induced myopathy\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    One such exception might be elite or professional athletes in important competitions treated under the guidance of experienced sports medicine physicians. As an example, a retrospective case series of 58 players in the United States National Football League treated over a 13 year period with intramuscular glucocorticoid injections following a hamstring injury reported no negative outcomes and all the athletes were able to return to play [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/64\">",
"     64",
"    </a>",
"    ]. Glucocorticoids reduce pain, inhibit cytokine production and the inflammatory cascade, and they may reduce fibroblast proliferation, collagen synthesis, and scar formation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/56,65\">",
"     56,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H515453\">",
"    <span class=\"h2\">",
"     PRP and other injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of injectable medications, including platelet-rich plasma (PRP) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/66,67\">",
"     66,67",
"    </a>",
"    ], have been used or proposed for the treatment of acute muscle injury, but evidence supporting their use in humans is limited and conflicting. Other injectable substances that some researchers have considered for use in acute muscle injury include autologous blood, autologous conditioned serum [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/68\">",
"     68",
"    </a>",
"    ], prolotherapy, Actovegin (protein-free extract obtained from calf blood), anti-fibrotic agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/50/30498?source=see_link\">",
"     suramin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/69\">",
"     69",
"    </a>",
"    ], and isolated growth factors, such as IGF-1. Pending further research, we do not suggest using any of these substances for the treatment of acute muscle injury.",
"   </p>",
"   <p>",
"    PRP is anecdotally being used in elite athletes, but there is little scientific data to support its use for hamstring injuries, and current preparations are expensive [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/67\">",
"     67",
"    </a>",
"    ]. A consensus statement from the International Olympic Committee on the use of PRP in sports medicine states: &ldquo;At present there is little scientific support for the use of PRP for the management of muscle strain injuries&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/70\">",
"     70",
"    </a>",
"    ]. Although PRP is no longer prohibited by the World Anti-Doping Agency, purified or recombinant growth factors (ie, IGF-1, VEGF, PDGF) remain banned substances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H515489\">",
"    <span class=\"h2\">",
"     Unproven treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little evidence to support other proposed treatments for hamstring injuries, including low-intensity pulsed ultrasound, therapeutic laser, electrical stimulation, massage, and extracorporeal shockwave treatment. According to several systematic reviews, therapeutic ultrasound is no better than placebo and the data regarding electrical stimulation and therapeutic laser is conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/4,44,56,57\">",
"     4,44,56,57",
"    </a>",
"    ]. There is some evidence that application of heat within the first three days may prolong rehabilitation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23895010\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE AND REHABILITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical therapy has been used for many years to treat acute muscle injuries, but there is limited evidence to support the majority of these treatments. Pending further study, several reasonable approaches to rehabilitation may be used. We suggest using the functional rehabilitation program described in the attached table and reference (",
"    <a class=\"graphic graphic_table graphicRef77519 \" href=\"UTD.htm?16/62/17390\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/9\">",
"     9",
"    </a>",
"    ]. This program incorporates the following elements:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiplanar movements",
"     </li>",
"     <li>",
"      Exercises to enhance trunk stability and proprioception",
"     </li>",
"     <li>",
"      Agility training",
"     </li>",
"     <li>",
"      Eccentric strength exercises for the hamstring",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For each of the three phases of this program, it is important that the intensity of the exercises is increased gradually.",
"    <strong>",
"    </strong>",
"    Video demonstrations of several rehabilitative techniques used in this program are available to those with access to the Journal of Orthopaedic and Sports Physical Therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Controlled studies of hamstring injury rehabilitation are scant [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/4,71\">",
"     4,71",
"    </a>",
"    ]. Prospective studies include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of 80 athletes with Grade II hamstring tears found that static stretching started 48 hours after injury and performed four times a day shortened the time needed to regain normal range of motion (5.6 versus 7.3 days) and unrestricted activity (13.3 versus 15 days) when compared to patients performing stretches once a day [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Treatment with isolated static stretching and progressive resistance exercises (STST group) or with progressive agility and trunk stabilization exercises (PATS group) was compared in a randomized trial involving 24 athletes with hamstring muscle strains [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/8\">",
"       8",
"      </a>",
"      ]. The PATS group demonstrated lower reinjury rates two weeks after returning to sport",
"      <span class=\"nowrap\">",
"       (0/13",
"      </span>",
"      athletes versus",
"      <span class=\"nowrap\">",
"       6/11)",
"      </span>",
"      and at one year",
"      <span class=\"nowrap\">",
"       (1/13",
"      </span>",
"      athletes versus",
"      <span class=\"nowrap\">",
"       7/10).",
"      </span>",
"     </li>",
"     <li>",
"      A randomized trial of 20 patients found that those with hamstring strain and sacroiliac (SI) joint pain who were treated with SI joint manipulation showed increased hamstring peak torque compared to those who did not receive such treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/37\">",
"       37",
"      </a>",
"      ]. This study did not evaluate patient-oriented outcomes such as reinjury rates or the time required to return to activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results support incorporating frequent static stretching early during rehabilitation, depending upon the severity of injury, and agility and trunk stabilization exercises as part of a comprehensive rehabilitation program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23895024\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1693775\">",
"    <span class=\"h2\">",
"     Overview of interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few adequately powered, prospective studies evaluating the effectiveness of hamstring injury prevention programs have been performed. Therefore, recommendations for prevention programs are necessarily based upon a small number of primarily nonrandomized studies and clinical experience. The accompanying table outlines a prevention plan for athletes at high risk for recurrent hamstring injury (",
"    <a class=\"graphic graphic_table graphicRef80999 \" href=\"UTD.htm?20/48/21261\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A systematic review of seven studies concluded that there was insufficient evidence from randomized trials to draw conclusions about the effectiveness of interventions for preventing hamstring injuries among athletes involved in high-risk activities [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/72\">",
"     72",
"    </a>",
"    ]. An underpowered study of manual therapy showed some benefit, but adequately powered follow-up studies are needed.",
"   </p>",
"   <p>",
"    Interventions evaluated in the systematic review, as well as those from other studies, include strengthening exercises [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/10,73,74\">",
"     10,73,74",
"    </a>",
"    ], stretching [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/75\">",
"     75",
"    </a>",
"    ], mobilization of the sacroiliac joint and pelvis, sport-specific training and correction of dysfunctional movement, manual therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/76,77\">",
"     76,77",
"    </a>",
"    ], proprioceptive neuromuscular training [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/78,79\">",
"     78,79",
"    </a>",
"    ], and generalized warm-up and conditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional interventions that have been used to prevent hamstring injury include exercises to alter pelvic angulation, which may increase peak torque [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/37\">",
"     37",
"    </a>",
"    ], improve core strength [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/8\">",
"     8",
"    </a>",
"    ], and improve neuromuscular control and proprioception.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1693782\">",
"    <span class=\"h2\">",
"     Eccentric hamstring strengthening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eccentric strength training of the hamstrings may reduce the risk of injury. The performance of Nordic hamstring lowers, a common example of such training, is included in the accompanying prevention plan (",
"    <a class=\"graphic graphic_table graphicRef80999 \" href=\"UTD.htm?20/48/21261\">",
"     table 2",
"    </a>",
"    ), while proper positioning for the exercise is demonstrated in the following photographs (",
"    <a class=\"graphic graphic_picture graphicRef76640 \" href=\"UTD.htm?26/2/26657\">",
"     picture 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef56698 \" href=\"UTD.htm?0/29/465\">",
"     picture 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Several studies support the use of eccentric hamstring strengthening exercises (Nordic hamstring lowers) for reducing the risk of hamstring tears:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial involving 50 professional and amateur Danish soccer teams, players (n = 461) who participated in a progressive eccentric hamstring strengthening program sustained hamstring injuries at a significantly lower rate than players (n = 4 81) who engaged in standard training (15 versus 67 injuries) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/80\">",
"       80",
"      </a>",
"      ]. Overall, acute hamstring injury rates per 100 player seasons were 3.8 versus 13.1 (RR 0.29; 95% CI 0.15-0.57); new injury rates per 100 player seasons were 3.1 versus 8.1 (RR 0.41; 95% CI 0.18-0.93); and the number needed to treat (NNT) to prevent 1 recurrent hamstring injury was 3 (95% CI 2-6).",
"     </li>",
"     <li>",
"      In a nonrandomized study involving members of 21 to 34 first division professional soccer teams from Norway and Iceland, approximately half of the players enrolled practiced the interventions, which included a progressive eccentric hamstring strength protocol that was performed three times weekly during the preseason and two times weekly during the competitive season [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/81\">",
"       81",
"      </a>",
"      ]. Over approximately 330,000 exposure hours, the athletes involved sustained 183 hamstring injuries. Teams that followed the eccentric training protocol had a significantly lower incidence of hamstring injury (RR 0.35; 95% CI 0.19-0.62).",
"     </li>",
"     <li>",
"      Several smaller trials support the concept that eccentric exercises improve hamstring strength and reduce the risk of injury [",
"      <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/10,82,83\">",
"       10,82,83",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23895031\">",
"    <span class=\"h1\">",
"     RETURN TO WORK OR SPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hamstring injuries vary widely in severity and therefore general recommendations about returning to work and sport are unhelpful. Furthermore, sport and work conditions also vary. Participants in less demanding sports or sedentary occupations often can resume activity within a few days of injury. For patients with severe hamstring injuries who engage in high-risk sports, months may be needed before they can return to unrestricted play. According to observational studies, the time needed to return to preinjury fitness is longer in athletes with strains sustained from stretching type injuries compared to those sustained from high-speed running (mean 31 versus 16 weeks), although these differences did not reach statistical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/39,42,43,46\">",
"     39,42,43,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With aggressive rehabilitation programs, athletes with significant hamstring injuries return to sport in approximately two weeks, but timing ranges from weeks to months, according to limited data [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/8,59\">",
"     8,59",
"    </a>",
"    ]. For patients with physically demanding work, clinicians must consider the functional requirements of the job. In many such cases, a rehabilitation protocol similar to that used for participants in high-risk sports is appropriate, and the time needed to return to activity similar. Nevertheless, data for specific occupations does not exist and all recommendations about returning to work must be tailored to the individual&rsquo;s job and clinical status.",
"   </p>",
"   <p>",
"    Given the variability in healing rates following hamstring injuries, clinical assessment must guide decisions about returning to activity. Before returning to sport or physically demanding work, individuals need near-normal knee range of motion and normal bilateral concentric and eccentric strength, tested at 90 degrees and 15 to 30 degrees of knee flexion with the patient prone. Functional testing, including running, cutting, and any sport-specific or work-specific motions, should be evaluated, and there should be no sign of functional deficits, gait abnormalities, or pain. (See",
"    <a class=\"local\" href=\"#H23894954\">",
"     'Physical examination'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15303391\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15303399\">",
"    <span class=\"h2\">",
"     Reinjury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary complication after a hamstring injury is the increased risk of reinjury to the same muscle. The rate of reinjury is at least 30 percent, and some studies report rates as high as 60 to 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/4,5,7,8\">",
"     4,5,7,8",
"    </a>",
"    ]. Lifetime reinjury rates vary considerably by activity.",
"   </p>",
"   <p>",
"    A systematic review of recurrent hamstring injury reported that increased severity of the initial injury and ipsilateral anterior cruciate ligament reconstruction are associated with an increased risk of reinjury while rehabilitation consisting primarily of functional stability and agility training is associated with a decreased risk. However, the authors of the review emphasized the low quality of the available evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23894884\">",
"     'Risk factors'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H23894891\">",
"     'Sport-specific risks'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15303406\">",
"    <span class=\"h2\">",
"     Hamstring syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another potential complication is chronic, radiating, sciatica-type pain centered around the region of the gluteal muscles and ischial tuberosity. Different terms have been used to describe this syndrome, which is associated with prior hamstring tears, including hamstring syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/12\">",
"     12",
"    </a>",
"    ] and proximal hamstring syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of explanations for this syndrome have been proposed. There is operative and radiological evidence that scar tissue forms around the sciatic nerve following some hamstring injuries, and scar tissue may play a role in this syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/13-15,17,51,52\">",
"     13-15,17,51,52",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Some researchers believe the syndrome may be due to a proximal hamstring tendinopathy. A study of the histopathology from cases of persistent ischial tuberosity and gluteal pain following hamstring injury reported that all specimens exhibited classic findings of tendinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/35/14906/abstract/48\">",
"     48",
"    </a>",
"    ]. Chronic pain is associated with tendinopathy of numerous tendons, including the Achilles, extensor carpi radialis brevis (tennis elbow), and patellar, and this study suggests that the proximal hamstring syndrome may result from tendon degradation, release of pain producing substances, and diminished tendon heterogeneity, similar to other chronic tendinopathies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2215?source=see_link\">",
"     \"Overview of overuse (chronic) tendinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The proximal hamstring syndrome is not well understood and there is insufficient data to provide clear guidance about treatment. Surgery may be needed for cases in which a well-conceived and rigorously followed physical therapy program is unsuccessful at improving symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/0/39938?source=see_link\">",
"       \"Patient information: Muscle strain (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/3/1074?source=see_link\">",
"       \"Patient information: Hamstring injury (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23894861\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hamstring injuries are common in sports, particularly those involving high-speed running. They can be defined as any strain or tear of any of the muscles or tendons within the hamstring group of the posterior thigh, including the biceps femoris, semitendinosus, and semimembranosus muscles. (See",
"      <a class=\"local\" href=\"#H23894869\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23894877\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The hamstring muscles&rsquo; primary function is to decelerate the lower limb during the forward swing phase of running or walking; the hamstrings also contribute to the stability of the hip and knee during movement. Secondary functions include knee flexion and hip extension. (See",
"      <a class=\"local\" href=\"#H1615166\">",
"       'Anatomy and physiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Modifiable risk factors for hamstring injury may include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Inadequate warm-up",
"     </li>",
"     <li>",
"      Increased training volume",
"     </li>",
"     <li>",
"      Muscle fatigue",
"     </li>",
"     <li>",
"      Hamstring inflexibility",
"     </li>",
"     <li>",
"      Hamstring weakness (may be weakness relative to quadriceps)",
"     </li>",
"     <li>",
"      Cross-pelvic posture (ie, lumbar lordosis with anterior pelvic tilt)",
"     </li>",
"     <li>",
"      Lumbar-pelvic weakness",
"     </li>",
"     <li>",
"      Poor biomechanics (eg, running or change of direction) (see",
"      <a class=\"local\" href=\"#H23894884\">",
"       'Risk factors'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hamstring injury occurs when a sudden, forceful, eccentric contraction of the hamstring occurs against resistance. Most individuals with hamstring injuries present acutely complaining of the sudden onset of posterior thigh pain while performing a high-risk activity. Focal warmth and tenderness at the site are common. Injury can usually be diagnosed on the basis of the history and physical examination. (See",
"      <a class=\"local\" href=\"#H4095548\">",
"       'History and mechanism of injury'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23894954\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the diagnosis is unclear or a more detailed assessment of the hamstrings is needed, musculoskeletal ultrasonography (US) and magnetic resonance imaging (MRI) are the best methods for assessing hamstring injuries. US allows for bedside evaluation of the muscles and tendons while they move. (See",
"      <a class=\"local\" href=\"#H4095799\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cause of posterior thigh pain may be more difficult to determine in athletes with long standing pain, recurrent symptoms, or an unclear mechanism of injury. A differential diagnosis for posterior thigh pain is provided in the text. (See",
"      <a class=\"local\" href=\"#H23894975\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The great majority of hamstring injuries can be managed successfully with rest and physical therapy. However, in some circumstances, operative repair may yield favorable results. Orthopedic consultation should be obtained in such circumstances, which include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Severe avulsion injuries with significant hamstring retraction (generally occurs in children)",
"     </li>",
"     <li>",
"      Complete (Grade III) proximal hamstring rupture",
"     </li>",
"     <li>",
"      High-grade (Grade II or III) distal hamstring tears (see",
"      <a class=\"local\" href=\"#H23894996\">",
"       'Indications for orthopedic consultation'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Standard treatment for acute hamstring injuries includes protection, rest, ice, compression, and elevation (PRICE). Rehabilitation involves a gradual progression of exercises designed to improve the function of the hamstring muscles and the entire posterior kinetic chain. Successful hamstring rehabilitation programs emphasize eccentric strengthening. Programs for rehabilitation and prevention have much in common; sample programs are provided. (See",
"      <a class=\"local\" href=\"#H23895010\">",
"       'Follow-up care and rehabilitation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23895024\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/1\">",
"      Brooks JH, Fuller CW, Kemp SP, Reddin DB. Incidence, risk, and prevention of hamstring muscle injuries in professional rugby union. Am J Sports Med 2006; 34:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/2\">",
"      Croisier JL. Factors associated with recurrent hamstring injuries. Sports Med 2004; 34:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/3\">",
"      Gabbe BJ, Bennell KL, Finch CF. Why are older Australian football players at greater risk of hamstring injury? J Sci Med Sport 2006; 9:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/4\">",
"      Mason DL, Dickens V, Vail A. Rehabilitation for hamstring injuries. Cochrane Database Syst Rev 2007; :CD004575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/5\">",
"      Orchard JW. Intrinsic and extrinsic risk factors for muscle strains in Australian football. Am J Sports Med 2001; 29:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/6\">",
"      Petersen J, H&ouml;lmich P. Evidence based prevention of hamstring injuries in sport. Br J Sports Med 2005; 39:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/7\">",
"      Prior M, Guerin M, Grimmer K. An evidence-based approach to hamstring strain injury: A systematic review of the literature. Sports Health: A Multidisciplinary Approach 2009; 1:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/8\">",
"      Sherry MA, Best TM. A comparison of 2 rehabilitation programs in the treatment of acute hamstring strains. J Orthop Sports Phys Ther 2004; 34:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/9\">",
"      Heiderscheit BC, Sherry MA, Silder A, et al. Hamstring strain injuries: recommendations for diagnosis, rehabilitation, and injury prevention. J Orthop Sports Phys Ther 2010; 40:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/10\">",
"      Askling C, Karlsson J, Thorstensson A. Hamstring injury occurrence in elite soccer players after preseason strength training with eccentric overload. Scand J Med Sci Sports 2003; 13:244.",
"     </a>",
"    </li>",
"    <li>",
"     Netter FH. Arteries and nerves of the posterior thigh. In: Atlas of Human Anatomy, 2nd, Novartis Medical Education, East Hanover 1997. p.468.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/12\">",
"      Puranen J, Orava S. The hamstring syndrome. A new diagnosis of gluteal sciatic pain. Am J Sports Med 1988; 16:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/13\">",
"      Lempainen L, Sarimo J, Heikkil&auml; J, et al. Surgical treatment of partial tears of the proximal origin of the hamstring muscles. Br J Sports Med 2006; 40:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/14\">",
"      Sallay PI, Ballard G, Hamersly S, Schrader M. Subjective and functional outcomes following surgical repair of complete ruptures of the proximal hamstring complex. Orthopedics 2008; 31:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/15\">",
"      Sarimo J, Lempainen L, Mattila K, Orava S. Complete proximal hamstring avulsions: a series of 41 patients with operative treatment. Am J Sports Med 2008; 36:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/16\">",
"      Young IJ, van Riet RP, Bell SN. Surgical release for proximal hamstring syndrome. Am J Sports Med 2008; 36:2372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/17\">",
"      Wood DG, Packham I, Trikha SP, Linklater J. Avulsion of the proximal hamstring origin. J Bone Joint Surg Am 2008; 90:2365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/18\">",
"      Woods C, Hawkins RD, Maltby S, et al. The Football Association Medical Research Programme: an audit of injuries in professional football--analysis of hamstring injuries. Br J Sports Med 2004; 38:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/19\">",
"      Gabbe BJ, Finch CF, Bennell KL, Wajswelner H. Risk factors for hamstring injuries in community level Australian football. Br J Sports Med 2005; 39:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/20\">",
"      Murphy DF, Connolly DA, Beynnon BD. Risk factors for lower extremity injury: a review of the literature. Br J Sports Med 2003; 37:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/21\">",
"      Bahr R, Holme I. Risk factors for sports injuries--a methodological approach. Br J Sports Med 2003; 37:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/22\">",
"      Arnason A, Sigurdsson SB, Gudmundsson A, et al. Risk factors for injuries in football. Am J Sports Med 2004; 32:5S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/23\">",
"      Bennell K, Wajswelner H, Lew P, et al. Isokinetic strength testing does not predict hamstring injury in Australian Rules footballers. Br J Sports Med 1998; 32:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/24\">",
"      H&auml;gglund M, Wald&eacute;n M, Ekstrand J. Previous injury as a risk factor for injury in elite football: a prospective study over two consecutive seasons. Br J Sports Med 2006; 40:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/25\">",
"      Verrall GM, Slavotinek JP, Barnes PG, et al. Clinical risk factors for hamstring muscle strain injury: a prospective study with correlation of injury by magnetic resonance imaging. Br J Sports Med 2001; 35:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/26\">",
"      Gabbe BJ, Bennell KL, Finch CF, et al. Predictors of hamstring injury at the elite level of Australian football. Scand J Med Sci Sports 2006; 16:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/27\">",
"      Upton PA, Noakes TD, Juritz JM. Thermal pants may reduce the risk of recurrent hamstring injuries in rugby players. Br J Sports Med 1996; 30:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/28\">",
"      Wallden M, Walters N. Does lumbo-pelvic dysfunction predispose to hamstring strain in professional soccer players? J Bodyw Mov Ther 2005; 9:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/29\">",
"      Koulouris G, Connell D. Hamstring muscle complex: an imaging review. Radiographics 2005; 25:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/30\">",
"      Connell DA, Schneider-Kolsky ME, Hoving JL, et al. Longitudinal study comparing sonographic and MRI assessments of acute and healing hamstring injuries. AJR Am J Roentgenol 2004; 183:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/31\">",
"      Slavotinek JP, Verrall GM, Fon GT. Hamstring injury in athletes: using MR imaging measurements to compare extent of muscle injury with amount of time lost from competition. AJR Am J Roentgenol 2002; 179:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/32\">",
"      Verrall GM, Slavotinek JP, Barnes PG, et al. Assessment of physical examination and magnetic resonance imaging findings of hamstring injury as predictors for recurrent injury. J Orthop Sports Phys Ther 2006; 36:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/33\">",
"      Watsford ML, Murphy AJ, McLachlan KA, et al. A prospective study of the relationship between lower body stiffness and hamstring injury in professional Australian rules footballers. Am J Sports Med 2010; 38:2058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/34\">",
"      Bennell K, Tully E, Harvey N. Does the toe-touch test predict hamstring injury in Australian Rules footballers? Aust J Physiother 1999; 45:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/35\">",
"      Yamamoto T. Relationship between hamstring strains and leg muscle strength. A follow-up study of collegiate track and field athletes. J Sports Med Phys Fitness 1993; 33:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/36\">",
"      Orchard J, Marsden J, Lord S, Garlick D. Preseason hamstring muscle weakness associated with hamstring muscle injury in Australian footballers. Am J Sports Med 1997; 25:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/37\">",
"      Cibulka MT, Rose SJ, Delitto A, Sinacore DR. Hamstring muscle strain treated by mobilizing the sacroiliac joint. Phys Ther 1986; 66:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/38\">",
"      Comerford MJ, Mottram SL. Functional stability re-training: principles and strategies for managing mechanical dysfunction. Man Ther 2001; 6:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/39\">",
"      Askling CM, Tengvar M, Saartok T, Thorstensson A. Proximal hamstring strains of stretching type in different sports: injury situations, clinical and magnetic resonance imaging characteristics, and return to sport. Am J Sports Med 2008; 36:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/40\">",
"      Yeung SS, Suen AM, Yeung EW. A prospective cohort study of hamstring injuries in competitive sprinters: preseason muscle imbalance as a possible risk factor. Br J Sports Med 2009; 43:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/41\">",
"      Elliott MC, Zarins B, Powell JW, Kenyon CD. Hamstring muscle strains in professional football players: a 10-year review. Am J Sports Med 2011; 39:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/42\">",
"      Askling CM, Tengvar M, Saartok T, Thorstensson A. Acute first-time hamstring strains during high-speed running: a longitudinal study including clinical and magnetic resonance imaging findings. Am J Sports Med 2007; 35:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/43\">",
"      Askling CM, Tengvar M, Saartok T, Thorstensson A. Acute first-time hamstring strains during slow-speed stretching: clinical, magnetic resonance imaging, and recovery characteristics. Am J Sports Med 2007; 35:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/44\">",
"      Copland ST, Tipton JS, Fields KB. Evidence-based treatment of hamstring tears. Curr Sports Med Rep 2009; 8:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/45\">",
"      De Smet AA, Best TM. MR imaging of the distribution and location of acute hamstring injuries in athletes. AJR Am J Roentgenol 2000; 174:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/46\">",
"      Askling C, Saartok T, Thorstensson A. Type of acute hamstring strain affects flexibility, strength, and time to return to pre-injury level. Br J Sports Med 2006; 40:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/47\">",
"      Lempainen L, Sarimo J, Mattila K, et al. Distal tears of the hamstring muscles: review of the literature and our results of surgical treatment. Br J Sports Med 2007; 41:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/48\">",
"      Lempainen L, Sarimo J, Mattila K, et al. Proximal hamstring tendinopathy: results of surgical management and histopathologic findings. Am J Sports Med 2009; 37:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/49\">",
"      Ekstrand J, Healy JC, Wald&eacute;n M, et al. Hamstring muscle injuries in professional football: the correlation of MRI findings with return to play. Br J Sports Med 2012; 46:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/50\">",
"      Lazovi�� D, Wegner U, Peters G, Goss&eacute; F. Ultrasound for diagnosis of apophyseal injuries. Knee Surg Sports Traumatol Arthrosc 1996; 3:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/51\">",
"      Cohen S, Bradley J. Acute proximal hamstring rupture. J Am Acad Orthop Surg 2007; 15:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/52\">",
"      Chakravarthy J, Ramisetty N, Pimpalnerkar A, Mohtadi N. Surgical repair of complete proximal hamstring tendon ruptures in water skiers and bull riders: a report of four cases and review of the literature. Br J Sports Med 2005; 39:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/53\">",
"      Harris JD, Griesser MJ, Best TM, Ellis TJ. Treatment of proximal hamstring ruptures - a systematic review. Int J Sports Med 2011; 32:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/54\">",
"      Reurink G, Goudswaard GJ, Tol JL, et al. Therapeutic interventions for acute hamstring injuries: a systematic review. Br J Sports Med 2012; 46:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/55\">",
"      Drezner JA. Practical management: hamstring muscle injuries. Clin J Sport Med 2003; 13:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/56\">",
"      Scott A, Khan KM, Roberts CR, et al. What do we mean by the term \"inflammation\"? A contemporary basic science update for sports medicine. Br J Sports Med 2004; 38:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/57\">",
"      Hoskins W, Pollard H. Hamstring injury management--Part 2: Treatment. Man Ther 2005; 10:180.",
"     </a>",
"    </li>",
"    <li>",
"     J��rvinen TA, K����ri��inen M, ����rimaa V, et al. Skeletal muscle repair after exercise-induced injury. In: Skeletal Muscle Repair and Regeneration, Partridge T, Schiaffino S (Eds), Springer- Verlag, New York 2008. p.224.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/59\">",
"      Malliaropoulos N, Papalexandris S, Papalada A, Papacostas E. The role of stretching in rehabilitation of hamstring injuries: 80 athletes follow-up. Med Sci Sports Exerc 2004; 36:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/60\">",
"      Reynolds JF, Noakes TD, Schwellnus MP, et al. Non-steroidal anti-inflammatory drugs fail to enhance healing of acute hamstring injuries treated with physiotherapy. S Afr Med J 1995; 85:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/61\">",
"      Almekinders LC. Anti-inflammatory treatment of muscular injuries in sport. An update of recent studies. Sports Med 1999; 28:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/62\">",
"      Tempfer H, Gehwolf R, Lehner C, et al. Effects of crystalline glucocorticoid triamcinolone acetonide on cultered human supraspinatus tendon cells. Acta Orthop 2009; 80:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/63\">",
"      Ford LT, DeBender J. Tendon rupture after local steroid injection. South Med J 1979; 72:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/64\">",
"      Levine WN, Bergfeld JA, Tessendorf W, Moorman CT 3rd. Intramuscular corticosteroid injection for hamstring injuries. A 13-year experience in the National Football League. Am J Sports Med 2000; 28:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/65\">",
"      Toumi H, Best TM. The inflammatory response: friend or enemy for muscle injury? Br J Sports Med 2003; 37:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/66\">",
"      Borrione P, Gianfrancesco AD, Pereira MT, Pigozzi F. Platelet-rich plasma in muscle healing. Am J Phys Med Rehabil 2010; 89:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/67\">",
"      Hamilton B, Knez W, Eirale C, Chalabi H. Platelet enriched plasma for acute muscle injury. Acta Orthop Belg 2010; 76:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/68\">",
"      Creaney L, Hamilton B. Growth factor delivery methods in the management of sports injuries: the state of play. Br J Sports Med 2008; 42:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/69\">",
"      Chan YS, Li Y, Foster W, et al. The use of suramin, an antifibrotic agent, to improve muscle recovery after strain injury. Am J Sports Med 2005; 33:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/70\">",
"      Engebretsen L, Steffen K, Alsousou J, et al. IOC consensus paper on the use of platelet-rich plasma in sports medicine. Br J Sports Med 2010; 44:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/71\">",
"      Mason DL, Dickens VA, Vail A. Rehabilitation for hamstring injuries. Cochrane Database Syst Rev 2012; 12:CD004575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/72\">",
"      Goldman EF, Jones DE. Interventions for preventing hamstring injuries. Cochrane Database Syst Rev 2010; :CD006782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/73\">",
"      Engebretsen AH, Myklebust G, Holme I, et al. Prevention of injuries among male soccer players: a prospective, randomized intervention study targeting players with previous injuries or reduced function. Am J Sports Med 2008; 36:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/74\">",
"      Gabbe BJ, Branson R, Bennell KL. A pilot randomised controlled trial of eccentric exercise to prevent hamstring injuries in community-level Australian Football. J Sci Med Sport 2006; 9:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/75\">",
"      van Mechelen W, Hlobil H, Kemper HC, et al. Prevention of running injuries by warm-up, cool-down, and stretching exercises. Am J Sports Med 1993; 21:711.",
"     </a>",
"    </li>",
"    <li>",
"     Hoskins W, Pollard H. A randomized controlled trial of manual therapy for hamstring injury prevention. Direct correspondence with the Cochrane Collaboration, unpublished. 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/77\">",
"      Hoskins WT, Pollard HT, Orchard JW. The effect of sports chiropractic on the prevention of hamstring injuries: A randomized controlled trial [abstract]. Med Sci Sports Exerc 2006; 38:s27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/78\">",
"      Emery CA, Rose MS, McAllister JR, Meeuwisse WH. A prevention strategy to reduce the incidence of injury in high school basketball: a cluster randomized controlled trial. Clin J Sport Med 2007; 17:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/79\">",
"      S&ouml;derman K, Werner S, Pietil&auml; T, et al. Balance board training: prevention of traumatic injuries of the lower extremities in female soccer players? A prospective randomized intervention study. Knee Surg Sports Traumatol Arthrosc 2000; 8:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/80\">",
"      Petersen J, Thorborg K, Nielsen MB, et al. Preventive effect of eccentric training on acute hamstring injuries in men's soccer: a cluster-randomized controlled trial. Am J Sports Med 2011; 39:2296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/81\">",
"      Arnason A, Andersen TE, Holme I, et al. Prevention of hamstring strains in elite soccer: an intervention study. Scand J Med Sci Sports 2008; 18:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/82\">",
"      Mj&oslash;lsnes R, Arnason A, &Oslash;sthagen T, et al. A 10-week randomized trial comparing eccentric vs. concentric hamstring strength training in well-trained soccer players. Scand J Med Sci Sports 2004; 14:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/83\">",
"      Holcomb WR, Rubley MD, Lee HJ, Guadagnoli MA. Effect of hamstring-emphasized resistance training on hamstring:quadriceps strength ratios. J Strength Cond Res 2007; 21:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/35/14906/abstract/84\">",
"      de Visser HM, Reijman M, Heijboer MP, Bos PK. Risk factors of recurrent hamstring injuries: a systematic review. Br J Sports Med 2012; 46:124.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13810 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-220.255.2.104-06CD6EBEF0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_35_14906=[""].join("\n");
var outline_f14_35_14906=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23894861\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23894869\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23894877\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1615166\">",
"      ANATOMY AND PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23894884\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2453276\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2453283\">",
"      Previous injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2453290\">",
"      Muscle inflexibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2453304\">",
"      Muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2453318\">",
"      Problems with related structures (kinetic chain)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2453311\">",
"      Age and other factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23894891\">",
"      Sport-specific risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4095688\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4095548\">",
"      History and mechanism of injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23894954\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23894968\">",
"      Injury location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4095428\">",
"      Injury severity and grading system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4095799\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23894975\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23894996\">",
"      INDICATIONS FOR ORTHOPEDIC CONSULTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23895003\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H515439\">",
"      Acute management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H515446\">",
"      Glucocorticoid injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H515453\">",
"      PRP and other injections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H515489\">",
"      Unproven treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23895010\">",
"      FOLLOW-UP CARE AND REHABILITATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23895024\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1693775\">",
"      Overview of interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1693782\">",
"      Eccentric hamstring strengthening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23895031\">",
"      RETURN TO WORK OR SPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15303391\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15303399\">",
"      Reinjury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15303406\">",
"      Hamstring syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23894861\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13810\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13810|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/27/40374\" title=\"diagnostic image 1\">",
"      MRI acute hamstring tear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/17/24851\" title=\"diagnostic image 2\">",
"      MRI hamstring avulsion fracture ischial tuberosity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/42/20133\" title=\"diagnostic image 3\">",
"      MRI retracted hamstring complete avulsion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/45/9941\" title=\"diagnostic image 4\">",
"      MRI non-retracted partial tear of hamstring tendons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/3/42034\" title=\"diagnostic image 5\">",
"      X-ray hamstring avulsion fracture of the ischial tuberosity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13810|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/34/12841\" title=\"figure 1\">",
"      Muscles of gluteal region and posterior thigh",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13810|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/6/26722\" title=\"picture 1\">",
"      Posterior thigh superficial anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/11/42162\" title=\"picture 2\">",
"      Concentric hamstring strength testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/26/3489\" title=\"picture 3\">",
"      Eccentric hamstring strength testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/3/9265\" title=\"picture 4\">",
"      Hamstring strength testing with ER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/43/21168\" title=\"picture 5\">",
"      Hamstring strength testing with IR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/46/8930\" title=\"picture 6\">",
"      Thigh sleeve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/2/26657\" title=\"picture 7\">",
"      Nordic lower starting position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/29/465\" title=\"picture 8\">",
"      Nordic lower descent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13810|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/62/17390\" title=\"table 1\">",
"      Hamstring injury rehabilitation program",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/48/21261\" title=\"table 2\">",
"      Hamstring injury prevention program",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34296?source=related_link\">",
"      Ankle sprain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32138?source=related_link\">",
"      Anterior cruciate ligament injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=related_link\">",
"      Approach to the diagnosis and evaluation of low back pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28215?source=related_link\">",
"      Chronic exertional compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=related_link\">",
"      Diagnosis of suspected deep vein thrombosis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=related_link\">",
"      Glucocorticoid-induced myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=related_link\">",
"      Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/15/16632?source=related_link\">",
"      Meniscal injury of the knee",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2215?source=related_link\">",
"      Overview of overuse (chronic) tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23866?source=related_link\">",
"      Overview of stress fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/3/1074?source=related_link\">",
"      Patient information: Hamstring injury (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/0/39938?source=related_link\">",
"      Patient information: Muscle strain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27016?source=related_link\">",
"      Popliteal (Baker's) cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8500?source=related_link\">",
"      Proof, p-values, and hypothesis testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_35_14907="Success single dose MTX";
var content_f14_35_14907=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Success of single dose methotrexate  for ectopic pregnancy according to hCG concentration",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       hCG concentration (IU/L)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Number of women successfully treated (percent)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Number of women failing treatment (percent)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &lt;1000",
"      </td>",
"      <td>",
"       133 (99)",
"      </td>",
"      <td>",
"       2 (1)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1000 to 1999",
"      </td>",
"      <td>",
"       51 (94)",
"      </td>",
"      <td>",
"       3 (6)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2000 to 4999",
"      </td>",
"      <td>",
"       106 (96)",
"      </td>",
"      <td>",
"       4 (4)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5000 to 9999",
"      </td>",
"      <td>",
"       42 (86)",
"      </td>",
"      <td>",
"       7 (14)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10,000 to 150,000",
"      </td>",
"      <td>",
"       18 (82)",
"      </td>",
"      <td>",
"       4 (18)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Menon, S, et al. Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review. Fertil Steril 2007; 87:481.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_35_14907=[""].join("\n");
var outline_f14_35_14907=null;
var title_f14_35_14908="Amelogenesis imperfecta";
var content_f14_35_14908=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical and hereditary characteristics of amelogenesis imperfecta",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical appearance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Enamel thickness",
"       </td>",
"       <td class=\"subtitle1\">",
"        Radiographic appearance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Inheritance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoplastic",
"        <br/>",
"        (type 1)",
"       </td>",
"       <td>",
"        Crown size varies from small to normal, small teeth may lack proximal contacts, color varies from normal to opaque white/yellow-brown",
"       </td>",
"       <td>",
"        Varies from thin and smooth to normal thickness with grooves, furrows, or pits",
"       </td>",
"       <td>",
"        Enamel has normal to slightly reduced contrast, thin",
"       </td>",
"       <td>",
"        Autosomal dominant, recessive, or X-linked",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Hypomaturation",
"        <br/>",
"        (type 2)",
"       </td>",
"       <td>",
"        Varies from creamy opaque to marked yellow or brown, surface of teeth soft and rough, dental sensitivity and open bite common",
"       </td>",
"       <td>",
"        Normal thickness with enamel that often chips and abrades easily",
"       </td>",
"       <td>",
"        Enamel has contrast similar to dentin, unerupted crowns have normal morphology",
"       </td>",
"       <td>",
"        Autosomal dominant, recessive, or X-linked",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Hypocalcified",
"        <br/>",
"        (type 3)",
"       </td>",
"       <td>",
"        Opaque white to yellow-brown, soft rough enamel surface, dental sensitivity and open bite common, heavy calculus formation common",
"       </td>",
"       <td>",
"        Normal thickness with enamel that often chips and abrades easily",
"       </td>",
"       <td>",
"        Enamel has contrast similar to or &lt; dentin, unerupted crowns have normal morphology",
"       </td>",
"       <td>",
"        Autosomal dominant, recessive",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Hypomaturation/ hypoplasia/ taurodomism",
"        <br/>",
"        (type 4)",
"       </td>",
"       <td>",
"        White/yellow-brown mottled, teeth can appear small and lack proximal contact",
"       </td>",
"       <td>",
"        Reduced, hypomineralized areas and pits",
"       </td>",
"       <td>",
"        Enamel contrast normal to slightly &gt; dentin, large pulp chambers",
"       </td>",
"       <td>",
"        Autosomal dominant",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wright JT. Pediatr Clin North Am 2000; 47:986. Copyright 2000 W.B. Saunders Company.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_35_14908=[""].join("\n");
var outline_f14_35_14908=null;
var title_f14_35_14909="Asthma severity 5 to 11 yrs";
var content_f14_35_14909=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classifying asthma severity in children 5-11 years of age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"3\">",
"        Components of severity",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Classification of asthma severity (children 5-11 years of age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Intermittent",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"4\">",
"        Persistent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Mild",
"       </td>",
"       <td class=\"subtitle3\">",
"        Moderate",
"       </td>",
"       <td class=\"subtitle3\">",
"        Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Impairment",
"       </td>",
"       <td>",
"        Symptoms",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week but not daily",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        Throughout the day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nighttime awakenings",
"       </td>",
"       <td>",
"        &le;2x/month",
"       </td>",
"       <td>",
"        3-4x/month",
"       </td>",
"       <td>",
"        &gt;1x/week but not nightly",
"       </td>",
"       <td>",
"        Often 7x/week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short-acting beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonist use for symptom control (not prevention of EIB)",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week but not daily",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        Several times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interference with normal activity",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Minor limitation",
"       </td>",
"       <td>",
"        Some limitation",
"       </td>",
"       <td>",
"        Extremely limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lung function",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Normal FEV",
"         <sub>",
"          1",
"         </sub>",
"         between exacerbations",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         &gt;80 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC &gt;85 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         = &gt;80 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC &gt;80 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         = 60-80 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC = 75-80 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         &lt;60 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC &lt;75 percent",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Risk",
"       </td>",
"       <td rowspan=\"4\">",
"        <strong>",
"         Exacerbations requiring oral systemic corticosteroids",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0-1/year (see footnote)",
"        </strong>",
"       </td>",
"       <td colspan=\"3\">",
"        <strong>",
"         &ge;2 in 1 year (see footnote)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Consider severity and interval since last exacerbation",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Frequency and severity may fluctuate over time for patients in any severity category",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Relative annual risk of exacerbations may be related to FEV",
"         <sub>",
"          1",
"         </sub>",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Classifying severity in children who are not currently taking long-term control medication.",
"    </strong>",
"    Level of severity is determined by both impairment and risk. Assess impairment domain by patient's/caregiver's recall of the previous 2-4 weeks and spirometry. Assign severity to the most severe category in which any feature occurs. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma severity. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate greater underlying disease severity. For treatment purposes, patients who had &ge;2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_35_14909=[""].join("\n");
var outline_f14_35_14909=null;
var title_f14_35_14910="Gram stain urethral discharge 6";
var content_f14_35_14910=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain urethral discharge 6",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_35_14910=[""].join("\n");
var outline_f14_35_14910=null;
var title_f14_35_14911="Contents: Head and neck cancer";
var content_f14_35_14911=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/43/3774\">",
"       Oncology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Head and neck cancer",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Head and neck cancer",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Clinical features and staging",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/21/11608\">",
"           Differential diagnosis of a neck mass",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/24/7558\">",
"           Evaluation of a neck mass",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/55/887\">",
"           Human papillomavirus associated head and neck cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/42/30378\">",
"           Management of late complications of head and neck cancer and its treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/44/30407\">",
"           Overview of head and neck cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/43/36537\">",
"           Overview of the diagnosis and staging of head and neck cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/58/36775\">",
"           Posttreatment surveillance of squamous carcinoma of the head and neck",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/6/15459\">",
"           Squamous cell carcinoma of unknown primary site",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pathogenesis and risk factors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/6/20583\">",
"           Epidemiology and risk factors for head and neck cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/0/34825\">",
"           Head and neck squamous cell carcinogenesis: Molecular and genetic alterations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/4/12362\">",
"           Pathology of head and neck neoplasms",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Prevention",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/36/19017\">",
"           Chemoprevention in oral dysplasia and head and neck cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Reconstructive surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/45/8919\">",
"           Management of acquired maxillary defects: Prosthetic rehabilitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/56/39815\">",
"           Mandibular and palatal reconstruction in patients with head and neck cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Specific tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/45/13013\">",
"           Cancer of the nasal vestibule",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/36/26184\">",
"           Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/50/34602\">",
"           Head and neck sarcomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/28/19911\">",
"           Head and neck squamous cell carcinoma of unknown primary",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/34/11816\">",
"           Malignant salivary gland tumors: Treatment of recurrent and metastatic disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/44/23241\">",
"           Paranasal sinus cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/44/9927\">",
"           Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/41/28313\">",
"           Salivary gland tumors: Treatment of locoregional disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/58/15270\">",
"           Second primary malignancies in patients with head and neck cancers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/6/15459\">",
"           Squamous cell carcinoma of unknown primary site",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/27/34232\">",
"           Treatment of early (stage I and II) head and neck cancer: The hypopharynx",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/4/20552\">",
"           Treatment of early (stage I and II) head and neck cancer: The larynx",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/29/32217\">",
"           Treatment of early (stage I and II) head and neck cancer: The oral cavity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/6/3174\">",
"           Treatment of early (stage I and II) head and neck cancer: The oropharynx",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/3/8250\">",
"           Treatment of early and locoregionally advanced nasopharyngeal carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/45/41689\">",
"           Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/18/1321\">",
"           Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oral cavity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/55/15224\">",
"           Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oropharynx",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/57/16280\">",
"           Treatment of recurrent and metastatic nasopharyngeal carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/18/39206\">",
"           Tumors of the nasal cavity",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/54/16231\">",
"           Alaryngeal speech rehabilitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/45/13013\">",
"           Cancer of the nasal vestibule",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/57/23446\">",
"           Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/7/17525\">",
"           General principles of radiation therapy for head and neck cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/15/29946\">",
"           Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/34/11816\">",
"           Malignant salivary gland tumors: Treatment of recurrent and metastatic disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/1/22554\">",
"           Management and prevention of complications of head and neck cancer during initial treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/42/30378\">",
"           Management of late complications of head and neck cancer and its treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/62/28649\">",
"           Methods to overcome radiation resistance in head and neck cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/44/30407\">",
"           Overview of head and neck cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/59/43959\">",
"           Overview of treatment for head and neck squamous cell cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/44/23241\">",
"           Paranasal sinus cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/7/25719\">",
"           Postoperative radiation therapy in the management of head and neck cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/58/36775\">",
"           Posttreatment surveillance of squamous carcinoma of the head and neck",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/24/3466\">",
"           Quality of life in head and neck cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/23/38265\">",
"           Reirradiation for locally recurrent head and neck cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/44/9927\">",
"           Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/41/28313\">",
"           Salivary gland tumors: Treatment of locoregional disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/58/15270\">",
"           Second primary malignancies in patients with head and neck cancers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/51/31545\">",
"           Speech and swallowing rehabilitation of the patient with head and neck cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/6/15459\">",
"           Squamous cell carcinoma of unknown primary site",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/27/34232\">",
"           Treatment of early (stage I and II) head and neck cancer: The hypopharynx",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/4/20552\">",
"           Treatment of early (stage I and II) head and neck cancer: The larynx",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/29/32217\">",
"           Treatment of early (stage I and II) head and neck cancer: The oral cavity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/6/3174\">",
"           Treatment of early (stage I and II) head and neck cancer: The oropharynx",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/3/8250\">",
"           Treatment of early and locoregionally advanced nasopharyngeal carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/21/9559\">",
"           Treatment of locally recurrent head and neck cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/45/41689\">",
"           Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/18/1321\">",
"           Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oral cavity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/55/15224\">",
"           Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oropharynx",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/25/40345\">",
"           Treatment of metastatic and recurrent head and neck cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/57/16280\">",
"           Treatment of recurrent and metastatic nasopharyngeal carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/18/39206\">",
"           Tumors of the nasal cavity",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-5B24083F94-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f14_35_14911=[""].join("\n");
var outline_f14_35_14911=null;
